Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection: the umbrella phase IIa CHABLIS-T randomised clinical trial

Xin Cheng,1,2 Lan Hong,1,3 Leonid Churilov,4 Longting Lin,5 Yifeng Ling,6 Jin Zhang,2 Jianhong Yang,7 Yu Geng,5 Danhong Wu,7 Xueyuan Liu,5 Xiaoyu Zhou,8 Yuwu Zhao,9 Qijin Zhai,10 Liandong Zhao,10 Yangmei Chen,11 Ling Guo,12 Xiaofei Yu,13 Fan Gong,13 Yi Sui,14 Gang Li,15 Lumeng Yang,1 Hong-Qiu Gu,16 Yilong Wang,16,17 Mark Parsons,3 Qiang Dong,1 the CHABLIS-T collaborators

ABSTRACT
Background The performance of intravenous tenecteplase in patients who had an acute ischaemic stroke with large/medium vessel occlusion or severe stenosis in an extended time window remains unknown. We investigated the promise of efficacy and safety of different doses of tenecteplase manufactured in China, in patients who had an acute ischaemic stroke with large/medium vessel occlusion beyond 4.5-hour time window.

Methods The Chinese Acute Tissue-Based imaging selection for Lysis In Stroke-Tenecteplase was an investigator-initiated, umbrella phase IIa, open-label, blinded-endpoint, Simon’s two-stage randomised clinical trial in 13 centres across mainland China. Participants who had salvageable brain tissue on automated perfusion imaging and presented within 4.5–24 hours from time of last seen well were randomised to receive 0.25 mg/kg tenecteplase or 0.32 mg/kg tenecteplase, both with a bolus infusion over 5–10 s. The primary outcome was proportion of patients with promise of efficacy and safety defined as reaching major reperfusion without symptomatic intracranial haemorrhage at 24–48 hours after thrombolysis. Assessors were blinded to treatment allocation. All participants who received tenecteplase were included in the analysis.

Results A total of 86 patients who had an acute ischaemic stroke identified with anterior large/medium vessel occlusion or severe stenosis were included in this study from November 2019 to December 2021. All of the 86 patients enrolled either received 0.25 mg/kg (n=43) or 0.32 mg/kg (n=43) tenecteplase, and were available for primary outcome analysis. Fourteen out of 43 patients in the 0.25 mg/kg tenecteplase group and 10 out of 43 patients in the 0.32 mg/kg tenecteplase group reached the primary outcome, providing promise of efficacy and safety for both doses based on Simon’s two-stage design.

Discussion Among patients with anterior large/medium vessel occlusion and significant penumbra mismatch presented within 4.5–24 hours from time of last seen well, tenecteplase 0.25 mg/kg and 0.32 mg/kg both provided sufficient promise of efficacy and safety.

WHAT IS ALREADY KNOWN ON THIS TOPIC
⇒ Tenecteplase has now been proven to be non-inferior to alteplase, in patients who had an acute ischaemic stroke within the 4.5-hour time window. However, its performance in patients who had an acute stroke with large/medium vessel occlusion or severe stenosis in an extended time window remains unknown.

WHAT THIS STUDY ADDS
⇒ Among patients with anterior large/medium vessel occlusion and significant penumbral mismatch presented within 4.5–24 hours from time of last seen well, tenecteplase 0.25 mg/kg and 0.32 mg/kg both provided sufficient promise of efficacy and safety.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY
⇒ It seems feasible to extend the time window of intravenous tenecteplase thrombolysis to 24 hours after last seen well through perfusion imaging selection.


INTRODUCTION
Thrombolysis with alteplase is limited by its short halftime and low recanalisation rate of large vessel occlusion.1 Tenecteplase—a genetically modified variant of alteplase—has gained increasing interest as an alternative for alteplase over the past decade. This is mainly due to its practical advantages (single bolus, rather than 1-hour infusion) and a number of hypothetical advantages over alteplase, including greater fibrin specificity.2 It has been demonstrated that tenecteplase is non-inferior to alteplase in unselected patients who had an ischaemic stroke,3–5

To cite: Cheng X, Hong L, Churilov L, et al. Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection: the umbrella phase IIa CHABLIS-T randomised clinical trial. Stroke & Vascular Neurology 2024;0. doi:10.1136/svn-2023-002820

Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi.org/10.1136/svn-2023-002820).

Received 4 September 2023
Accepted 14 December 2023

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC: No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to Dr Qiang Dong; qiang_dong163@163.com
and may be superior to alteplase in acute large vessel occlusion. Prior tenecteplase trials have recruited acute ischemic stroke presenting no longer than 6 hours from symptom onset. Thus, the evidence of performance promise design is to determine whether tenecteplase has sufficient safety of various doses of tenecteplase in Chinese patients who had an acute ischemic stroke with large/medium vessel occlusion or severe stenosis in the anterior circulation and a favourable penumbral profile between 4.5 and 24 hours from time of last seen well. The tenecteplase used in the trial was produced and approved for treating acute myocardial infarction in China and has been used in Tenecteplase Reperfusion therapy in Acute ischemic Cerebrovascular Events (TRACE) trials, which had the same terminal amino acid sequence and different production process to the tenecteplase made by Boehringer (Metalysé) and Genentech (TNKase).

**METHODS**

**Study design**

When the trial started, the appropriate dose of tenecteplase in acute stroke, especially in Asian population, was unknown. Moreover, the bioequivalence of tenecteplase produced in China was also unclear. The CHABLIS-T trial adopted a Simon’s two-stage design for individual dose stratum. The purpose of Simon’s two-stage design is to determine whether tenecteplase has sufficient promise against acute stroke with large/medium vessel occlusion or severe stenosis in an extended time window in Chinese patients to warrant further investigation. Under this design, a small group of patients were enrolled in the first stage, and the activation of the second stage depended on a prespecified number of positive responses observed from the first stage. The trial was conducted in 13 centres across mainland China from November 2019 to December 2021.

The protocol and statistical analysis plan are provided in online supplemental file.

**Participants**

Participants were considered eligible if they (1) presented with acute ischemic stroke within 4.5–24 hours from time of last seen well and were aged 18 years or older; (2) had a clinically significant acute neurological deficit measured by the baseline National Institutes of Health Stroke Scale (NIHSS) score; (3) had a prestroke modified Rankin Scale (mRS) 0–2; (4) fulfilled the ‘dual target’ imaging criteria, on baseline multimodal CT imaging.

Participants were identified with anterior circulation large/medium vessel occlusion or severe stenosis (defined as more than 70% narrowing compared with the adjacent vessel calibre), including the extracranial or intracranial internal carotid artery (ICA-IC/EC), first or second segment of the middle cerebral artery (MCA-M1/M2), and first or second segment of the anterior cerebral artery (ACA-A1/A2) on CT angiography. Additionally, a favourable penumbral profile was required on CTP imaging using automated real-time perfusion volumetric software, AutoMIStar (Apollo Medical Imaging Technology, Melbourne, Victoria, Australia). A favourable penumbral profile was a hypoperfusion lesion volume (delay time >3 s) to infarct core volume (relative cerebral blood flow <30%) ratio that was greater than 1.2 with an absolute difference of volume greater than 10 mL, and an ischemic core volume less than 70 mL.

Detailed inclusion and exclusion criteria are listed in online supplemental file.

**Randomisation, intervention and blinding**

Eligible patients were enrolled and randomly assigned in a 1:1 ratio to either dose stratum (0.25 mg/kg, maximum 25 mg, and 0.32 mg/kg, maximum 40 mg) of tenecteplase (Guangzhou Recomgen Biotech Co), as a bolus over 5–10 s and a following 2 mL bolus of saline for injection. Randomisation was performed using permuted blocks through a centralised website by local stroke neurologists. Patients were stratified according to time from last seen well (4.5–12 hours, 12–24 hours) and site of occlusion or severe stenosis (ICA-IC and MCA-M1; ICA-EC, MCA-M2 and ACA). The dosage of tenecteplase was open label to the patients and the clinicians involved in the treatment of participants. Bridging endovascular treatment was performed according to local guidelines. Guideline-based intensive care for patients who had an acute ischaemic stroke with intravenous thrombolysis was recommended for every patient. The investigators involved in the subsequent radiological and clinical evaluation were blinded to the allocation.

**Outcomes**

The primary outcome was a binary composite of efficacy and safety, that is, presence of major reperfusion at the initial catheter angiography or repeated CTP 4–6 hours in the absence of symptomatic intracerebral occlusion. Prior tenecteplase trials have recruited acute ischemic stroke presenting no longer than 6 hours from symptom onset.
haemorrhage (sICH) at 24–48 hours after intravenous tenecteplase. Major reperfusion was defined as the restoration of blood flow of greater than 50% of the involved territory. For patients not transferred to the catheter laboratory after thrombolysis, major reperfusion was considered as the hypoperfusion lesion volume (delay time >3s) of the repeated CTP 4–6 hours decreased to less than 50% of the hypoperfusion lesion volume of the baseline CTP. For patients transferred to the catheter laboratory, major reperfusion was evaluated as a modified Treatment In Cerebral Ischemia (mTICI) score 2b/3 at the initial catheter angiography. SICH was defined according to the European Co-operative Acute Stroke Study-II criteria. The secondary radiological efficacy outcomes included recanalisation and infarct growth. The secondary clinical efficacy outcomes included mRS 0–1, mRS 0–2 and mRS distribution at 90 days, major neurological improvement at 24–48 hours and change in the NIHSS score within 24–48 hours. The secondary radiological safety outcomes included parenchymal haematoma type 2 (PH2), sICH and any ICH at 24–48 hours post-treatment. The secondary clinical safety outcomes included mRS 5–6 at 90 days and systemic bleeding. Additionally, Barthel Index at 90 days was also collected. The details of the secondary outcomes can be found in online supplemental file.

The imaging protocol of multimodal CT at each centre was centrally standardised through careful quality control. All of the imaging results were centrally analysed in a core laboratory. Baseline multimodal CT imaging was reanalysed to make sure that the entry criteria were met. The radiological outcome measurements were evaluated by two independent neuroradiologists, and a third independent rater was consulted in cases of disagreement.

### Sample size calculations

The sample size was calculated based on the results derived from the Tenecteplase vs Alteplase before Endovascular Therapy for Ischemic Stroke (EXTEND-IA TNK) trial, where 22% of patients in the intravenous tenecteplase group and 10% of patients in the intravenous alteplase group reached major reperfusion, and 1% of patients, respectively, in both groups were found to have sICH. To adopt a conservative approach, for each dose stratum within the umbrella design, the null hypothesis was that not more than 10% of patients would achieve a positive primary outcome following the respective dose of tenecteplase, while the alternative hypothesis was that, not less than 25% of patients would achieve a positive primary outcome following the respective dose of tenecteplase. Sample size estimation using Simon’s two-stage design was conducted for each dose stratum, according to which the null hypothesis that the true response rate was 10% was tested against a one-sided alternative. In the first stage, 18 patients were to be accrued. If there were two or fewer positive responses in these 18 patients, the dose stratum was to be stopped. Otherwise, 25 additional patients were to be accrued for a total of 43 patients for each dose stratum. The null hypothesis for each stratum was to be rejected if eight or more positive responses were observed in 43 patients. This design was to yield a type I error rate of 0.05 and a power of 0.8 when the true response rate was 25%. Overall, at least 36 patients were to be enrolled with a maximum enrolment of 86 patients equally distributed between the two dose strata (figure 1).

### Statistical analysis

All participants receiving tenecteplase were included in the analysis. For the analysis of the primary endpoint, as described above, if 8 or more out of the 43 patients reached the primary endpoint within a given stratum, the respective tenecteplase dose could be considered of being sufficient promise in terms of efficacy and safety and as a qualified candidate dose for the subsequent phase IIb trial.

Since the design of this study did not aim to compare the safety and efficacy of the two tenecteplase doses within the umbrella design, the analyses of secondary outcomes were descriptive. Secondary outcomes were described using percentages, mean with standard deviation (SD) and median with interquartile range (IQR as appropriate). Normality was tested using Shapiro-Wilk test.

In order to inform the design and planning for the subsequent phase IIb trial, we also estimated the proportions of participants achieving primary and secondary outcomes in patients without severe stenosis in the two tenecteplase dose strata.

No missing data for baseline information and primary outcome analysis were observed. Although 13.95% of participants had missing data on Barthel Index, its influence was considered to be minimal since it is a secondary outcome and the analyses did not involve a comparison between tenecteplase dose strata.

The statistical analysis was performed on STATA V.15.1 (StataCorp, College Station, Texas, USA).

A data safety monitoring board oversaw the enrolment of the total 86 patients in this trial.

### RESULTS

From 27 November 2019 to 30 September 2021, a total of 2193 patients who had an acute ischaemic stroke presented within 4.5–24 hours from time of last seen well at 13 sites, where 86 patients were randomised and received tenecteplase treatment in this trial. The flow diagram of patient selection is shown in figure 2. The preplanned interim analysis according to Simon’s two-stage design was conducted in December 2020, demonstrating that each tenecteplase dose stratum had three or more patients reaching the primary endpoint, enabling...
progression to stage 2 in both dose strata. Forty-three patients were assigned to each 0.25 mg/kg tenecteplase and 0.32 mg/kg tenecteplase strata, and received corresponding tenecteplase treatment as allocated. The baseline demographic, clinical and imaging characteristics of the two tenecteplase dose strata are listed in table 1.

All of the 86 patients were available for the primary outcome analysis. The primary outcome analysis showed that 14 out of 43 (32.6%, 95% CI 20.2% to 48.0%) patients in the 0.25 mg/kg tenecteplase stratum and 10 out of 43 (23.3%, 95% CI 12.9% to 38.3%) patients in the 0.32 mg/kg tenecteplase stratum reached major reperfusion without sICH after tenecteplase thrombolysis. Additionally, regardless of the occurrence of haemorrhagic events, the numbers of patients achieving major reperfusion were 15 (34.9%, 95% CI 22.1% to 50.3%) and 12 (27.9%, 95% CI 16.5% to 43.2%) in the 0.25 mg/kg and 0.32 mg/kg dose strata, respectively.

Prespecified secondary efficacy and safety outcomes are presented in table 2. Recanalisation was attained in 18 (43.9%, 95% CI 29.5% to 59.4%) patients in both tenecteplase dose strata (with 41 patients available for analysis each arm) post-thrombolysis. Excellent functional outcome (mRS 0–1) was achieved in 12 (27.9%, 95% CI 16.5% to 43.2%) patients in the 0.25 mg/kg tenecteplase stratum and in 21 (48.8%, 95% CI 34.2% to 63.6%) patients in the 0.32 mg/kg tenecteplase stratum at 90 days. sICH occurred in 4 (9.3%, 95% CI 3.5% to 22.6%) patients in the 0.25 mg/kg tenecteplase stratum and in 4 (9.3%, 95% CI 3.5% to 22.6%) in the 0.32 mg/kg tenecteplase stratum. Details of severe adverse events are displayed in online supplemental table 1.

When excluding 13 patients with severe arterial stenosis, the baseline characteristics of the 73 patients with complete artery occlusion are listed in online supplemental table 2. The primary outcome was still achieved in 9 out of 35 (25.7%, 95% CI 13.8% to 42.8%) patients in the 0.25 mg/kg tenecteplase stratum and in 9 out of 38 (23.7%, 95% CI 12.7% to 39.9%) patients in the 0.32 mg/kg tenecteplase stratum. Secondary outcomes in patients with complete artery occlusion of two tenecteplase dose strata are shown in online supplemental table 3. Additionally, the baseline characteristics of the 52 patients without bridging endovascular treatment were listed in online supplemental table 4.

DISCUSSION

In this randomised trial, among 86 patients recruited, 14 out of 43 patients in the 0.25 mg/kg dose stratum and 10 out of 43 patients in the 0.32 mg/kg dose stratum achieved major reperfusion without occurrence of sICH, both surpassing the predefined eight-patient threshold of reaching the primary outcome. Therefore, both
tenecteplase 0.25 mg/kg and tenecteplase 0.32 mg/kg demonstrated sufficient promise of efficacy and safety. CHABLIS-T is also one of the few trials that reported the performance of tenecteplase thrombolysis in the extended time window.

In TRACE Study, three doses of 0.1, 0.25, 0.32 mg/kg tenecteplase were compared with 0.9 mg/kg alteplase in Chinese patients with acute ischaemic stroke within 3 hours from symptom onset, which showed similar safety profiles. However, in another phase IIb trial, two doses of 0.1 and 0.25 mg/kg tenecteplase were compared with alteplase, which showed the higher dose of tenecteplase was superior to the lower dose and to alteplase for all efficacy outcomes. Therefore, we abandoned the lower dose of 0.1 mg/kg tenecteplase, and examined the promise of efficacy and safety in the other higher doses of tenecteplase, that is, 0.25 mg/kg and 0.32 mg/kg.

### Table 1  Baseline characteristics of the patients randomised

<table>
<thead>
<tr>
<th></th>
<th>Tenecteplase 0.25 mg/kg (n=43)</th>
<th>Tenecteplase 0.32 mg/kg (n=43)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>68.3 (13.1)</td>
<td>67.1 (11.5)</td>
</tr>
<tr>
<td>Male sex</td>
<td>25 (58.1%)</td>
<td>31 (72.1%)</td>
</tr>
<tr>
<td>NIHSS score at randomisation</td>
<td>11 (8–15)</td>
<td>9 (6–13)</td>
</tr>
<tr>
<td>Stroke aetiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardioembolism</td>
<td>15 (34.9%)</td>
<td>7 (16.3%)</td>
</tr>
<tr>
<td>Large artery atherosclerosis</td>
<td>20 (46.5%)</td>
<td>28 (65.2%)</td>
</tr>
<tr>
<td>Undetermined aetiology</td>
<td>8 (18.6%)</td>
<td>8 (18.6%)</td>
</tr>
<tr>
<td>Medical history</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>14 (32.6%)</td>
<td>4 (9.3%)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>27 (62.8%)</td>
<td>29 (67.4%)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>12 (27.9%)</td>
<td>16 (37.2%)</td>
</tr>
<tr>
<td>Smoking</td>
<td>15 (34.9%)</td>
<td>25 (58.1%)</td>
</tr>
<tr>
<td>Ischaemic stroke or transient ischaemic attack</td>
<td>6 (14.0%)</td>
<td>5 (11.6%)</td>
</tr>
<tr>
<td>TLSW to randomisation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.5–12 hours</td>
<td>25 (58.1%)</td>
<td>26 (60.5%)</td>
</tr>
<tr>
<td>12-24 hours</td>
<td>18 (41.9%)</td>
<td>17 (39.5%)</td>
</tr>
<tr>
<td>Witnessed stroke</td>
<td>21 (48.8%)</td>
<td>28 (65.1%)</td>
</tr>
<tr>
<td>Transferred to catheter lab</td>
<td>17 (39.5%)</td>
<td>18 (41.9%)</td>
</tr>
<tr>
<td>Underwent endovascular treatment</td>
<td>17 (39.5%)</td>
<td>17 (39.5%)</td>
</tr>
<tr>
<td>TLSW to hospital arrival, min</td>
<td>497 (310–815)</td>
<td>513 (394–632)</td>
</tr>
<tr>
<td>TLSW to initiation of intravenous therapy, min</td>
<td>645 (481–973)</td>
<td>674 (516–808)</td>
</tr>
<tr>
<td>Time from hospital arrival to initiation of intravenous therapy, min</td>
<td>130 (99–159)</td>
<td>140 (111–217)</td>
</tr>
<tr>
<td>Time from initiation of intravenous thrombolysis to initial angiographic assessment, min*</td>
<td>69.0 (45.0–94.5)</td>
<td>62.5 (41.8–93.3)</td>
</tr>
<tr>
<td>Site of artery occlusion or severe stenosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Extracranial segment of intracranial carotid artery</td>
<td>3 (7.0%)</td>
<td>6 (14.0%)</td>
</tr>
<tr>
<td>Intracranial segment of intracranial carotid artery</td>
<td>3 (7.0%)</td>
<td>4 (9.3%)</td>
</tr>
<tr>
<td>First segment of middle cerebral artery</td>
<td>25 (58.1%)</td>
<td>15 (34.9%)</td>
</tr>
<tr>
<td>Second segment of middle cerebral artery</td>
<td>9 (20.9%)</td>
<td>11 (25.6%)</td>
</tr>
<tr>
<td>Anterior cerebral artery</td>
<td>3 (7.0%)</td>
<td>6 (14.0%)</td>
</tr>
<tr>
<td>Tandem occlusion</td>
<td>0 (0.0%)</td>
<td>1 (2.3%)</td>
</tr>
<tr>
<td>Vessel severe stenosis at baseline</td>
<td>8 (18.6%)</td>
<td>5 (11.6%)</td>
</tr>
<tr>
<td>Hypoperfusion lesion volume at baseline, mL</td>
<td>77 (50–114)</td>
<td>76 (46–120)</td>
</tr>
<tr>
<td>Ischaemic core volume at baseline, mL</td>
<td>8 (4–15)</td>
<td>8 (4–19)</td>
</tr>
</tbody>
</table>

Data are mean (SD), n (%), median (IQR).
*Tenecteplase 0.25 mg/kg: n=17; tenecteplase 0.32 mg/kg: n=18.
IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale; SD, standard deviation; TLSW, time from last seen well.
Prompt reperfusion is of great importance for patients who had an acute ischaemic stroke with large vessel occlusion. Previous studies have shown that tenecteplase, as a single bolus administration, could achieve more rapid and substantial reperfusion compared with alteplase.21–23 The recently reported TIMELESS trial (NCT03785678) has also reported a higher rate of recanalisation at 24 hours in the tenecteplase group than the placebo group.17 The current trial showed that both 0.25 mg/kg and 0.32 mg/kg tenecteplase dose groups could reach a substantial reperfusion rate of around 30%, compared with the 20% in the EXTEND-IA TNK trials. One possible explanation is that we included medium vessel occlusion or severe stenosis, which could have higher reperfusion rate treated by tenecteplase. Another possible explanation is that the time window of reperfusion assessment in CHABLIS-T was around 60 min for patients transferred for catheter angiography (similar to EXTEND-IA TNK), and 4–6 hours for patients not transferred (60% of CHABLIS-T participants).7 8 Apart from the time window, the imaging modality of reperfusion assessments may also play a part, since reperfusion status was mainly assessed through repeated perfusion imaging rather than catheter angiography in the CHABLIS-T trial, which was the opposite to the EXTEND-IA TNK trials.7 8 However, reperfusion status assessed through perfusion imaging has been proven to have at least equivalent predictive ability for functional outcome compared with mTICI scores in catheter angiography.24 25

### Table 2 Primary and secondary efficacy and safety outcomes

<table>
<thead>
<tr>
<th></th>
<th>Tenecteplase 0.25 mg/kg (n=43)</th>
<th>Tenecteplase 0.32 mg/kg (n=43)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary outcome</strong>†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(major reperfusion without the occurrence of symptomatic ICH)</td>
<td>14 (32.6%)</td>
<td>10 (23.3%)</td>
</tr>
<tr>
<td><strong>Secondary outcome</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Efficacy</strong></td>
<td>18 (43.9%)</td>
<td>18 (43.9%)</td>
</tr>
<tr>
<td>Recanalisation†</td>
<td>18 (43.9%)</td>
<td>18 (43.9%)</td>
</tr>
<tr>
<td>Infarct growth at 3–5 days, mL‡</td>
<td>23.9 (3.5–55.3)</td>
<td>16.9 (6.7–81.0)</td>
</tr>
<tr>
<td>Major neurological improvement at 24–48 hours§</td>
<td>7 (17.1%)</td>
<td>8 (18.6%)</td>
</tr>
<tr>
<td>Change in NIHSS score at 24–48 hours compared with baseline§</td>
<td>−1.0 (−6.5, 2.0)</td>
<td>0.0 (−3.0, 2.0)</td>
</tr>
<tr>
<td>mRS score 0–1 at 90 days</td>
<td>12 (27.9%)</td>
<td>21 (48.8%)</td>
</tr>
<tr>
<td>mRS score 0–2 at 90 days</td>
<td>20 (46.5%)</td>
<td>26 (60.5%)</td>
</tr>
<tr>
<td>mRS score at 90 days</td>
<td>7 (16.3%)</td>
<td>8 (18.6%)</td>
</tr>
<tr>
<td>0</td>
<td>5 (11.6%)</td>
<td>13 (30.2%)</td>
</tr>
<tr>
<td>1</td>
<td>8 (18.6%)</td>
<td>5 (11.6%)</td>
</tr>
<tr>
<td>2</td>
<td>5 (11.6%)</td>
<td>3 (7.0%)</td>
</tr>
<tr>
<td>3</td>
<td>7 (16.3%)</td>
<td>7 (16.3%)</td>
</tr>
<tr>
<td>4</td>
<td>5 (11.6%)</td>
<td>5 (11.6%)</td>
</tr>
<tr>
<td>5</td>
<td>6 (14.0%)</td>
<td>2 (4.7%)</td>
</tr>
<tr>
<td><strong>Safety</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptomatic ICH</td>
<td>4 (9.3%)</td>
<td>4 (9.3%)</td>
</tr>
<tr>
<td>Any ICH</td>
<td>21 (48.8%)</td>
<td>13 (30.2%)</td>
</tr>
<tr>
<td>Parenchymal haematoma type 2</td>
<td>5 (11.6%)</td>
<td>1 (2.3%)</td>
</tr>
<tr>
<td>mRS score 5–6 at 90 days</td>
<td>11 (25.6%)</td>
<td>7 (16.3%)</td>
</tr>
<tr>
<td>Systematic haemorrhage</td>
<td>3 (7.0%)</td>
<td>1 (2.3%)</td>
</tr>
<tr>
<td>Barthel Index at 90 days¶</td>
<td>95.0 (60.0–100.0)</td>
<td>95.0 (47.5–100.0)</td>
</tr>
</tbody>
</table>

Data are n (%), median (IQR).

*Major reperfusion was assessed at the initial catheter angiography or repeated CTP 4–6 hours and symptomatic ICH was assessed at 24–48 hours after intravenous tenecteplase treatment.
†Tenecteplase 0.25 mg/kg: n=41; tenecteplase 0.32 mg/kg: n=41.
‡Tenecteplase 0.25 mg/kg: n=36; tenecteplase 0.32 mg/kg: n=41.
§Tenecteplase 0.25 mg/kg: n=41.
¶Tenecteplase 0.25 mg/kg: n=33; tenecteplase 0.32 mg/kg: n=41.
CTP, perfusion CT; ICH, intracranial haemorrhage; IQR, interquartile range; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale.
sICH or PH2 in the higher dose stratum. However, the percentages of haemorrhagic transformation (including symptomatic and asymptomatic) in this trial were notably higher than those of randomised controlled trials with patients with large vessel occlusion treated with intravenous thrombolysis. Since the thrombolytic time windows of prior trials range from ≤4.5 hours to ≤9 hours after last seen well, the higher risk of haemorrhagic transformation in this trial can be partly explained by the longer onset-to-reperfusion time. Additionally, though patients in CHABLIS-T have been selected with benign perfusion profiles, they may exhibit risk factors of sICH that could not be detected simply by automatically post-processed perfusion imaging (ie, larger volumes of very low cerebral blood flow), which should be further explored by post-hoc analysis. Despite the higher sICH rates, both doses of 0.25 mg/kg and 0.32 mg/kg tenecteplase appear to be of sufficient promise in patients who had an acute ischaemic stroke with large/medium vessel occlusion or severe stenosis in the extended time window. Though the design of the study was not driven by the direct comparison between 0.25 mg/kg and 0.32 mg/kg tenecteplase, more patients in the 0.25 mg/kg tenecteplase dose stratum reached the primary outcome but failed to achieve 3-month mRS 0–1 or 0–2, compared with patients in the 0.32 mg/kg dose stratum. This discrepancy may be explained by the higher baseline NIHSS, higher prevalence of cardioembolic stroke and higher rate of PH2 in the 0.25 mg/kg dose stratum.

In the CHABLIS-T trial, we included both patients with complete large/medium vessel occlusion as well as those with severe stenosis. The reason why patients with severe stenosis were also eligible for this trial is that a considerable number of acute ischaemic stroke events in East Asian population are due to acute in-situ thrombosis with underlying chronic stenosis resulting from intracranial large artery atherosclerosis. Such patients were also candidates for acute reperfusion therapy and as such excluding patients with severe stenosis would undermine the generalisability of this trial. Notably, when excluding patients with severe stenosis, the primary outcome was still achieved in more than seven patients of each dose stratum in patients with complete artery occlusion.

A novel feature of CHABLIS-T trial was using the umbrella Simon’s two-stage trial design in order to investigate the clinical promise of two doses of tenecteplase. Though not ever applied in stroke previously, Simon’s two-stage design is acknowledged as a simple and effective dose selection method allowing modest sample size, especially in oncology trials.

The study has the following limitations. First of all, the study design did not have an alteplase control group. However, the novel design (for a stroke trial) was aimed for dose finding rather than treatment comparison. Second, the design of this trial does not enable a direct comparison between 0.25 mg/kg and 0.32 mg/kg tenecteplase. With both dose strata reaching the predefined threshold for the primary outcome, both doses can be considered to be of sufficient promise. These results are in accordance with those of EXTEND-IA TNK Part2 trial, where 0.4 mg/kg tenecteplase had similar effect on reperfusion and other outcomes in patients with large vessel occlusions, compared with 0.25 mg/kg tenecteplase.

Third, the sample size of this study was underpowered to make reliable conclusions regarding the effect of tenecteplase on long-term functional outcomes (mRS at 90 days). Further, the primary outcome in this dose-finding study was different from that of phase III trials, making direct comparisons unreliable. However, the imaging composite primary outcome of both efficacy and safety is objective, immediate and straightforward, and more suitable for an adaptive sample size re-estimation early phase II design. Moreover, reperfusion without sICH usually translates to a good functional outcome at 90 days. Fourth, the tenecteplase used in the trial is manufactured locally, which limits its generalisability to other countries. Last but not least, the sample size calculation was based on a trial with shorter thrombolysis-to-reperfusion assessment time, while the reperfusion rate might be higher in CHABLIS-T than the assumed rate. However, the number of patients needed would be smaller than the 86 patients if higher reperfusion rate had been considered. Therefore, CHABLIS-T, with the current sample size, had sufficient power to detect the promise of efficacy and safety of tenecteplase.

In conclusion, among patients with large/medium vessel occlusion or severe stenosis in the anterior circulation and a favourable penumbral profile presenting within 4.5–24 hours from time of last seen well, both tenecteplase 0.25 mg/kg and 0.32 mg/kg doses demonstrated sufficient promise to achieve substantial reperfusion without sICH. Currently, other tenecteplase-related thrombolytic randomised controlled trials in patients with large vessel occlusion, including TIMELESS (NCT03785678), Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients With Large Vessel Occlusion (ETERNAL-LVO, NCT04454788) and TRACE III (NCT05141305), choose 0.25 mg/kg as the experimental tenecteplase dosage. Additionally, Tenecteplase vs alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2) trial failed to demonstrate superiority of 0.40 mg/kg tenecteplase compared with alteplase with a higher risk of bleeding events and worse functional outcomes in moderate and severe stroke. Based on the results of CHABLIS-T, TRACE and other completed tenecteplase-related randomised controlled trials, a subsequent phase IIIb trial, CHinese Acute tissue-Based imaging selection for Lysis In Stroke-Tenecteplase II (CHABLIS-T II) trial, is ongoing to investigate the performance of tenecteplase 0.25 mg/kg in comparison with best medical treatment (NCT04516993). The recent reported TIMELESS trial did not show superiority of tenecteplase in improvement of 3-month outcome though recanalisation rate was improved, which is probably due to the strong clinical benefit of endovascular treatment. Therefore, CHABLIS-T II, together with other ongoing
trials, may help to further explore the optimal clinical setting where the recanalisation benefit of tenecteplase can be maximally translated into clinical benefit.

Author affiliations
1Department of Neurology, National Center for Neurological Disorders, National Clinical Research Centre for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China
2Melbourne Medical School, The Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia
3University of New South Wales South Western Sydney Clinical School, Ingham Institute for Applied Medical Research, Department of Neurology, Liverpool Hospital, Sydney, New South Wales, Australia
4Department of Neurology, the First Hospital of Shanxi Medical University, Taiyuan, China
5Department of Neurology, Shenyang First People’s Hospital, Shenyang Medical University, Shenyang, China
6University of New South Wales South Western Sydney Clinical School, Ingham Institute for Applied Medical Research, Department of Neurology, Liverpool Hospital, Sydney, New South Wales, Australia
7Department of Neurology, the First Hospital of Shanxi Medical University, Taiyuan, China
8Department of Neurology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
9Department of Neurology, Shanghai Fifth People’s Hospital, Fudan University, Shanghai, China
10Department of Neurology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
11Department of Neurology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
12Department of Neurology, Xuzhou Medical University Affiliated Hospital of Huai’an, Huai’an, China
13Department of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
14Department of Neurology, Pu’er People’s Hospital, Pu’er, China
15Department of Neurology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China
16Department of Neurology, Shenyang First People’s Hospital, Shenyang Medical College Affiliated Brain Hospital, Shenyang, China
17Department of Neurology, Shanghai East Hospital, Tongji University, Shanghai, China
18China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Beijing, China
19Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Twitter Hong-Qiu Gu @hqgu and Yilong Wang @yilong

Acknowledgements We thank all the collaborators, patients and their relatives.

Collaborators The CHABLIS-T collaborators are listed in online supplemental file 1.

Contributors XC and DQ take full responsibility for the work and the conduct of the study, have access to the data, and control the decision to publish.XC, QD, YW and MZ contributed to the concept and design, and interpreted the data. LH, LC and H-LP conducted the statistical analyses. XC and DQ acquired funding. XC, LH, LL, LC, YL, LY, YW, GD and QS conducted the laboratory work. XC, LH, LL, LC, LY and YW wrote the methods. XC, LH, LL, LC, LY, LY, YW, MP and GD conducted the project administration. XC, LH, LL, LC, LY, YW, MP and GD wrote the article. XC, LH, LL, LC, YG and YG conducted the data analysis. QC and DQ conducted the data interpretation. XC, LH, LL, LC and DQ drafted the manuscript.

Funding This work was supported by the National Key R&D Program of China (2017YFC1308201), Clinical Research Plan of SHDC (SHDC2020CR10141B) and Shanghai Municipal Key Clinical Specialty (shlczdckz06102). Guangzhou Recomgen Biotech Co supplied the investigational product and the insurance for this trial.

Disclaimer Guangzhou Recomgen Biotech Co has no role in trial design, execution and management.

Competing interests XC reported grant support from the National Natural Science Foundation of China and Science and Technology Commission of Shanghai Municipality. YS reported honoraria from Boehringer Ingelheim (China) Investment Co. The other authors report no competing interests.

Patient consent for publication Obtained.

Ethics approval This study involves human participants and was approved by the Ethics Committee of Huashan Hospital, Fudan University (2019/474). Written informed consent was acquired from all the eligible patients or their legal proxies before randomisation.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. Readers should contact the corresponding author (at qiang_dong163@163.com) if they wish to enquire about data sharing.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Xin Cheng http://orcid.org/0000-0001-7816-0547
Dan Hong http://orcid.org/0000-0002-4002-4627
Huangxi Zhou http://orcid.org/0000-0002-3947-1788
Yi Su http://orcid.org/0000-0002-2898-7877
Gang Li http://orcid.org/0000-0003-1009-2124
Hong-Qiu Gu http://orcid.org/0000-0003-1688-1856
Yilong Wang http://orcid.org/0000-0002-3267-0039

REFERENCES


Supplementary Material

Catalogue

Supplementary Tables ................................................................. 2
Enrolling Sites and collaborators ................................................ 11
Protocol v1.0 .............................................................................. 14
Protocol v2.0 .............................................................................. 40
Protocol v3.0 .............................................................................. 66
Summary of protocol amendments ............................................. 92
Statistical Analysis Plan ................................................................. 94
# Supplementary Tables

cTable 1 Reported serious adverse events including deaths

<table>
<thead>
<tr>
<th>SAE #</th>
<th>Age</th>
<th>Sex</th>
<th>Event description</th>
<th>Category</th>
<th>Causality</th>
<th>SAE #</th>
<th>Age</th>
<th>Sex</th>
<th>Event description</th>
<th>Category</th>
<th>Causality</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>73</td>
<td>Male</td>
<td>Intracranial hemorrhage transformation</td>
<td>Death</td>
<td>Possibly not related</td>
<td>16</td>
<td>76</td>
<td>Male</td>
<td>Left hemiparalysis</td>
<td>Significant disability</td>
<td>Not related</td>
</tr>
<tr>
<td>2</td>
<td>84</td>
<td>Male</td>
<td>Death</td>
<td>Death</td>
<td>Possibly not related</td>
<td>17</td>
<td>75</td>
<td>Male</td>
<td>Aspiration pneumonia</td>
<td>Prolongation of hospitalization</td>
<td>Possibly not related</td>
</tr>
<tr>
<td>3</td>
<td>57</td>
<td>Female</td>
<td>Left hemiparalysis</td>
<td>Significant disability</td>
<td>Not related</td>
<td>18</td>
<td>68</td>
<td>Male</td>
<td>Right hemiparalysis</td>
<td>Significant disability</td>
<td>Not related</td>
</tr>
<tr>
<td>4</td>
<td>76</td>
<td>Male</td>
<td>Intracranial hemorrhage transformation</td>
<td>Death</td>
<td>Related</td>
<td>19</td>
<td>69</td>
<td>Male</td>
<td>Left hemiparalysis</td>
<td>Significant disability</td>
<td>Possibly not related</td>
</tr>
<tr>
<td>5</td>
<td>74</td>
<td>Female</td>
<td>Hemorrhagic transformation</td>
<td>Prolongation of hospitalization</td>
<td>Possibly not related</td>
<td>20</td>
<td>73</td>
<td>Female</td>
<td>Right hemiparalysis</td>
<td>Significant disability</td>
<td>Not related</td>
</tr>
<tr>
<td>No.</td>
<td>Age</td>
<td>Gender</td>
<td>Diagnosis</td>
<td>Event</td>
<td>Duration</td>
<td>Cause</td>
<td>Relationship</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----</td>
<td>-----</td>
<td>--------</td>
<td>-----------------------------------------------</td>
<td>-------------------------------</td>
<td>----------</td>
<td>---------------------------------</td>
<td>------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>74</td>
<td>Female</td>
<td>Pleural Effusion</td>
<td>Prolongation of hospitalization</td>
<td>Possibly not related</td>
<td>Right hemiparesis</td>
<td>Possibly not related</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>86</td>
<td>Male</td>
<td>Respiratory Failure</td>
<td>Death</td>
<td>Possibly not related</td>
<td>Septic shock</td>
<td>Possibly not related</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>68</td>
<td>Female</td>
<td>Left hemiparesis</td>
<td>Significant disability</td>
<td>Possibly not related</td>
<td>Venous thrombus embolism in left lower limb</td>
<td>Related</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>66</td>
<td>Male</td>
<td>Left hemiparesis</td>
<td>Significant disability</td>
<td>Not related</td>
<td>Parenchymal hematoma with intraventricular extension</td>
<td>Related</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>75</td>
<td>Female</td>
<td>Left hemiparesis</td>
<td>Significant disability</td>
<td>Not related</td>
<td>Parenchymal hematoma with intraventricular extension</td>
<td>Related</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>61</td>
<td>Male</td>
<td>Right hemiparesis</td>
<td>Significant disability</td>
<td>Not related</td>
<td>Hemorrhagic transformation</td>
<td>Related</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>58</td>
<td>Female</td>
<td>Large infarct volume with brain edema</td>
<td>Not related</td>
<td></td>
<td>Venous thrombus embolism in left lower limb</td>
<td>Not related</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>73</td>
<td>Male</td>
<td>Atrial fibrillation</td>
<td>Prolongation of hospitalization</td>
<td>Not related</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Case</td>
<td>Age</td>
<td>Gender</td>
<td>Condition</td>
<td>Severity</td>
<td>Relationship</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>-----</td>
<td>--------</td>
<td>----------------------------</td>
<td>----------</td>
<td>--------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>66</td>
<td>Male</td>
<td>Right hemiparesis</td>
<td>Significant disability</td>
<td>Not related</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>66</td>
<td>Male</td>
<td>Respiratory Failure</td>
<td>Death</td>
<td>Possibly not related</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: SAE Serious adverse events
**Table 2** Baseline characteristics of patients with complete artery occlusion

<table>
<thead>
<tr>
<th></th>
<th>Tenecteplase 0.25mg/kg (n=35)</th>
<th>Tenecteplase 0.32mg/kg (n=38)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), y</td>
<td>67.5 (13.8)</td>
<td>66.3 (11.4)</td>
</tr>
<tr>
<td>Male sex, No. (%)</td>
<td>19 (54.3%)</td>
<td>29 (76.3%)</td>
</tr>
<tr>
<td>NIHSS score at randomization, median (IQR)</td>
<td>12.0 (10.0, 16.0)</td>
<td>9.0 (5.8, 13.0)</td>
</tr>
<tr>
<td>Stroke etiology, No. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardio-embolism</td>
<td>13 (37.1%)</td>
<td>6 (15.8%)</td>
</tr>
<tr>
<td>Large artery atherosclerosis</td>
<td>15 (42.9%)</td>
<td>25 (65.8%)</td>
</tr>
<tr>
<td>Undetermined etiology</td>
<td>7 (20.0%)</td>
<td>7 (18.4%)</td>
</tr>
<tr>
<td>Medical history, No. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>12 (34.3%)</td>
<td>3 (7.9%)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>21 (60.0%)</td>
<td>24 (63.2%)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>10 (28.6%)</td>
<td>13 (34.2%)</td>
</tr>
<tr>
<td>Smoking</td>
<td>12 (34.3%)</td>
<td>23 (60.5%)</td>
</tr>
<tr>
<td>Ischemic stroke or transient ischemic attack</td>
<td>6 (17.1%)</td>
<td>5 (13.2%)</td>
</tr>
<tr>
<td>TLSW to randomization, No. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.5-12h</td>
<td>22 (62.9%)</td>
<td>24 (63.2%)</td>
</tr>
<tr>
<td>12-24h</td>
<td>13 (37.1%)</td>
<td>14 (36.8%)</td>
</tr>
<tr>
<td>Witnessed stroke, No. (%)</td>
<td>17 (48.6%)</td>
<td>25 (65.8%)</td>
</tr>
<tr>
<td>Transferred to catheter room, No. (%)</td>
<td>16 (45.7%)</td>
<td>16 (42.1%)</td>
</tr>
<tr>
<td>Underwent endovascular treatment, No. (%)</td>
<td>16 (45.7%)</td>
<td>15 (39.5%)</td>
</tr>
<tr>
<td>TLSW to hospital arrival, median (IQR), min</td>
<td>447.0 (273.0, 764.0)</td>
<td>513.5 (381.0, 636.8)</td>
</tr>
<tr>
<td>TLSW to initiation of intravenous therapy, median (IQR), min</td>
<td>627.0 (470.0, 888.0)</td>
<td>667.5 (546.0, 791.0)</td>
</tr>
<tr>
<td>Time from hospital arrival to initiation of intravenous therapy, median (IQR), min</td>
<td>123.0 (93.0, 156.0)</td>
<td>138.0 (109.8, 190.5)</td>
</tr>
<tr>
<td>Time from initiation of intravenous thrombolysis to initial angiographic assessment, median (IQR), min*</td>
<td>65.0 (45.0, 80.8)</td>
<td>59.5 (41.3, 74.5)</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Site of artery occlusion, No. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Extracranial segment of intracranial carotid artery</td>
<td>3 (8.6%)</td>
<td>6 (15.8%)</td>
</tr>
<tr>
<td>Intracranial segment of intracranial carotid artery</td>
<td>3 (8.6%)</td>
<td>3 (7.9%)</td>
</tr>
<tr>
<td>First segment of middle cerebral artery</td>
<td>20 (57.1%)</td>
<td>14 (36.8%)</td>
</tr>
<tr>
<td>Second segment of middle cerebral artery</td>
<td>6 (17.1%)</td>
<td>8 (21.1%)</td>
</tr>
<tr>
<td>Anterior cerebral artery</td>
<td>3 (8.6%)</td>
<td>6 (15.8%)</td>
</tr>
<tr>
<td>Tandem occlusion</td>
<td>0 (0.0%)</td>
<td>1 (2.6%)</td>
</tr>
<tr>
<td>Hypoperfusion lesion volume at baseline, median (IQR), ml</td>
<td>79.0 (48.0, 104.0)</td>
<td>82.0 (49.8, 121.0)</td>
</tr>
<tr>
<td>Ischemic core volume at baseline, median (IQR), ml</td>
<td>9.0 (5.0, 16.0)</td>
<td>8.5 (5.8, 20.5)</td>
</tr>
</tbody>
</table>

* Tenecteplase 0.25mg/kg: n=16; Tenecteplase 0.32mg/kg: n=16

Abbreviations: SD=standard deviation; IQR=interquartile range; TLSW=time from last-seen-well
Table 3 Exploratory analysis of primary and secondary efficacy and safety outcomes in patients with complete artery occlusion

<table>
<thead>
<tr>
<th></th>
<th>Tenecteplase 0.25mg/kg (n=35)</th>
<th>Tenecteplase 0.32mg/kg (n=38)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary outcome</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recanalization^a</td>
<td>12 (36.4%)</td>
<td>15 (41.7%)</td>
</tr>
<tr>
<td>Infarct growth at 3-5 days, mL^b</td>
<td>25.9 (11.4, 68.7)</td>
<td>23.7 (7.3, 91.1)</td>
</tr>
<tr>
<td><strong>Secondary Outcome</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Efficacy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Major Neurological Improvement at 24-48 hours^c</td>
<td>4 (12.1%)</td>
<td>7 (18.4%)</td>
</tr>
<tr>
<td>Change in NIHSS score at 24-48 hours compared with baseline^c</td>
<td>0.0 (-6.5, 2.5)</td>
<td>0.0 (-3.0, 3.3)</td>
</tr>
<tr>
<td>mRS score 0-1 at 90 days</td>
<td>8 (22.9%)</td>
<td>17 (44.7%)</td>
</tr>
<tr>
<td>mRS score 0-2 at 90 days</td>
<td>14 (40.0%)</td>
<td>22 (57.9%)</td>
</tr>
<tr>
<td>mRS score at 90 days</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>4 (11.4%)</td>
<td>7 (18.4%)</td>
</tr>
<tr>
<td>1</td>
<td>4 (11.4%)</td>
<td>10 (26.3%)</td>
</tr>
<tr>
<td>2</td>
<td>6 (17.1%)</td>
<td>5 (13.2%)</td>
</tr>
<tr>
<td>3</td>
<td>4 (11.4%)</td>
<td>3 (7.9%)</td>
</tr>
<tr>
<td>4</td>
<td>6 (17.1%)</td>
<td>6 (15.8%)</td>
</tr>
<tr>
<td>5</td>
<td>5 (14.3%)</td>
<td>5 (13.2%)</td>
</tr>
<tr>
<td>6</td>
<td>6 (17.1%)</td>
<td>2 (5.3%)</td>
</tr>
<tr>
<td><strong>Safety</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptomatic intracranial haemorrhage</td>
<td>4 (11.4%)</td>
<td>4 (10.5%)</td>
</tr>
<tr>
<td>Any intracranial haemorrhage</td>
<td>18 (51.4%)</td>
<td>12 (31.6%)</td>
</tr>
<tr>
<td>Parenchymal haemorrhage type 2</td>
<td>5 (14.3%)</td>
<td>1 (2.6%)</td>
</tr>
<tr>
<td>mRS score 5-6 at 90 days</td>
<td>11 (31.4%)</td>
<td>7 (18.4%)</td>
</tr>
</tbody>
</table>

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s).
<table>
<thead>
<tr>
<th>Systematic Haemorrhage</th>
<th>3 (8.6%)</th>
<th>1 (2.6%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barthel Index at 90 days$^d$</td>
<td>100.0 (50.0, 100.0)</td>
<td>95 (52.5, 100.0)</td>
</tr>
</tbody>
</table>

Data are n (%), median (IQR).

$^a$ tenecteplase 0.25mg/kg: n=33; tenecteplase 0.32mg/kg: n=36

$^b$ tenecteplase 0.25mg/kg: n=29; tenecteplase 0.32mg/kg: n=36

$^c$ tenecteplase 0.25mg/kg: n=33

$^d$ tenecteplase 0.25mg/kg: n=25; tenecteplase 0.32mg/kg: n=36
<table>
<thead>
<tr>
<th></th>
<th>Tenecteplase 0.25mg/kg (n=26)</th>
<th>Tenecteplase 0.32mg/kg (n=26)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age, mean (SD), y</strong></td>
<td>70.4 (11.0)</td>
<td>67.0 (13.0)</td>
</tr>
<tr>
<td><strong>Male sex, No. (%)</strong></td>
<td>15 (57.7%)</td>
<td>19 (73.1%)</td>
</tr>
<tr>
<td><strong>NIHSS score at randomization, median (IQR)</strong></td>
<td>10.5 (7.8, 16.0)</td>
<td>8.0 (4.0, 10.8)</td>
</tr>
<tr>
<td><strong>Stroke etiology, No. (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardio-embolism</td>
<td>10 (38.5%)</td>
<td>5 (19.2%)</td>
</tr>
<tr>
<td>Large artery atherosclerosis</td>
<td>12 (46.2%)</td>
<td>15 (57.7%)</td>
</tr>
<tr>
<td>Undetermined etiology</td>
<td>4 (15.4%)</td>
<td>6 (23.1%)</td>
</tr>
<tr>
<td><strong>Medical history, No. (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>10 (38.5%)</td>
<td>3 (11.5%)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>17 (65.4%)</td>
<td>18 (69.2%)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>9 (34.6%)</td>
<td>9 (34.6%)</td>
</tr>
<tr>
<td>Smoking</td>
<td>9 (34.6%)</td>
<td>15 (57.7%)</td>
</tr>
<tr>
<td>Ischemic stroke or transient ischemic attack</td>
<td>4 (15.4%)</td>
<td>3 (11.5%)</td>
</tr>
<tr>
<td><strong>TLSW to randomization, No. (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.5-12h</td>
<td>15 (57.7%)</td>
<td>14 (53.9%)</td>
</tr>
<tr>
<td>12-24h</td>
<td>11 (42.3%)</td>
<td>12 (46.2%)</td>
</tr>
<tr>
<td><strong>Witnessed stroke, No. (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transferred to catheter room, No. (%)</td>
<td>0 (0.0%)</td>
<td>1 (3.9%)</td>
</tr>
<tr>
<td><strong>TLSW to hospital arrival, median (IQR), min</strong></td>
<td>491.0 (272.8, 796.3)</td>
<td>528.0 (403.5, 637.5)</td>
</tr>
<tr>
<td><strong>TLSW to initiation of intravenous therapy, median (IQR), min</strong></td>
<td>652.5 (459.0, 979.8)</td>
<td>730.0 (596.8, 817.0)</td>
</tr>
<tr>
<td><strong>Time from hospital arrival to initiation of intravenous therapy, median (IQR), min</strong></td>
<td>153.5 (109.5, 189.8)</td>
<td>153.0 (117.8, 238.3)</td>
</tr>
<tr>
<td><strong>Site of artery occlusion, No. (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Extracranial segment of intracranial carotid artery</td>
<td>2 (7.7%)</td>
<td>5 (19.2%)</td>
</tr>
<tr>
<td>Location Description</td>
<td>Count</td>
<td>Percentage</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-------</td>
<td>------------</td>
</tr>
<tr>
<td>Intracranial segment of intracranial carotid artery</td>
<td>1 (3.9%)</td>
<td>1 (3.9%)</td>
</tr>
<tr>
<td>First segment of middle cerebral artery</td>
<td>12 (46.2%)</td>
<td>6 (23.1%)</td>
</tr>
<tr>
<td>Second segment of middle cerebral artery</td>
<td>8 (30.8%)</td>
<td>7 (26.9%)</td>
</tr>
<tr>
<td>Anterior cerebral artery</td>
<td>3 (11.5%)</td>
<td>6 (23.1%)</td>
</tr>
<tr>
<td>Tandem occlusion</td>
<td>0 (0.0%)</td>
<td>1 (3.9%)</td>
</tr>
</tbody>
</table>

**Hypoperfusion lesion volume at baseline, median (IQR), ml**

<table>
<thead>
<tr>
<th></th>
<th>Count 1</th>
<th>Count 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>60.5 (46.0, 106.5)</td>
<td>64.0 (41.0, 112.5)</td>
<td></td>
</tr>
</tbody>
</table>

**Ischemic core volume at baseline, median (IQR), ml**

<table>
<thead>
<tr>
<th></th>
<th>Count 1</th>
<th>Count 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.5 (4.0, 16.0)</td>
<td>7.5 (3.5, 16.3)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: SD=standard deviation; IQR=interquartile range; TLSW=time from last-seen-well
Enrolling Sites and collaborators

Trial steering committee: Qiang Dong (Principal Investigator), Mark Parsons, Xin Cheng, Leonid Churilov, Yilong Wang

Trial management group: Renyu Liu (Senior trial manager), Jiali Xu (trial manager), Longting Lin (imaging manager), Nali Shi (data manager), Lan Hong, Lumeng Yang, Cheng Liu, Hongqiu Gu (statistician)

Data & Safety Monitoring Board: Anding Xu (chair), Bo Song, Huisheng Chen

Brain imaging assessors: Longting Lin, Yifeng Ling

Clinical research associates, Clinical research coordinators

Funders: National Key Research and Development Program of China (2017YFC1308201), Ministry of Science and Technology, China; Clinical Research Plan of Shanghai Hospital Development Center (SHDC2020CR1041B)

Enrolling Sites

Huashan Hospital, Fudan University, Shanghai, China

Site PI: Qiang Dong

Other Site Investigators: Xin Cheng, Wenjie Cao, Kun Fang, Yi Dong, Liang Ge, Yifeng Ling, Lumeng Yang, Lan Hong

Participants Enrolled: 23

The First Hospital of Shanxi Medical University, Taiyuan, China

Site PI: Jin Zhang

Other Site Investigators: Zuopeng Li, Dongtian Wang, Ling Li, Yating Zhang, Jie Miao, Shaoshuai Wang

Participants Enrolled: 16

Ningbo First Hospital, Ningbo, Zhejiang Province, China

Site PI: Jianhong Yang

Other Site Investigators: Yidong Zhou, Yuefei Wu, Yueshi Huang
Participants Enrolled: 10

Zhejiang Provincial People’s Hospital, Hangzhou, Zhejiang Province, China
Site PI: Yu Geng
Other Site Investigators: Gaoping Lin, Yongmei Fan, Sheng Zhang, Yanqi Shao, Yichu Du, Bo Jin, Fang Liu, Mei Liu

Participants Enrolled: 10

Shanghai Fifth People’s Hospital, Fudan University, Shanghai, China
Site PI: Danhong Wu
Other Site Investigators: Wenpeng Wu, Liwei Shen, Weijie Chen

Participants Enrolled: 6

Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China
Site PI: Xueyuan Liu
Other Site Investigators: Xiaoyu Zhou, Quanbin Zhang, You Lu, Xiang Zhang, Yi Xu, Yongju Shen, Li Li

Participants Enrolled: 5

Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China
Site PI: Yuwu Zhao
Other Site Investigators: Feng Wang, Jiangshan Deng, Yueqi Zhu, Jingjiong Chen, Jingyan Xiang, Jiguo Yao, Yajun Zhou, Hongmei Wang, Feng Chen

Participants Enrolled: 4

Xuzhou Medical University Affiliated Hospital of Huaian, Huai’an, Jiangsu Province, China
Site PI: Liandong Zhao
Other Site Investigators: Qijin Zhai, Qianyu Wang, Luxia Yan

Participants Enrolled: 3
The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
Site PI: Yangmei Chen
Other Site Investigators: Xiong Zhang
Participants Enrolled: 3

Pu'er people's Hospital, Pu'er, Yunnan Province, China
Site PI: Ying Guo
Other Site Investigators: Dongxue Li
Participants Enrolled: 2

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China
Site PI: Xiaofei Yu
Other Site Investigators: Fan Gong
Participants Enrolled: 2

Shenyang First People's Hospital, Shenyang Medical College Affiliated Brain Hospital, Shenyang Brain Institute, Shenyang, Liaoning Province, China
Site PI: Yi Sui
Participants Enrolled: 1
CHinese Acute tissue-Based imaging selection for Lysis In Stroke -Tenecteplase (CHABLIS-T)

Protocol

Research Team: Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China

Principle Investigator: Qiang Dong, MD, PhD, Professor of Neurology

Protocol Version: 1.0

Sept. 2019
Catalogue

Protocol Summary ........................................................................................................................................... 16

1. Introduction ................................................................................................................................................. 19

2. Study Objective ........................................................................................................................................... 20

3. Study Design ............................................................................................................................................... 20

4. Patient Population .................................................................................................................................. 21

5. Subject withdrawal, removal and study termination ..................................................................................... 22

6. Sample size calculation .............................................................................................................................. 23

7. Treatment intervention .............................................................................................................................. 23

8. Radiological and clinical assessment .......................................................................................................... 25

9. Adverse Events (AEs) and Severe Adverse Events (SAEs) ........................................................................... 26

10. Study Plan .................................................................................................................................................. 27

11. Data analysis and statistical consideration ............................................................................................. 31

12. Ethical and regulatory standards .............................................................................................................. 32

13. Study monitoring ...................................................................................................................................... 33

14. Funding ...................................................................................................................................................... 35

15. Study Organization ................................................................................................................................. 36

16. References .................................................................................................................................................. 36

Table 1 Study Visits in CHABLIS-T .................................................................................................................. 39
# Protocol Summary

<table>
<thead>
<tr>
<th>Protocol Title</th>
<th>CHABLIS-T: CHinese Acute tissue-Based imaging selection for Lysis In Stroke - Tenecteplase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protocol Number</td>
<td>KY2019-474</td>
</tr>
<tr>
<td>Development Phase</td>
<td>Phase 2a</td>
</tr>
<tr>
<td>Study Population</td>
<td>Acute ischemic stroke patients with large/medium vessel occlusion or severe stenosis presented within 4.5 to 24 hours from last known well, with penumbral mismatch identified by multimodal CT.</td>
</tr>
<tr>
<td>Study Objective</td>
<td>To explore the promise of efficacy and safety of different doses of tenecteplase (0.25mg/kg vs. 0.32mg/kg) in Chinese acute ischemic stroke patients with large/medium vessel occlusion or severe stenosis in an extended time window.</td>
</tr>
<tr>
<td>Trial Design</td>
<td>The CHABLIS-T trial is a phase IIa, randomized, multicenter, open-label, blinded-endpoint, Simon’s two-stage, umbrella design study. Eligible patients will be enrolled and 1:1 randomized into 2 dose group (0.25mg/kg and 0.32mg/kg) of tenecteplase (Guangzhou Recomgen Biotech Co., Ltd). An interim analysis will be conducted when each treatment arm recruits 18 patients. If three or more patients achieve the primary endpoint in either arm, then the study would continue to the 2nd stage, which would enroll an addition of 25 patients in that tenecteplase dose group (resulting in a total of 43 patients in that dose group), otherwise the dose group would be stopped. The intervention dose would be deemed to be of sufficient promise if 8 or more out of 43 patients achieved the primary outcome.</td>
</tr>
</tbody>
</table>
| Inclusion criteria | 1. Patients presenting with acute ischemic stroke within 4.5-24 hours from time last known well  
2. Patients’ age ≥ 18 years  
3. Premorbid modified Rankin Scale 0-2  
4. Clinically significant acute neurologic deficit (with no lower or upper limit of the National Institutes of Health Stroke Scale [NIHSS] score) at the discretion of the investigator  
5. Anterior large/medium vessel occlusion or severe stenosis (>70% of the vessel caliber), including extracranial or intracranial ICA, M1 or M2 segment of MCA, and A1 or A2 segment of ACA, identified on head and neck CTA  
6. Penumbral mismatch on CTP: Hypoperfusion lesion volume (Delay time[DT]> 3 s) to infarct core volume ratio (relative cerebral blood flow [rCBF]<30%) > 1.2, an absolute difference of volume > 10 ml, and an ischemic core volume < 70ml  
7. Patient/Legally Authorized Representative has signed the Informed Consent form. |
### Exclusion criteria

1. Extensive hypoattenuation region (more than 1/3 of the MCA territory) identified on baseline non-contrast CT (NCCT)
2. Any sign of an acute intracranial hemorrhage or subarachnoid hemorrhage identified on baseline NCCT
3. Previous ischemic stroke within 3 months
4. Past history of intracranial hemorrhage
5. Acute head trauma at presentation or recent major head trauma within 3 months
6. Recent history of intracranial/intraspinal surgery within 3 months
7. Gastrointestinal malignancy or gastrointestinal bleed within 21 days
8. Known bleeding diatheses: platelets count <100,000/mm$^3$, INR >1.7, APTT >40 s, or PT >15 s
9. Use of a full dosage of low-molecular weighted heparin treatment within the previous 24 hours
10. Use of direct thrombin inhibitors or direct factor Xa inhibitors within the previous 48 hours unless the laboratory test of coagulation function is normal
11. Symptoms consistent with infective endocarditis
12. Known or suspected with aortic arch dissection
13. Presence of an intra-axial intracranial neoplasm

In addition to:

1. Rapidly improving symptoms at the discretion of the investigator, which may indicate spontaneous recanalization
2. Contraindications for CT contrast precluding a CT angiography or perfusion study.
3. Pregnancy or breastfeeding
4. Recent Participation in another investigational drug or device study or registry in the past 30 days
5. Allergy to the test drug and its ingredients
6. Any terminal illness such that the patient would not be expected to survive more than three months
7. Other conditions in which investigators believe that participating in this study may be harmful to the patient

### Investigational drug

**Intravenous tenecteplase**

### Interventions

Patients were randomized in a 1:1 ratio into 2 tenecteplase dose groups, 0.25mg/kg and 0.32 mg/kg. Randomization was performed using permuted blocks through a centralized website. Patients were stratified according to time of randomization after last known well (4.5-12 hours, 12-24 hours) and site of occlusion/severe stenosis (ICA-IC and MCA-M1; ICA-EC, MCA-M2 and ACA).

Patients received either dose of intravenous tenecteplase (0.25mg/kg, maximum 25 mg, or 0.32mg/kg, maximum 40mg) as a bolus over 5-10s and a following 2 mL bolus of saline for injection.

### Study outcome

**Primary outcome**

The primary outcome is a binary composite of efficacy and safety, i.e. major reperfusion and absence of sICH at 24-48 hours after intravenous tenecteplase.

**Secondary outcomes**
1. Secondary radiological efficacy outcomes:
   1) Recanalization defined by the Thrombolysis in Myocardial Infarction (TIMI) scale of 2/3 at
      the 4- to 6- hour CTA (reconstructed from CTP) for patients not transferred to the catheter
      room, or at the first digital subtraction angiography run prior to thrombectomy for patients
      transferred to the catheter room after thrombolysis
2. Secondary clinical efficacy outcomes
   1) Excellent functional outcome (mRS 0-1) at 90 days
   2) Good functional outcome (mRS 0-2) at 90 days
   3) mRS distribution at 90 days
   4) Neurological improvement at 24-48 hours (NIHSS 0-1 or a NIHSS-improvement of ≥8)
   5) Change in NIHSS as a continuous variable at 24-48 hours
3. Secondary radiological safety outcomes
   1) Type 2 parenchymal hematoma at 24-48 hours
   2) sICH according to the ECASS II criteria at 24-48 hours
   3) Any intracranial hemorrhagic transformation at 24-48 hours post-treatment
4. Secondary clinical safety outcomes
   1) Poor functional outcome (mRS 5-6) at 90 days
   2) Systemic bleeding defined by The Global Utilization of Streptokinase and Tissue
      Plasminogen Activator for Occluded Coronary Arteries before discharge
5. Others:
   Barthel Index at 90 days

Primary analysis

For the analysis of the primary endpoint, if more than 2 out of the 18 patients in the first stage
of either dosage group reach the primary endpoint, then another additive 25 patients will be
enrolled in that group. If more than 7 out of the 43 patients reach the primary endpoint after the
second stage, then the tenecteplase dosage could be considered as a qualified candidate dosage for
a phase IIb trial.

Secondary outcomes will be described using percentages, mean and standard deviation, median
and interquartile range (IQR) as appropriate. Normality will be tested using the Shapiro-Wilk test.
1. Introduction

Intravenous thrombolysis using alteplase is recommended as the first-line therapy for acute ischemic stroke (AIS) patients presented within 4.5 hours after stroke onset. However, only a very limited number of patients are able to receive the treatment due to its short treatment time window. A comparison study based on the data of China National Stroke Registry (CNSR) and the American Heart Association Get With The Guidelines Stroke Program (GWTG-Stroke Program) has shown that only 2.5% patients in CNSR and 8.1% patients in the GWTG-Stroke Program received intravenous thrombolytic therapy. Therefore, extending the treatment time window for AIS patients has become a hot research topic of clinical trials recently. Additionally, because alteplase acquires 1-hour continuous infusion after bolus and its efficacy can be undermined by any infusion delay and interruption, the necessity for alteplase in patients with large vessel occlusion has been questioned since the effect of endovascular treatment has been validated and acknowledged.

Existence of penumbral mismatch (substantial volume of tissue to salvage) is of great importance to the effect of reperfusion therapy. Recent randomized controlled trials (RCTs) using perfusion imaging to select patients with penumbral mismatch have demonstrated that intravenous thrombolysis may also be beneficial for AIS patients in an extend time window beyond 4.5 hours.

Tenecteplase (TNK) is a mutant variant of alteplase with a longer half-time life and higher fibrin specificity. TNK currently is recommended as the first-line intravenous medication for myocardial infarction with a dose of 0.5mg/kg, and its safety and efficacy in acute ischemic stroke patients have long been studied. The meta-analysis of the 5 RCTs (Haley et al., Australian TNK, ATTEST, NOR-TEST, EXTEND-IA TNK) comparing the effect of TNK and alteplase reveals that though the imaging selection criteria and treatment time window for each trial differ, the dose of 0.25mg/kg and 0.4 mg/kg TNK are non-inferior to alteplase in AIS patients (the noninferiority test of 0.1mg/kg TNK was underpowered due to limited sample size).

Furthermore, pooled analyses using data of Australian TNK and ATTEST show that TNK may have superior recanalization efficacy in patients with complete large vessel occlusion to alteplase, especially in patients with penumbral mismatch on perfusion imaging. EXTEND-IA TNK has proven that for anterior circulation stroke patients with large vessel occlusion and perfusion mismatch, TNK could lead to a significantly higher rate of major reperfusion preceding endovascular treatment and better functional outcome, compared with alteplase in the 4.5-hour time window (rate of major of reperfusion: TNK 22% vs. alteplase 10%; median [IQR] mRS at 90 days: TNK 2[0-3] vs. alteplase 3[1-4]). These previous results implicate that based on the noninferiority of TNK to alteplase in AIS patients without advanced imaging selection, the superiority of TNK to alteplase may emerge in large vessel occlusion patients with perfusion mismatch.

Endovascular treatment has become a routine practice for the treatment of AIS patients with large vessel occlusion, and its time window has been extended to 24 hours after last known normal through advanced imaging selection. However, Chinese LVO patients have been faced with the challenge of a longer reperfusion time compared with the Western population. One of the main reasons may relate to the high prevalence of in-situ thrombosis due to intracranial atherosclerotic disease (ICAD) in Asian patients with acute LVO, which is refractory to the...
current stent retrievers or aspiration systems\(^2\). Additionally, the number of comprehensive stroke centers with capability of endovascular treatment is still insufficient given the broad landscape of China, and the drip-and-ship transfer system is still under-developed. Therefore, TNK can be a great candidate for reperfusion therapy considering its performance in large/medium vessel occlusion patients to extend the time window of intravenous thrombolysis, improving the clinical outcome of Chinese AIS patients with large/medium vessel occlusion.

The doses of TNK tested in the previous RCTs in acute ischemic stroke patients are generally 0.1mg/kg, 0.25mg/kg and 0.4mg/kg. Tenecteplase has been approved for the intravenous thrombolysis in myocardial infarction by China Food and Drug Administration (CFDA). The tenecteplase dose proven to be safe during the dose escalation study in Chinese myocardial infarction patients ranges from 0.08mg/kg to 0.32mg/kg. However, the optimal dose of tenecteplase for Chinese acute ischemic stroke patients with large/medium vessel occlusion still remains undetermined. Additionally, Australia TNK\(^1\) demonstrated that 0.25mg/kg TNK was superior to 0.1mg/kg TNK in reperfusion efficacy. Therefore, the doses of 0.25mg/kg and 0.32mg/kg tenecteplase are chosen as candidates of this Phase IIa trial to select an optimal dose of Chinese AIS patients with large/medium vessel occlusion.

Umbrella design is a trial design allowing evaluation of multiple therapies of a single disease without a control group in a minimal sample size, and is frequently applied in trials of oncology therapies\(^2\). Based on the umbrella design, Simon’s two-stage design is further acknowledged as a simpler and more effective dose selection study method\(^3\), especially in oncology trials\(^4-6\). In order to evaluate the promise of efficacy and safety of 0.25mg/kg and 0.32 mg/kg tenecteplase in AIS patients with large/medium vessel occlusion with a minimal sample size, we therefore adopted the Simon’s two stage umbrella design in the CHABLIS-T trial and designed it as a phase IIa, randomized, multicenter, open-label, blinded-endpoint study.

2. **Study Objective**

To explore the promise of efficacy and safety of different doses of tenecteplase (0.25mg/kg vs. 0.32mg/kg) in Chinese acute ischemic stroke patients with large/medium vessel occlusion in an extended time window.

3. **Study Design**

3.1 Overall design

The CHALIS-T trial is a phase IIa, randomized, multicenter, open-label, blinded-endpoint, Simon’s two-stage, umbrella design study.

3.2 Investigational Drug

Tenecteplase (Guangzhou Recomgen Biotech Co., Ltd)

3.3 Treatment allocation

Eligible patients will be enrolled and 1:1 randomized into 2 dose group (0.25mg/kg and 0.32mg/kg) of tenecteplase (Guangzhou Recomgen Biotech Co., Ltd). An interim analysis will be conducted when each treatment arm recruits 18 patients. If three or more patients achieve the primary endpoint in either arm, then the study would continue to the second stage, which would enroll an addition of 25 patients in that tenecteplase dose group (resulting in a total of 43 patients...
in that dose group), otherwise the dose group would be stopped. The intervention dose would be deemed to be of sufficient promise if 8 or more out of 43 patients achieved the primary outcome.

4. Patient Population

4.1 Inclusion criteria
1) Patients presenting with acute ischemic stroke within 4.5-24 hours from time last known well
2) Patients’ age \( \geq 18 \) years
3) Premorbid modified Rankin Scale 0-2
4) Clinically significant acute neurologic deficit (with no lower or upper limit of the National Institutes of Health Stroke Scale [NIHSS] score) at the discretion of the investigator
5) Anterior large/medium vessel occlusion or severe stenosis (>70% of the vessel caliber), including extracranial or intracranial ICA, M1 or M2 segment of MCA, and A1 or A2 segment of ACA, identified on head and neck CTA
6) Penumbral mismatch on CTP: Hypoperfusion lesion volume (Delay time[DT] > 3 s) to infarct core volume ratio (relative cerebral blood flow [rCBF]<30%) > 1.2, an absolute difference of volume > 10 ml, and an ischemic core volume < 70ml
7) Patient/Legally Authorized Representative has signed the Informed Consent form.

4.2 Exclusion criteria
Patients are not allowed to participate if they are presented with any of the following standard intravenous thrombolysis exclusion criteria:
1) Extensive hypoattenuation region (more than 1/3 of the MCA territory) identified on baseline non-contrast CT (NCCT)
2) Any sign of an acute intracranial hemorrhage or subarachnoid hemorrhage identified on baseline NCCT
3) Previous ischemic stroke within 3 months
4) Past history of intracranial hemorrhage
5) Acute head trauma at presentation or recent major head trauma within 3 months
6) Recent history of intracranial/intraspinal surgery within 3 months
7) Gastrointestinal malignancy or gastrointestinal bleeding within 21 days
8) Known bleeding diatheses: platelets count <100,000/mm\(^3\), INR >1.7, APTT >40 s, or PT >15 s
9) Use of a full dosage of low-molecular weighted heparin treatment within the previous 24 hours
10) Use of direct thrombin inhibitors or direct factor Xa inhibitors within the previous 48 hours unless the laboratory test of coagulation function is normal
11) Symptoms consistent with infective endocarditis
12) Known or suspected aortic arch dissection
13) Presence with an intra-axial intracranial neoplasm

In addition to:
1) Rapidly improving symptoms at the discretion of the investigator, which may indicate spontaneous recanalization
2) Contraindications for CT contrast precluding a CT angiography or perfusion study
3) Pregnancy or breastfeeding
4) Recent participation in another investigational drug or device study or registry in the past 30 days
5) Allergy to the test drug and its ingredients
6) Any terminal illness such that the patient would not be expected to survive more than three months
7) Other conditions in which investigators believe that participating in this study may be harmful to the patient

5. Subject withdrawal, removal and study termination

5.1 Subject withdrawal
Subjects who meet the inclusion criteria but fail to complete the study for some reasons are considered as withdrawers. Subject withdrawal includes two situations where subject withdraws by himself/herself and subjects withdraws by the discretion of investigators.

Subjects have the right to withdraw at any time during the study and are subjected to withdraw with occurrence of any of the following situations:
1) Poor study compliance: subjects do not take medication as prescribed or participate in study visits in time, affecting the analysis of efficacy and safety outcomes;
2) Suffering from adverse events or serious adverse events and are considered unsuitable to continue participating in the study by the judgement of the investigators;
3) Other situations that an investigator decides the subject’s participation should be ceased;
4) Subjects require to withdraw from the study.
   Subjects who withdraw from the study should attend a final withdrawal visit. The date and reason for patient withdrawal should be recorded.

5.2 Subject removal
Subjects should be removed from the study if one of the following situations occurs.
1) Subject do not meet one of the inclusion criteria or meet one of the exclusion criteria after enrollment;
2) Violation of the principles of concomitant medication according to study protocol;
3) Subjects do not receive allocated treatment after enrollment;
4) Subjects do not complete any study visits after treatment;
5) Subjects with poor compliance that cannot guarantee to follow the prescribed treatment, therefore, affecting the analysis of efficacy and safety outcomes.
5.3 Study early termination

The study may be terminated prematurely by the principal investigator. Reasons include but are not limited to:

1) The number and/or severity of adverse events justifies discontinuation of the study
2) The number and/or severity of protocol violation justifies discontinuation of the study
3) New data become available which raise concern about the safety of the investigational product, so that continuation might cause unacceptable risks to subjects.

After such a decision, the Investigator must contact all participating subjects within two weeks, and written notification must be sent to the Ethics Committee.

6. Sample size calculation

The sample size is calculated based on the results derived from the EXTEND-IA TNK trial: 22% patients of the intravenous tenecteplase group and 10% patients of the intravenous alteplase group reached major reperfusion, and 1% patients in both groups respectively were found to have sICH. To adopt a conservative approach, for each dose stratum within the umbrella design, the null hypothesis was that not more than 10% of patients would achieve a positive primary outcome following the respective dose of tenecteplase, while the alternative hypothesis was that, not less than 25% of patients would achieve a positive primary outcome following the respective dose of tenecteplase. Sample size estimation using Simon’s two-stage design was conducted for each dose stratum, according to which the null hypothesis that the true response rate was 10% was tested against a one-sided alternative. In the first stage, 18 patients were to be accrued. If there were 2 or fewer positive responses in these 18 patients, meaning that the null hypothesis was not rejected and the dose stratum was to be stopped. Otherwise, 25 additional patients were to be accrued for a total of 43 patients for each dose stratum. The null hypothesis for each stratum was to be rejected if 8 or more positive responses were observed in 43 patients. This design was to yield a type I error rate of 0.05 and a power of 0.8 when the true response rate was 25%. Overall, at least 36 patients were to be enrolled with a maximum enrollment of 86 patients equally distributed between the 2 dose strata. This design would yield a one-sided type I error of 0.5 and a power of 80% to detect the presumed significant difference. In all, at least 36 patients would be enrolled with a maximum enrollment of 86 patients in sum of the 2 dose strata.

7. Treatment intervention

7.1 Investigational Product

1) Investigational product:
   Tenecteplase (Guangzhou Recomgen Biotech Co., Ltd)

2) Product labelling
   Commercial packages of tenecteplase (Guangzhou Recomgen Biotech Co., Ltd) are labelled by the manufacturer, Guangzhou Recomgen Biotech Co., Ltd, with storage conditions (store below 25°C), batch number and expiry date. The study sponsor shall provide supplementary labels which include protocol name and identification number, coordinating Principal Investigator details, sponsor contact details, and the words ‘for clinical trial use only’.

23
3) Administration

Patients will receive either dose of intravenous tenecteplase (0.25mg/kg, maximum 25 mg, or 0.32mg/kg, maximum 32mg) as a bolus over 5-10s and a following 2 mL bolus of saline for injection. Bridging endovascular treatment is optional.

4) Transportation and storage

Investigational products are delivered by the manufacturer Guangzhou Recomgen Biotech Co., Ltd with temperature controlled below 25°C through the whole process of transportation.

Investigational product will be stored below 25°C until use in accordance with manufacturer’s instructions.

The investigator or his/her designee must maintain an adequate record regarding the administration of all investigational product within the trial. Used vials of investigational product must be labelled and retained for accountability purposes.

7.2 Randomization and blinding

Randomization is allowed when all the inclusion criteria are confirmed to be met (including signed informed consent by the patient or the proxies) and all the exclusion criteria have been ruled out. Randomization is performed using permuted blocks through a centralized website named Easy Random Trial (ERT) designed by Chuang Da medical science and Technology (Shanghai) Co., Ltd. by a team of professional and independent statisticians. Patients are stratified according to the time of randomization after last known well (4.5-12 hours, 12-24 hours) and site of occlusion/severe stenosis (intracranial segment of internal carotid artery and M1-segment of middle cerebral artery; extracranial segment of internal carotid artery, M2-segment of middle cerebral artery and anterior cerebral artery). The purpose of randomization in the Phase IIa umbrella-designed trial with multiple strata is not to enable subsequent comparisons between dose strata, but to ensure that participants in both strata are equally representative of the patient population. The dosage of tenecteplase is open-label while the raters involved in the subsequent radiological and clinical evaluation are blinded to the allocation. The independent data safety monitoring board (DSMB) has the access to all the unblinded data.

7.3 Endovascular treatment

If endovascular treatment is consented by the patient or the proxies and is considered feasible at the discretion of the neuro-interventionalists, the patient would be transferred to the interventional catheter suite to receive bridging endovascular treatment after thrombolysis. Thrombectomy will not be considered if hemorrhagic transformation or complete recanalization occurred before any operation of thrombectomy or angioplasty. Before any thrombectomy operation, catheter angiography should be performed to confirm the occlusion site and primary score on the modified Treatment In Cerebral Infarction (mTICI) scale. Maximally 3 passes of thrombectomy operation are allowed for each occluded artery. Digital subtraction angioplasty (DSA) should be performed following each pass and at the completion of the thrombectomy operation. Type of anesthesia should be recorded. Angioplasty and/or stenting are allowed if necessary.

7.4 Concomitant medication

If endovascular treatment is not performed, any drugs that can affect coagulation is prohibited within 24 hours after tenecteplase thrombolysis, including antiplatelet agents, anticoagulation agents, defibrinated agents, thrombolytic agents, any drug that can affect the function of platelets, and any traditional Chinese medicine agents that can affect coagulation.
If only thrombectomy operation is performed during endovascular treatment, any drugs that can affect coagulation is prohibited within 24 hours after tenecteplase thrombolysis, including antiplatelet agents, anticoagulation agents, defibrinated agents, thrombolytic agents, any drug that can affect the function of platelets, and any traditional Chinese medicine agents that can affect coagulation.

If angioplasty and/or stenting is performed during endovascular treatment, antiplatelets and/or anticoagulants are allowed if necessary, within 24 hours after tenecteplase thrombolysis.

Any concomitant treatment is allowed (including antihypertensive treatment) except for the medications mentioned above.

Any prescription and treatment before randomization and during the study should be recorded in the case report form (CRF).

8. Radiological and clinical assessment

8.1 Radiological assessment

Standard multimodal CT (non-contrast head CT, CTP, head and neck CTA) imaging of each potentially eligible patient is acquired before enrollment. Perfusion imaging is real-time processed using fully-automated MIStar (Apollo Medical Imaging Technology, Melbourne, Victoria, Australia) with single value deconvolution with delay and dispersion correction to calculate volumes of hypoperfusion lesion (delay time [Delay Time]>3s) and infarct core (relative cerebral blood flow [rCBF] <30% within areas of DT>3s) at each site.

For patients not transferred to the catheter room after thrombolysis, repeat CT perfusion imaging (and neck CTA for patients with ICA-EC occlusion/severe stenosis) is performed at 4-6 hours after thrombolysis to assess reperfusion. For patients transferred to the catheter room, reperfusion is evaluated as a modified Treatment In Cerebral Ischemia (mTICI) score on the initial catheter angiography. CT angiography is centrally reconstructed from repeat CTP imaging also using MIStar to evaluate recanalization status at 4-6 hours after treatment for patients without catheter angiography. For patients transferred to the catheter room, recanalization status prior to thrombectomy/angioplasty is evaluated also using the first-run imaging of digital subtraction angiography (DSA).

A non-contrast head CT scan is performed at 24-48 hours after thrombolysis to check the occurrence of intracranial hemorrhagic transformation. Diffusion-weighted imaging (DWI) or non-contrast head CT for magnetic resonance (MR)-incompatible patients is performed at 3-5 days to calculate volumes of final infarct core using MIStar.

All of the imaging protocols of multimodal CT at each center will be centrally standardized through careful quality control. All of the imaging were centrally analyzed in a core lab. Baseline multimodal CT imaging will be re-analyzed to make sure that the entry criteria are met. The radiological outcome measurements will be evaluated by two independent and neuroradiologists, and a third independent rater will be consulted in cases of disagreement, who are all blinded to the treatment allocation.

8.2 Clinical assessments

Neurological defects and functional scores are measured by one certified investigator blinded to treatment allocation in each participating center.
1) NIHSS is evaluated before randomization, 4-6 hours and 24-48 hours after tenecteplase treatment, and repeated at 3-5 days, 7±1 days (or at discharge), 30±7 days and 90±7 days post treatment.
2) Modified Rankin Scale is assessed at 7±1 days (or at discharge), 30±7 days and 90±7 days post treatment through in-person visit or standardized telephone follow-up.
3) Barthel Index (BI) is assessed at 7±1 days (or at discharge), 30±7 days and 90±7 days post treatment through in-person visit or standardized telephone follow-up.
4) Cognitive evaluation is optional 90±7 days post treatment using MoCA and MMSE through in-person visit.

9. Adverse Events (AEs) and Severe Adverse Events (SAEs)

The investigator is responsible for the detection and documentation of events meeting the criteria and definition of an adverse event (AE) or a serious adverse event (SAE) as provided in this protocol. During the study, when there is a safety evaluation, the investigator or site staff will be responsible for detecting AEs and SAEs, as detailed in this section of the protocol.

9.1 Definitions of AE and SAE

An Adverse Event (AE) is any untoward medical occurrence in a patient temporarily associated with the use of an investigational product, whether or not considered related to the investigational product. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the product, whether or not considered related to the product.

Events belonging to the normal procedure of disease diagnosis and treatment (e.g. rehospitalization for second-stage stenting) are not reported as AEs.

A Serious Adverse Event (SAE) is any untoward medical occurrence that, at any dose, meeting at least one of the following criteria
1) Results in death;
2) Is life threatening;
3) Requires hospitalization or prolongation of an existing hospitalization;
4) Results in permanent or severe disability;
5) Is a congenital abnormality/birth defect;
6) Is a significant medical event

Medical and scientific judgement should be exercised in deciding whether reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalization, but may jeopardize the subject or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These should also be considered serious. SAEs require immediate report to the ethics committee within 24 hours.

9.2 Recording of AEs/SAEs

1) AE
When an AE occurs, the investigator should record all relevant information regarding an AE in the CRF regardless of its severity and causality with the investigational product, from the moment when the participant signs the informed consent or from the first study visit to the last study visit. The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. In the absence of a diagnosis, the individual signs/symptoms should be documented. For each adverse event, start and stop dates, action taken, outcome, intensity and relationship to study product (causality) must be documented.

2) SAEs

Serious Adverse Events require immediate action.

Once an investigator becomes aware that an SAE has occurred, he/she should immediately notify the principal investigator, and fax the AE page in the CRF with all available details of the event and any non-serious AEs related to the SAE, to the principal investigator and the ethics committee, within 24 hours.

9.3 Follow-up of AEs and SAEs

After the initial AE/SAE report, the investigator is required to actively follow each subject and provide further information to the Steering Committee on the subject’s condition.

All AEs and SAEs documented at a previous visit/contact and are designated as ongoing, will be reviewed at subsequent visits/contacts.

All AEs and SAEs will be followed until resolution, until the condition stabilizes, until the event is otherwise explained, or until the subject is lost to follow-up. Once resolved, the appropriate AE/SAE CRF page(s) will be updated. The investigator will ensure that follow-up includes any supplemental investigations as may be indicated to elucidate the nature and/or causality of the AE or SAE. This may include additional laboratory tests or investigations, or consultation with other health care professionals.

New or updated information will be recorded on the originally completed SAE form, with all changes signed and dated by the investigator.

10. Study Plan

Standard multi-modal CT are performed to assess the eligibility of patients, including non-contrast head CT, CTP, head and neck CTA. CTP imaging will be real-time processed by MIStar (Apollo Medical Imaging Technology, Melbourne, Victoria, Australia).

Neurological impairment and functional scores (NIHSS, pre-stroke mRS) will be assessed by a trained stroke neurologist.

Bloods for standard care diagnostic evaluations will be collected and analyzed. Patients will be assessed for trial eligibility according to the Inclusion/Exclusion criteria including a reprocessing of the baseline imaging data for assessment of the occlusion site by the core imaging lab.

An informed consent will be obtained from patients or their authorized representative prior to enrollment.

10.1 Baseline assessments

1) Demographic Information: Name, sex, age, ethnics, telephone number, type of health insurance

2) Time of last known well, time of symptom recognition and time of hospital arrival
3) Risk factor (medical history): hypertension, diabetes mellitus, stroke, transient ischemic attack, coronary heart disease, myocardial infarction, arrhythmia, history of medication (aspirin, clopidogrel, warfarin, antihypertensive drugs, lipid-lowering drugs, antidiabetic drugs, heart rate control drugs), dementia, peripheral artery disease, dyslipidemia, hepatic and/or renal dysfunction, cervical and intracranial artery stenosis or malformation, smoking, drinking

4) Clinical assessments: vital signs (blood pressure, heart rate, respiratory rate and body temperature), NIHSS, and pre-stroke mRS

5) Imaging: Patients will have standardized multimodal CT (non-contrast head CT, CTP, head and neck CTA) prior to treatment, as previously described (9.1 Radiological assessments).

6) ECG

7) Laboratory test (including HCG test for women of reproductive age, routine hematology, biochemistry and coagulation screening tests)
   - Routine hematology: red blood cell count, mean corpuscular volume, white blood cell count, neutrophil (count, percent), eosinophil (count, percent), basophils (count, percent), lymphocyte (count, percent), monocyte (count, percent), hematocrit, hemoglobin, mean corpuscular hemoglobin, platelet count
   - Biochemistry: Renal function (creatinine, uric acid, urea nitrogen or urea), hepatic function (aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, glutamyl transpeptidase, total bilirubin, direct bilirubin, indirect bilirubin, total protein, albumin), glucose
   - Cardiac markers and pro-BNP: Troponin-T, Myoglobin, CK-MB, NT-pro BNP
   - Coagulation: PT, APTT, TT, FIB, INR, D-Dimer, fibrinogen degradation products (FDP)

10.2 Randomization
   Randomization is allowed when all the inclusion criteria are confirmed to be met (including signed informed consent by the patient or the proxies) and all the exclusion criteria have been ruled out. Randomization is performed using permuted blocks through a centralized website named Easy Random Trial (ERT) designed by Chuang Da medical science and Technology (Shanghai) Co., Ltd. by a team of professional and independent statisticians. Patients are stratified according to the time of randomization after last known well (4.5-12 hours, 12-24 hours) and site of occlusion/severe stenosis (intracranial segment of internal carotid artery and M1-segment of middle cerebral artery; extracranial segment of internal carotid artery, M2-segment of middle cerebral artery and anterior cerebral artery). The purpose of randomization in the Phase IIa umbrella-designed trial with multiple strata is not to enable subsequent comparisons between dose strata, but to ensure that participants in both strata are equally representative of the patient population. The dosage of tenecteplase is open-label while the raters involved in the subsequent radiological and clinical evaluation are blinded to the allocation.

10.3 Treatment administration
   1) Intravenous thrombolysis: Patients will receive intravenous tenecteplase, either 0.25mg/kg (maximum 25mg) or 0.32mg/kg (maximum 32mg), administered as a bolus over 5–10 seconds. Vital signs will be recorded during and after the period of infusion as per standard
2) Endovascular treatment: Endovascular treatment is optional. If endovascular treatment is consented by the patient or the proxies and is considered feasible at the discretion of the neuro-interventionalists, the patient will be transferred to the interventional catheter suite to receive bridging endovascular treatment after thrombolysis. Thrombectomy will not be considered if hemorrhagic transformation or complete recanalization occurred before any operation of thrombectomy or angioplasty. Before any thrombectomy operation, catheter angiography should be performed to confirm the occlusion site and primary score on the modified Treatment In Cerebral Infarction (mTICI) scale. Maximally 3 passes of thrombectomy operation are allowed for each occluded artery. Digital subtraction angioplasty (DSA) should be performed following each pass and at the completion of the thrombectomy operation. Type of anesthesia should be recorded. Angioplasty and/or stenting are allowed if necessary and may require the use of antiplatelets. Attention should be paid to stabilize blood pressure and minimize delays in starting the procedure. The initial and final angiograms will be centrally graded for angiographic reperfusion using the mTICI classification.

Vital signs and any occurrence of AEs or SAEs during treatment should be documented. Close neurological observation will be conducted primarily during the first 48 hours after treatment administration according to local clinical practice.

10.4 Study visits (Table 1)

1) 4-6 hours
- Vital signs, concomitant medication, NIHSS, new-onset cardio-cerebral vascular events, AEs/SAEs
- For patients transferred to the catheter room: time of arterial puncture, time of first angiographic run, time of recanalization
- Imaging:
  - For patients not transferred to the catheter room: CTP (+neck CTA if stroke is primarily due to severe stenosis/occlusion at ICA-EC)
  - For patients transferred to the catheter room: DSA

2) 24-48 hours
- Vital signs, concomitant medication, NIHSS, new-onset cardio-cerebral vascular events, AEs/SAEs
- Imaging: Non-contrast head CT
- Laboratory test: routine hematologic, renal and hepatic function, cardiac markers, cardiac enzymes, pro-BNP, blood lipid, routine urine analysis, coagulation
- Symptomatic intracranial hemorrhage (ECASS II criteria)
- Systematic hemorrhage (GUSTO criteria)

3) 3-5 days
- Vital signs, concomitant medication, NIHSS, new-onset cardio-cerebral vascular events, AEs/SAEs
- Imaging: head MRI (including DWI), head TOF-MRA (+neck MRA if stroke is primarily due to severe stenosis/occlusion at ICA-EC) SWI (optional).
- Symptomatic intracranial hemorrhage (ECASS II criteria)
- Systematic hemorrhage (GUSTO criteria)

4) 7±1 days (or at discharge)
- Vital signs, concomitant medication, NIHSS, mRS, BI, new-onset cardio-cerebral vascular events, AEs/SAEs
- Laboratory test: routine hematology, renal and hepatic function, cardiac markers, cardiac enzymes, pro-BNP, blood lipid, routine urine analysis, coagulation

5) 30±7 days
- Vital signs, concomitant medication, NIHSS, mRS, BI, new-onset cardio-cerebral vascular events, AEs/SAEs
- Cognitive tests (optional): MoCA, MMSE

6) 90±7 days
- Vital signs, concomitant medication, NIHSS, mRS, BI, new-onset cardio-cerebral vascular events, AEs/SAEs
- Cognitive tests (optional): MoCA, MMSE

10.5 Study outcomes

1) Primary outcome
The primary outcome is a binary composite of efficacy and safety, i.e. major reperfusion and absence of symptomatic intracranial hemorrhagic transformation (ICH) at 24-48 hours after intravenous tenecteplase. Major reperfusion was considered as the restoration of blood flow of greater than 50% of the involved territory.
- For patients not transferred to the catheter room after thrombolysis, major reperfusion was assessed as reperfusion greater than 50% of the involved baseline hypoperfusion lesion volume (delay time > 3s) on repeat CT perfusion imaging at 4-6 hours after thrombolysis.
- For patients transferred to the catheter room, major reperfusion was evaluated as a modified Treatment In Cerebral Ischemia (mTICI) score 2b/3 at the initial catheter angiography.

Symptomatic ICH was defined according to the European Co-operative Acute Stroke Study-II (ECASS II) criteria, where the patients presented any type of intracranial hemorrhage with no less than 4 point-increase in National Institutes of Health Stroke Scale (NIHSS) from baseline or from the lowest NIHSS between baseline at 24-48 hours, or leading to death.

2) Secondary outcomes
- Secondary radiological efficacy outcomes
  - Recanalization defined by the Thrombolysis in Myocardial Infarction (TIMI) scale of 2/3 at the 4- to 6- hour CTA (reconstructed from CTP) for patients not transferred to the catheter room, or at digital subtraction angiography imaging prior to thrombectomy for patients transferred to the catheter room after thrombolysis;
  - Infarct growth on diffusion-weighted imaging (DWI) or non-contrast head CT at 3-5 days.
Secondary clinical efficacy outcomes

- Excellent functional outcome (disability-free, defined as modified Rankin Scale [mRS] 0-1) at 90 days;
- Good functional outcome (functional independence, defined as mRS 0-2) at 90 days; mRS distribution at 90 days;
- Major neurological improvement at 24-48 hours (NIHSS reduction greater than 7 points or NIHSS 0-1);
- Change in NIHSS as a continuous variable at 24-48 hours.

Secondary radiological safety outcomes

- Type 2 parenchymal hematoma (PH2);
- Symptomatic ICH;
- Any ICH at 24-48 hours post treatment.

Secondary clinical safety outcomes

- Poor functional outcome (severe disability or death, defined as mRS 5-6) at 90 days;
- Systemic bleeding defined by The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) before discharge.

Others:

- Barthel index at 90 days.

All of these clinical assessments will be conducted through on-site personnel who are blinded to the treatment allocation.

10.6 Protocol compliance

Study visits before discharge (4-6 hours, 24-48 hours, 3-5 days, 7±1 days or at discharge) will be completed together by a fellow doctor in charge of the treatment patients in hospital and one of the investigators both of whom are blinded to the treatment allocation.

Study visits after discharge (30±7 days, 90±7 days) will be completed through stroke clinic by one of the investigators who is blinded to the treatment allocation. Transportation fee of the participants will be covered by the trial. If the participant is incapable of arrival to the clinic in person due to disability, these visits will be completed through standardized telephone follow-up by a trained investigator who is blinded to the treatment allocation.

11. Data analysis and statistical consideration

11.1 Sample size calculation

The sample size is calculated based on the results derived from the EXTEND-IA TNK trial: 22% patients of the intravenous tenecteplase group and 10% patients of the intravenous alteplase group reached major reperfusion, and 1% patients in both groups respectively were found to have sICH. To adopt a conservative approach, for each dose stratum within the umbrella design, the null hypothesis was that not more than 10% of patients would achieve a positive primary outcome following the respective dose of tenecteplase, while the alternative hypothesis was that, not less than 25% of patients would achieve a positive primary outcome following the respective dose of tenecteplase. Sample size estimation using Simon’s two-stage design was conducted for each dose stratum, according to which the null hypothesis that the true response rate was 10% was tested against a one-sided alternative. In the first stage, 18 patients were to be accrued. If
there were 2 or fewer positive responses in these 18 patients, meaning that the null hypothesis was not rejected and the dose stratum was to be stopped. Otherwise, 25 additional patients were to be accrued for a total of 43 patients for each dose stratum. The null hypothesis for each stratum was to be rejected if 8 or more positive responses were observed in 43 patients. This design was to yield a type I error rate of 0.05 and a power of 0.8 when the true response rate was 25%. Overall, at least 36 patients were to be enrolled with a maximum enrollment of 86 patients equally distributed between the 2 dose strata. This design would yield a one-sided type I error of 0.5 and a power of 80% to detect the presumed significant difference. In all, at least 36 patients would be enrolled with a maximum enrollment of 86 patients in sum of the 2 dose strata.

11.2 General principles of data analysis

All of the statistical analysis will be performed on STATA v15.1 (StataCorp, Ltd, College Station, Texas).

11.3 Analysis of primary outcome

For the analysis of primary endpoint, as described above, if 3 or more of the 18 patients in the first stage of either dose stratum reach the primary endpoint, then additional 25 patients would be enrolled in that dose stratum. If 8 or more out of the 43 patients reach the primary endpoint within a given stratum after the second stage, then the corresponding tenecteplase dose could be considered to be of sufficient promise in terms of efficacy and safety and could be a qualified candidate dose for the subsequent phase IIb trial.

11.4 Analysis of secondary outcome

Since the design of this study is not aimed to compare the safety and efficacy of the two tenecteplase doses within the umbrella design, the analysis of secondary outcomes only involved data description without comparative analysis. Secondary outcomes were described using percentages, mean and standard deviation, median and interquartile range (IQR) as appropriate. Normality will be tested using Shapiro-Wilk test.

11.5 Sensitivity analysis

Preplanned sensitivity analysis is conducted by removing patients with severe stenosis and analyzing the primary and secondary outcomes of patients with complete artery occlusion in the two tenecteplase dose groups.

In case of any post-hoc subgroup analysis, they will be justified and identified as data-driven and, they will follow the principles and regulatory recommendations.

12. Ethical and regulatory standards

12.1 Ethical principles

This study will be conducted in accordance with the principles laid down by the 18th World Medical Assembly (Helsinki, 1964) and all applicable amendments laid down by the World Medical Assemblies and the ICH guidelines for Good Clinical Practice.

12.2 Laws and regulations

This study will be conducted in compliance with all international laws and regulations, and Chinese laws and regulations in which the Clinical Trial is performed, as well as any applicable guidelines.

12.3 Informed Consent
The investigator (according to applicable regulatory requirements), or a person designated by the investigator and under the investigator's responsibility, should fully inform the patient of all pertinent aspects of the Clinical Trial including the written information giving approval/favorable opinion by the Ethics Committee (IRB/IEC). All participants should be informed to the fullest extent possible about the study, in language and terms they are able to understand.

Prior to a patient's participation in the CHABLIS-T trial, the written informed consent form should be signed, name filled in and personally dated by the patient or by the patient's legally acceptable representative, and by the person who conducted the informed consent discussion. A copy of the signed and dated written Informed Consent Form will be provided to the patient.

The informed consent form used by the investigator for obtaining the patient's informed consent must be reviewed and approved by the sponsor prior to submission to the appropriate Ethics Committee (IRB/IEC) for approval/favorable opinion.

The protocol will be submitted for approval to the appropriate local institutional ethics committee, and written approval obtained, before participants are recruited and enrolled. The Investigators will receive all the documentation needed for submitting the present protocol to the ethics committee. A copy of the respective approval letters will be transmitted to the Study Monitor before starting the study. The compliance/composition of the Ethics Committee will also be provided to the Study Monitor. If approval is suspended or terminated by the ethics committee, the investigator will notify the Study Monitor immediately.

It is the responsibility of the Investigator to report study progress to the ethics committee as required, or at intervals not greater than one year.

The principal investigator, or his/her nominee, will be responsible for reporting any SAEs to the ethics committee as soon as possible, and in accordance with the guidelines of the Ethics Committee.

12.4 Institutional Review Board/ Independent Ethics Committee (IRB/IEC)

The investigator or the sponsor must submit this protocol to the appropriate ethics committee (IRB/IEC), and is required to forward to the Sponsor a copy of the written and dated approval/favorable opinion signed by the chairman with ethics committee (IRB/IEC) composition.

The clinical trial (study number, Clinical Trial Protocol title and version number), the documents reviewed (clinical trial protocol, informed consent form, investigator's brochure, investigator's CV, etc.), the list of voting members along with their qualification and the date of the review should be clearly stated on the written (IRB/IEC) approval/favorable opinion.

Investigational product will not be released at the study site and the trial will not start until a copy of this written and dated approval/favorable opinion has been received by the Sponsor.

During the study, any amendment or modification to the protocol should be submitted to the Ethics Committee (IRB/IEC). It should also be informed of any event likely to affect the safety of patients or the continued conduct of this trial, in particular any change in safety. All updates to the investigator's brochure will be sent to the ethics committee (IRB/IEC).

If requested, a progress report will be sent to the ethics committee (IRB/IEC) annually and a summary of the trial's outcome at the end of this trial.

13. Study monitoring

13.1 Responsibilities of the investigators
The Investigator(s) undertake(s) to perform the clinical trial in accordance with this protocol, ICH guidelines for Good Clinical Practice and the applicable regulatory requirements.

The investigator is required to ensure compliance with all procedures required by the protocol and with all study procedures provided by the Sponsor (including security rules). The investigator agrees to provide reliable data and all information requested by the Clinical Trial protocol (with the help of the Case Report Form [CRF], Discrepancy Resolution Form [DRF] or other appropriate instrument) in an accurate and legible manner according to the instructions provided and to ensure direct access to source documents by Sponsor representatives.

The investigator may appoint such other individuals as he/she may deem appropriate as sub-investigators to assist in the conduct of the trial in accordance with the protocol. All sub-investigators shall be appointed and listed in a timely manner. The sub-investigators will be supervised by and under the responsibility of the Investigator. The investigator will provide them with a copy of this protocol and all necessary information.

The Sponsor of this Clinical Trial is responsible to Health Authorities for taking all reasonable steps to ensure the proper conduct of the clinical trial protocol as regards ethics, clinical trial protocol compliance, and integrity and validity of the data recorded on the case report forms. Thus, the main duty of the monitoring team is to help the Investigator and the Sponsor maintain a high level of ethical, scientific, technical and regulatory quality in all aspects of the trial.

At regular intervals during the clinical trial, the site will be contacted, through monitoring visits, letters or telephone calls, by a representative of the Monitoring Team to review study progress, Investigator and patient compliance with the protocol requirements and any emergent problems. During these monitoring visits, the following, but not exhaustive, points will be scrutinized with the Investigator: patient informed consent, patient recruitment and follow-up, SAE documentation and reporting, investigational product allocation, patient compliance with the investigational product regimen, investigational product accountability, concomitant therapy use and quality of data.

13.2 Source document requirements

According to the ICH guidelines for Good Clinical Practice, the monitoring team must check the case report form entries against the source documents, except for the pre-identified source data directly recorded in the case report form. The informed consent form will include a statement by which the patient allows the sponsor's duly authorized personnel, the ethics committee (IRS/IEC), and the regulatory authorities to have direct access to source data which support the data on the case report forms (e.g., patient's medical file, appointment books, original laboratory records, etc.). Such personnel, bound by professional secrecy, must keep confidential all personal identity or personal medical information (according to confidentiality rules).

13.3 Data management

Paper-based case report form (CRF) and electronic data capture (EDC) system will be used for data collection and entry. All the content required by the protocol in the system must be provided, the unfilled content should be explained, and the reason needs to be filled in the remarks under each form of the EDC system.

Site investigators should use black or blue-black recording pens to fill out the paper-based CRF neatly and clearly to ensure that the data is clear and readable. If the paper-based CRF information needs to be modified, it should not be altered or overwritten. The correct information should be written next to the original information, signed and dated by the person who modified it. The
clinical research monitor (CRA) will review the completeness and accuracy of the case report form and guide the investigator to make necessary corrections and supplements. After the paper-based CRF is completed, the research coordinator (CRC) will input the content of the paper CRF into the EDC system. The paper-based CRF is submitted after the investigator has approved it. After the data is submitted, all data revisions and feedback are carried out through the EDC system. If the EDC system has submitted a form that needs to be modified, you need to contact the CRA of this center. After the CRA opens the form, the investigator can guide the CRC to modify the EDC system data. Data will then be monitored by the CRA according to a data monitoring plan in a regular basis. After the last study visit of the last participant is finished, the data from the EDC will be exported to a database (in excel sheets), then it will be proofread by the data administrator. Obvious errors will be corrected by the data administrator. Other errors or missing values will be filled in the data query form and returned to the participating center for solution through email, express, telephone and WeChat.

The participating centers are responsible for correcting the data in the EDC system after verifying the original data and related information. Site investigators must answer these queries by verifying or modifying relevant information or data.

13.4 Confidentiality

All of the personal data of research participants (subjects) must be kept strictly confidential. Information and data of the study participants (subjects) are identified only by subject numbers rather than names. Identifiable information of participants (subjects) will not be disclosed to members outside the investigator teams, unless permission is obtained from the research participants (subjects). All of the investigators are required to keep the identities of study participants (subjects) confidential. The files of study participants (subjects) will be kept in locked filing cabinets and will only be accessible to authorized investigators. In order to ensure that the study is carried out in accordance with laws and regulations, government authorities or members of the ethics committee can access to the personal data of the research participants (subjects) according to regulations when necessary. No personal information of the research participants (subjects) will be disclosed at the time of publication of this research.

The research data are also confidential. All of the investigators are required to keep confidential to the research data. They shall not disclose the research data without the permission of the principal investigator to anyone who is not the member of the research team, and shall not transfer the research data to other institute without the permission of the hospital. The research data are not allowed to be disclosed to foreign institutes, or domestic institutes with foreign capital, without the permission of Human Genetic Resource Administration Office of China, except for the publication of research results that meet regulatory requirements under normal circumstances.

14. Funding

The study is sponsored by the National Key Research and Development Program of China (2017YFC1308201), Science and Technology Ministry of China. Guangzhou Recomgen Biotech Co., Ltd. supplied the investigative drug and covered the trial insurance, but had no role in study design and execution.
15. Study Organization

15.1 Principle investigator
Qi Wang Dong, Huashan Hospital, Fudan University, Shanghai, China

15.2 Trial steering committee members
Qi Wang Dong (Principal Investigator), Mark Parsons, Xin Cheng, Leonid Churilov, Yilong Wang
✓ The steering committee will provide scientific and strategic direction for the trial and will have overall responsibility for its design, execution, and publication.
✓ The steering committee will also be responsible for ensuring that study execution and management are of the highest quality.
✓ It will approve the protocol and the operational guidelines of the trial prior to its commencement.
✓ The steering committee will convene regularly by teleconference or face-to-face meetings to discuss and report on the progress of the study.

15.3 Data safety and monitoring board
The DSMB will meet regularly and monitor the progress of the CHABLIS-T study to ensure that the study meets the highest standards of ethics and patient safety. It is composed of Academic Members, including an independent statistician, who are not otherwise participating in the trial. Written recommendations and their rationale will be provided to the Chairs of the Steering Committee immediately after each DSMB meeting.

16. References


Table 1 Study Visits in CHABLIS-T

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screening and Randomization</th>
<th>Thrombolysis Commencement</th>
<th>Visits</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-24h--4.5h</td>
<td>0h</td>
<td>24-48h</td>
</tr>
<tr>
<td>Demographic</td>
<td>X</td>
<td></td>
<td>7±1 days Discharge</td>
</tr>
<tr>
<td>Previous medical</td>
<td>X</td>
<td></td>
<td>30±7 days</td>
</tr>
<tr>
<td>Concomitant</td>
<td>X</td>
<td>X</td>
<td>90±7 days</td>
</tr>
<tr>
<td>Vital signs</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Physical examinations</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy test†</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood lab tests</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electrocardiography</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion and exclusion criteria</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomization</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imaging (CT/MRI/DSA)</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Symptomatic intracranial</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Modified Rankin Scale</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>NIH Stroke Scale</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Cognitive evaluations</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Adverse events</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Barthel Index</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

1. Only for female patients at reproductive age
CHinese Acute tissue-Based imaging selection for Lysis In Stroke -Tenecteplase (CHABLIS-T)

Protocol

Research Team: Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China

Principle Investigator: Qiang Dong, MD, PhD, Professor of Neurology

Protocol Version: 2.0

Nov. 2019
Catalogue

Protocol Summary ............................................................................................................. 42

1. Introduction ................................................................................................................. 45

2. Study Objective .......................................................................................................... 46

3. Study Design ................................................................................................................ 46

4. Patient Population ...................................................................................................... 47

5. Subject withdrawal, removal and study termination .................................................... 48

6. Sample size calculation .............................................................................................. 49

7. Treatment intervention ............................................................................................... 49

8. Radiological and clinical assessment ........................................................................... 51

9. Adverse Events (AEs) and Severe Adverse Events (SAEs) ........................................... 52

10. Study Plan .................................................................................................................. 53

11. Data analysis and statistical consideration .................................................................. 57

12. Ethical and regulatory standards .................................................................................. 58

13. Study monitoring ......................................................................................................... 60

14. Funding ....................................................................................................................... 61

15. Study Organization ..................................................................................................... 62

16. References .................................................................................................................. 62

Table 1 Study Visits in CHABLIS-T .................................................................................. 65
Protocol Summary

<table>
<thead>
<tr>
<th>Protocol Title</th>
<th>CHABLIS-T: CHinese Acute tissue-Based imaging selection for Lysis In Stroke - Tenecteplase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protocol Number</td>
<td>KY2019-474</td>
</tr>
<tr>
<td>Development Phase</td>
<td>Phase 2a</td>
</tr>
<tr>
<td>Study Population</td>
<td>Acute ischemic stroke patients with large/medium vessel occlusion or severe stenosis presented within 4.5 to 24 hours from last known well, with penumbral mismatch identified by multimodal CT.</td>
</tr>
<tr>
<td>Study Objective</td>
<td>To explore the promise of efficacy and safety of different doses of tenecteplase (0.25mg/kg vs. 0.32mg/kg) in Chinese acute ischemic stroke patients with large/medium vessel occlusion or severe stenosis in an extended time window.</td>
</tr>
</tbody>
</table>

**Trial Design**

The CHABLIS-T trial is a phase IIa, randomized, multicenter, open-label, blinded-endpoint, Simon’s two-stage, umbrella design study.

Eligible patients will be enrolled and 1:1 randomized into 2 dose group (0.25mg/kg and 0.32mg/kg) of tenecteplase (Guangzhou Recomgen Biotech Co., Ltd). An interim analysis will be conducted when each treatment arm recruits 18 patients. If three or more patients achieve the primary endpoint in either arm, then the study would continue to the 2nd stage, which would enroll an addition of 25 patients in that tenecteplase dose group (resulting in a total of 43 patients in that dose group), otherwise the dose group would be stopped. The intervention dose would be deemed to be of sufficient promise if 8 or more out of 43 patients achieved the primary outcome.

**Inclusion criteria**

1. Patients presenting with acute ischemic stroke within 4.5-24 hours from time last known well.
2. Patients’ age $\geq$ 18 years
3. Premorbid modified Rankin Scale 0-2
4. Clinically significant acute neurologic deficit (with no lower or upper limit of the National Institutes of Health Stroke Scale [NIHSS] score) at the discretion of the investigator
5. Anterior large/medium vessel occlusion or severe stenosis (>70% of the vessel caliber), including extracranial or intracranial ICA, M1 or M2 segment of MCA, and A1 or A2 segment of ACA, identified on head and neck CTA
6. Penumbral mismatch on CTP: Hypoperfusion lesion volume (Delay time [DT] > 3 s) to infarct core volume ratio (relative cerebral blood flow [rCBF] <30%) > 1.2, an absolute difference of volume > 10 ml, and an ischemic core volume < 70 ml.

7. Patient/Legally Authorized Representative has signed the Informed Consent form.

8. Extensive hypoattenuation region (more than 1/3 of the MCA territory) identified on baseline non-contrast CT (NCCT).

9. Any sign of an acute intracranial hemorrhage or subarachnoid hemorrhage identified on baseline NCCT.

10. Previous ischemic stroke within 3 months.


12. Acute head trauma at presentation or recent major head trauma within 3 months.

13. Recent history of intracranial/intraspinal surgery within 3 months.

14. Gastrointestinal malignancy or gastrointestinal bleed within 21 days.

15. Known bleeding diatheses: platelets count < 100 000/mm³, INR > 1.7, APTT > 40 s, or PT > 15 s.

16. Use of a full dosage of low-molecular weighted heparin treatment within the previous 24 hours.

17. Use of direct thrombin inhibitors or direct factor Xa inhibitors within the previous 48 hours unless the laboratory test of coagulation function is normal.

18. Symptoms consistent with infective endocarditis.

19. Known or suspected with aortic arch dissection.


In addition to:

1. Rapidly improving symptoms at the discretion of the investigator, which may indicate spontaneous recanalization.

2. Contraindications for CT contrast precluding a CT angiography or perfusion study.

3. Pregnancy or breastfeeding.

4. Recent Participation in another investigational drug or device study or registry in the past 30 days.

5. Allergy to the test drug and its ingredients.

6. Any terminal illness such that the patient would not be expected to survive more than three months.

7. Other conditions in which investigators believe that participating in this study may be harmful to the patient.

<table>
<thead>
<tr>
<th>Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>14. Extensive hypoattenuation region (more than 1/3 of the MCA territory) identified on baseline non-contrast CT (NCCT)</td>
</tr>
<tr>
<td>15. Any sign of an acute intracranial hemorrhage or subarachnoid hemorrhage identified on baseline NCCT</td>
</tr>
<tr>
<td>16. Previous ischemic stroke within 3 months</td>
</tr>
<tr>
<td>17. Past history of intracranial hemorrhage</td>
</tr>
<tr>
<td>18. Acute head trauma at presentation or recent major head trauma within 3 months</td>
</tr>
<tr>
<td>19. Recent history of intracranial/intraspinal surgery within 3 months</td>
</tr>
<tr>
<td>20. Gastrointestinal malignancy or gastrointestinal bleed within 21 days</td>
</tr>
<tr>
<td>21. Known bleeding diatheses: platelets count &lt; 100 000/mm³, INR &gt; 1.7, APTT &gt; 40 s, or PT &gt; 15 s</td>
</tr>
<tr>
<td>22. Use of a full dosage of low-molecular weighted heparin treatment within the previous 24 hours</td>
</tr>
<tr>
<td>23. Use of direct thrombin inhibitors or direct factor Xa inhibitors within the previous 48 hours unless the laboratory test of coagulation function is normal</td>
</tr>
<tr>
<td>24. Symptoms consistent with infective endocarditis</td>
</tr>
<tr>
<td>25. Known or suspected with aortic arch dissection</td>
</tr>
<tr>
<td>26. Presence of an intra-axial intracranial neoplasm</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Investigational drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intravenous Tenecteplase</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients were randomized in a 1:1 ratio into 2 tenecteplase dose groups, 0.25 mg/kg and 0.32 mg/kg. Randomization was performed using permuted blocks through a centralized website. Patients were stratified according to time of randomization after last known well (4.5-12 hours, 12-24 hours) and site of occlusion/severe stenosis (ICA-IC and MCA-M1; ICA-EC, MCA-M2 and ACA). Patients received either dose of intravenous tenecteplase (0.25 mg/kg, maximum 25 mg, or 0.32 mg/kg, maximum 40 mg) as a bolus over 5-10 s and a following 2 mL bolus of saline for injection.</td>
</tr>
<tr>
<td>Study outcome</td>
</tr>
<tr>
<td>--------------</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Secondary outcomes</td>
</tr>
<tr>
<td>1. Secondary radiological efficacy outcomes:</td>
</tr>
<tr>
<td>2) Recanalization defined by the Thrombolysis in Myocardial Infarction (TIMI) scale of 2/3 at the 4- to 6-hour CTA (reconstructed from CTP) for patients not transferred to the catheter room, or at the first digital subtraction angiography run prior to thrombectomy for patients transferred to the catheter room after thrombolysis</td>
</tr>
<tr>
<td>2. Secondary clinical efficacy outcomes</td>
</tr>
<tr>
<td>1) Excellent functional outcome (mRS 0-1) at 90 days</td>
</tr>
<tr>
<td>2) Good functional outcome (mRS 0-2) at 90 days</td>
</tr>
<tr>
<td>3) mRS distribution at 90 days</td>
</tr>
<tr>
<td>4) Neurological improvement at 24-48 hours (NIHSS 0-1 or a NIHSS-improvement of ≥8)</td>
</tr>
<tr>
<td>5) Change in NIHSS as a continuous variable at 24-48 hours</td>
</tr>
<tr>
<td>3. Secondary radiological safety outcomes</td>
</tr>
<tr>
<td>1) Type 2 parenchymal hematoma at 24-48 hours</td>
</tr>
<tr>
<td>2) sICH according to the ECASS II criteria at 24-48 hours</td>
</tr>
<tr>
<td>3) Any intracranial hemorrhagic transformation at 24-48 hours post-treatment</td>
</tr>
<tr>
<td>4. Secondary clinical safety outcomes</td>
</tr>
<tr>
<td>1) Poor functional outcome (mRS 5-6) at 90 days</td>
</tr>
<tr>
<td>2) Systemic bleeding defined by The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries before discharge</td>
</tr>
<tr>
<td>5. Others: Barthel Index at 90 days</td>
</tr>
</tbody>
</table>

| Primary analysis | For the analysis of the primary endpoint, if more than 2 out of the 18 patients in the first stage of either dosage group reach the primary endpoint, then another additive 25 patients will be enrolled in that group. If more than 7 out of the 43 patients reach the primary endpoint after the second stage, then the tenecteplase dosage could be considered as a qualified candidate dosage for a phase Ib trial. Secondary outcomes will be described using percentages, mean and standard deviation, median and interquartile range (IQR) as appropriate. Normality will be tested using the Shapiro-Wilk test. |
1. Introduction

Intravenous thrombolysis using alteplase is recommended as the first-line therapy for acute ischemic stroke (AIS) patients presented within 4.5 hours after stroke onset. However, only a very limited number of patients are able to receive the treatment due to its short treatment time window. A comparison study based on the data of China National Stroke Registry (CNSR) and the American Heart Association Get With The Guidelines Stroke Program (GWTG-Stroke Program) has shown that only 2.5% patients in CNSR and 8.1% patients in the GWTG-Stroke Program received intravenous thrombolytic therapy. Therefore, extending the treatment time window for AIS patients has become a hot research topic of clinical trials recently. Additionally, because alteplase acquires 1-hour continuous infusion after bolus and its efficacy can be undermined by any infusion delay and interruption, the necessity for alteplase in patients with large vessel occlusion has been questioned since the effect of endovascular treatment has been validated and acknowledged.

Existence of penumbral mismatch (substantial volume of tissue to salvage) is of great importance to the effect of reperfusion therapy. Recent randomized controlled trials (RCTs) using perfusion imaging to select patients with penumbral mismatch have demonstrated that intravenous thrombolysis may also be beneficial for AIS patients in an extend time window beyond 4.5 hours.

Tenecteplase (TNK) is a mutant variant of alteplase with a longer half-time life and higher fibrin specificity. TNK currently is recommended as the first-line intravenous medication for myocardial infarction with a dose of 0.5mg/kg, and its safety and efficacy in acute ischemic stroke patients have long been studied. The meta-analysis of the 5 RCTs (Haley et al. Australian TNK, ATTEST, NOR-TEST, EXTEND-IA TNK) comparing the effect of TNK and alteplase reveals that though the imaging selection criteria and treatment time window for each trial differ, the dose of 0.25mg/kg and 0.4 mg/kg TNK are non-inferior to alteplase in AIS patients (the noninferiority test of 0.1mg/kg TNK was underpowered due to limited sample size). Furthermore, pooled analyses using data of Australian TNK and ATTEST show that TNK may have superior recanalization efficacy in patients with complete large vessel occlusion to alteplase, especially in patients with penumbral mismatch on perfusion imaging. EXTEND-IA TNK has proven that for anterior circulation stroke patients with large vessel occlusion and perfusion mismatch, TNK could lead to a significantly higher rate of major reperfusion preceding endovascular treatment and better functional outcome, compared with alteplase in the 4.5-hour time window (rate of major of reperfusion: TNK 22% vs. alteplase 10%; median [IQR] mRS at 90 days: TNK 2[0-3] vs. alteplase 3[1-4]). These previous results implicate that based on the noninferiority of TNK to alteplase in AIS patients without advanced imaging selection, the superiority of TNK to alteplase may emerge in large vessel occlusion patients with perfusion mismatch.

Endovascular treatment has become a routine practice for the treatment of AIS patients with large vessel occlusion, and its time window has been extended to 24 hours after last known normal through advanced imaging selection. However, Chinese LVO patients have been faced with the challenge of a longer reperfusion time compared with the Western population. One of the main reasons may relate to the high prevalence of in-situ thrombosis due to intracranial atherosclerotic disease (ICAD) in Asian patients with acute LVO, which is refractory to the
current stent retrievers or aspiration systems. Additionally, the number of comprehensive stroke centers with capability of endovascular treatment is still insufficient given the broad landscape of China, and the drip-and-ship transfer system is still under-developed. Therefore, TNK can be a great candidate for reperfusion therapy considering its performance in large/medium vessel occlusion patients to extend the time window of intravenous thrombolysis, improving the clinical outcome of Chinese AIS patients with large/medium vessel occlusion.

The doses of TNK tested in the previous RCTs in acute ischemic stroke patients are generally 0.1mg/kg, 0.25mg/kg and 0.4mg/kg. Tenecteplase has been approved for the intravenous thrombolysis in myocardial infarction by China Food and Drug Administration (CFDA). The tenecteplase dose proven to be safe during the dose escalation study in Chinese myocardial infarction patients ranges from 0.08mg/kg to 0.32mg/kg. However, the optimal dose of tenecteplase for Chinese acute ischemic stroke patients with large/medium vessel occlusion still remains undetermined. Additionally, Australia TNK demonstrated that 0.25mg/kg TNK was superior to 0.1mg/kg TNK in reperfusion efficacy. Therefore, the doses of 0.25mg/kg and 0.32mg/kg tenecteplase are chosen as candidates of this Phase IIa trial to select an optimal dose of Chinese AIS patients with large/medium vessel occlusion.

Umbrella design is a trial design allowing evaluation of multiple therapies of a single disease without a control group in a minimal sample size, and is frequently applied in trials of oncology therapies. Based on the umbrella design, Simon’s two-stage design is further acknowledged as a simpler and more effective dose selection study method, especially in oncology trials. In order to evaluate the promise of efficacy and safety of 0.25mg/kg and 0.32 mg/kg tenecteplase in AIS patients with large/medium vessel occlusion with a minimal sample size, we therefore adopted the Simon’s two stage umbrella design in the CHABLIS-T trial and designed it as a phase IIa, randomized, multicenter, open-label, blinded-endpoint study.

2. Study Objective

To explore the promise of efficacy and safety of different doses of tenecteplase (0.25mg/kg vs. 0.32mg/kg) in Chinese acute ischemic stroke patients with large/medium vessel occlusion or severe stenosis in an extended time window.

3. Study Design

3.1 Overall design

The CHALIS-T trial is a phase IIa, randomized, multicenter, open-label, blinded-endpoint, Simon’s two-stage, umbrella design study.

3.2 Investigational Drug

Tenecteplase (Guangzhou Recomgen Biotech Co., Ltd)

3.3 Treatment allocation

Eligible patients will be enrolled and 1:1 randomized into 2 dose group (0.25mg/kg and 0.32mg/kg) of tenecteplase (Guangzhou Recomgen Biotech Co., Ltd). An interim analysis will be conducted when each treatment arm recruits 18 patients. If three or more patients achieve the primary endpoint in either arm, then the study would continue to the second stage, which would enroll an addition of 25 patients in that tenecteplase dose group (resulting in a total of 43 patients
in that dose group), otherwise the dose group would be stopped. The intervention dose would be deemed to be of sufficient promise if 8 or more out of 43 patients achieved the primary outcome.

4. Patient Population

4.1 Inclusion criteria
1) Patients presenting with acute ischemic stroke within 4.5-24 hours from time last known well
2) Patients’ age $\geq$ 18 years
3) Premorbid modified Rankin Scale 0-2
4) Clinically significant acute neurologic deficit (with no lower or upper limit of the National Institutes of Health Stroke Scale [NIHSS] score) at the discretion of the investigator
5) Anterior large/medium vessel occlusion or severe stenosis (>70% of the vessel caliber), including extracranial or intracranial ICA, M1 or M2 segment of MCA, and A1 or A2 segment of ACA, identified on head and neck CTA
6) Penumbral mismatch on CTP: Hypoperfusion lesion volume (Delay time[DT] $>$ 3 s) to infarct core volume ratio (relative cerebral blood flow [rCBF]$<$30%) $>$ 1.2, an absolute difference of volume $>$ 10 ml, and an ischemic core volume $<$ 70ml
7) Patient/Legally Authorized Representative has signed the Informed Consent form.

4.2 Exclusion criteria
Patients are not allowed to participate if they are presented with any of the following standard intravenous thrombolysis exclusion criteria:
1) Extensive hypoattenuation region (more than 1/3 of the MCA territory) identified on baseline non-contrast CT (NCCT)
2) Any sign of an acute intracranial hemorrhage or subarachnoid hemorrhage identified on baseline NCCT
3) Previous ischemic stroke within 3 months
4) Past history of intracranial hemorrhage
5) Acute head trauma at presentation or recent major head trauma within 3 months
6) Recent history of intracranial/intraspinal surgery within 3 months
7) Gastrointestinal malignancy or gastrointestinal bleeding within 21 days
8) Known bleeding diatheses: platelets count $<$100 000/mm$^3$, INR $>$1.7, APTT $>$40 s, or PT $>$15 s
9) Use of a full dosage of low-molecular weighted heparin treatment within the previous 24 hours
10) Use of direct thrombin inhibitors or direct factor Xa inhibitors within the previous 48 hours unless the laboratory test of coagulation function is normal
11) Symptoms consistent with infective endocarditis
12) Known or suspected aortic arch dissection
13) Presence with an intra-axial intracranial neoplasm

In addition to:
1) Rapidly improving symptoms at the discretion of the investigator, which may indicate spontaneous recanalization
2) Contraindications for CT contrast precluding a CT angiography or perfusion study
3) Pregnancy or breastfeeding
4) Recent participation in another investigational drug or device study or registry in the past 30 days
5) Allergy to the test drug and its ingredients
6) Any terminal illness such that the patient would not be expected to survive more than three months
7) Other conditions in which investigators believe that participating in this study may be harmful to the patient

5. Subject withdrawal, removal and study termination

5.1 Subject withdrawal
Subjects who meet the inclusion criteria but fail to complete the study for some reasons are considered as withdrawers. Subject withdrawal includes two situations where subject withdraws by himself/herself and subjects withdraws by the discretion of investigators.
Subjects have the right to withdraw at any time during the study and are subjected to withdraw with occurrence of any of the following situations:
1) Poor study compliance: subjects do not take medication as prescribed or participate in study visits in time, affecting the analysis of efficacy and safety outcomes;
2) Suffering from adverse events or serious adverse events and are considered unsuitable to continue participating in the study by the judgement of the investigators;
3) Other situations that an investigator decides the subject’s participation should be ceased;
4) Subjects require to withdraw from the study.
Subjects who withdraw from the study should attend a final withdrawal visit. The date and reason for patient withdrawal should be recorded.

5.2 Subject removal
Subjects should be removed from the study if one of the following situations occurs.
1) Subject do not meet one of the inclusion criteria or meet one of the exclusion criteria after enrollment;
2) Violation of the principles of concomitant medication according to study protocol;
3) Subjects do not receive allocated treatment after enrollment;
4) Subjects do not complete any study visits after treatment;
5) Subjects with poor compliance that cannot guarantee to follow the prescribed treatment, therefore, affecting the analysis of efficacy and safety outcomes.

5.3 Study early termination

The study may be terminated prematurely by the principal investigator. Reasons include but are not limited to:

1) The number and/or severity of adverse events justifies discontinuation of the study
2) The number and/or severity of protocol violation justifies discontinuation of the study
3) New data become available which raise concern about the safety of the investigational product, so that continuation might cause unacceptable risks to subjects.

After such a decision, the Investigator must contact all participating subjects within two weeks, and written notification must be sent to the Ethics Committee.

6. Sample size calculation

The sample size is calculated based on the results derived from the EXTEND-IA TNK trial: 22% patients of the intravenous tenecteplase group and 10% patients of the intravenous alteplase group reached major reperfusion, and 1% patients in both groups respectively were found to have sICH. To adopt a conservative approach, for each dose stratum within the umbrella design, the null hypothesis was that not more than 10% of patients would achieve a positive primary outcome following the respective dose of tenecteplase, while the alternative hypothesis was that, not less than 25% of patients would achieve a positive primary outcome following the respective dose of tenecteplase. Sample size estimation using Simon’s two-stage design was conducted for each dose stratum, according to which the null hypothesis that the true response rate was 10% was tested against a one-sided alternative. In the first stage, 18 patients were to be accrued. If there were 2 or fewer positive responses in these 18 patients, meaning that the null hypothesis was not rejected and the dose stratum was to be stopped. Otherwise, 25 additional patients were to be accrued for a total of 43 patients for each dose stratum. The null hypothesis for each stratum was to be rejected if 8 or more positive responses were observed in 43 patients. This design was to yield a type I error rate of 0.05 and a power of 0.8 when the true response rate was 25%. Overall, at least 36 patients were to be enrolled with a maximum enrollment of 86 patients equally distributed between the 2 dose strata. This design would yield a one-sided type I error of 0.5 and a power of 80% to detect the presumed significant difference. In all, at least 36 patients would be enrolled with a maximum enrollment of 86 patients in sum of the 2 dose strata.

7. Treatment intervention

7.1 Investigational Product

1) Investigational product:

Tenecteplase (Guangzhou Recomgen Biotech Co., Ltd)

2) Product labelling

Commercial packages of tenecteplase(Guangzhou Recomgen Biotech Co., Ltd) are labelled by the manufacturer, Guangzhou Recomgen Biotech Co., Ltd, with storage conditions (store below 25°C), batch number and expiry date. The study sponsor shall provide supplementary labels which include protocol name and identification number, coordinating...
Principal Investigator details, sponsor contact details, and the words ‘for clinical trial use only’.

3) Administration

Patients will receive either dose of intravenous tenecteplase (0.25mg/kg, maximum 25 mg, or 0.32mg/kg, maximum 32mg) as a bolus over 5-10s and a following 2 mL bolus of saline for injection. Bridging endovascular treatment is optional.

4) Transportation and storage

Investigational products are delivered by the manufacturer Guangzhou Recomgen Biotech Co., Ltd with temperature controlled below 25°C through the whole process of transportation. Investigational product will be stored below 25°C until use in accordance with manufacturer’s instructions.

The investigator or his/her designee must maintain an adequate record regarding the administration of all investigational product within the trial. Used vials of investigational product must be labelled and retained for accountability purposes.

7.2 Randomization and blinding

Randomization is allowed when all the inclusion criteria are confirmed to be met (including signed informed consent by the patient or the proxies) and all the exclusion criteria have been ruled out. Randomization is performed using permuted blocks through a centralized website named Easy Random Trial (ERT) designed by Chuang Da medical science and Technology (Shanghai) Co., Ltd. by a team of professional and independent statisticians. Patients are stratified according to the time of randomization after last known well (4.5-12 hours, 12-24 hours) and site of occlusion/severe stenosis (intracranial segment of internal carotid artery and M1-segment of middle cerebral artery; extracranial segment of internal carotid artery, M2-segment of middle cerebral artery and anterior cerebral artery). The purpose of randomization in the Phase IIa umbrella-designed trial with multiple strata is not to enable subsequent comparisons between dose strata, but to ensure that participants in both strata are equally representative of the patient population. The dosage of tenecteplase is open-label while the raters involved in the subsequent radiological and clinical evaluation are blinded to the allocation. The independent date safety monitoring board (DSMB) has the access to all the unblinded data.

7.3 Endovascular treatment

If endovascular treatment is consented by the patient or the proxies and is considered feasible at the discretion of the neuro-interventionalists, the patient would be transferred to the interventional catheter suite to receive bridging endovascular treatment after thrombolysis. Thrombectomy will not be considered if hemorrhagic transformation or complete recanalization occurred before any operation of thrombectomy or angioplasty. Before any thrombectomy operation, catheter angiography should be performed to confirm the occlusion site and primary score on the modified Treatment In Cerebral Infarction (mTICI) scale. Maximally 3 passes of thrombectomy operation are allowed for each occluded artery. Digital subtraction angioplasty (DSA) should be performed following each pass and at the completion of the thrombectomy operation. Type of anesthesia should be recorded. Angioplasty and/or stenting are allowed if necessary.

7.4 Concomitant medication

If endovascular treatment is not performed, any drugs that can affect coagulation is prohibited within 24 hours after tenecteplase thrombolysis, including antiplatelet agents, anticoagulation
agents, defibrinated agents, thrombolytic agents, any drug that can affect the function of platelets, and any traditional Chinese medicine agents that can affect coagulation.

If only thrombectomy operation is performed during endovascular treatment, any drugs that can affect coagulation is prohibited within 24 hours after tenecteplase thrombolysis, including antiplatelet agents, anticoagulation agents, defibrinated agents, thrombolytic agents, any drug that can affect the function of platelets, and any traditional Chinese medicine agents that can affect coagulation.

If angioplasty and/or stenting is performed during endovascular treatment, antiplatelets and/or anticoagulants are allowed if necessary, within 24 hours after tenecteplase thrombolysis.

Any concomitant treatment is allowed (including antihypertensive treatment) except for the medications mentioned above.

Any prescription and treatment before randomization and during the study should be recorded in the case report form (CRF).

8. Radiological and clinical assessment

8.1 Radiological assessment

Standard multimodal CT (non-contrast head CT, CTP, head and neck CTA) imaging of each potentially eligible patient is acquired before enrollment. Perfusion imaging is real-time processed using fully-automated MISTar (Apollo Medical Imaging Technology, Melbourne, Victoria, Australia) with single value deconvolution with delay and dispersion correction to calculate volumes of hypoperfusion lesion (delay time [Delay Time]>3s) and infarct core (relative cerebral blood flow [rCBF] <30% within areas of DT>3s) at each site.

For patients not transferred to the catheter room after thrombolysis, repeat CT perfusion imaging (and neck CTA for patients with ICA-EC occlusion/severe stenosis) is performed at 4-6 hours after thrombolysis to assess reperfusion. For patients transferred to the catheter room, reperfusion is evaluated as a modified Treatment In Cerebral Ischemia (mTICI) score on the initial catheter angiography. CT angiography is centrally reconstructed from repeat CTP imaging also using MISTar to evaluate recanalization status at 4-6 hours after treatment for patients without catheter angiography. For patients transferred to the catheter room, recanalization status prior to thrombectomy/angioplasty is evaluated also using the first-run imaging of digital subtraction angiography (DSA).

A non-contrast head CT scan is performed at 24-48 hours after thrombolysis to check the occurrence of intracranial hemorrhagic transformation. Diffusion-weighted imaging (DWI) or non-contrast head CT for magnetic resonance (MR)-incompatible patients is performed at 3-5 days to calculate volumes of final infarct core using MISTar.

All of the imaging protocols of multimodal CT at each center will be centrally standardized through careful quality control. All of the imaging were centrally analyzed in a core lab. Baseline multimodal CT imaging will be re-analyzed to make sure that the entry criteria are met. The radiological outcome measurements will be evaluated by two independent and neuroradiologists, and a third independent rater will be consulted in cases of disagreement, who are all blinded to the treatment allocation.

8.2 Clinical assessments
Neurological defects and functional scores are measured by one certified investigator blinded to treatment allocation in each participating center.

1) NIHSS is evaluated before randomization, 4-6 hours and 24-48 hours after tenecteplase treatment, and repeated at 3-5 days, 7±1 days (or at discharge), 30±7 days and 90±7 days post treatment.

2) Modified Rankin Scale is assessed at 7±1 days (or at discharge), 30±7 days and 90±7 days post treatment through in-person visit or standardized telephone follow-up.

3) Barthel Index (BI) is assessed at 7±1 days (or at discharge), 30±7 days and 90±7 days post treatment through in-person visit or standardized telephone follow-up.

4) Cognitive evaluation is optional 90±7 days post treatment using MoCA and MMSE through in-person visit.

9. **Adverse Events (AEs) and Severe Adverse Events (SAEs)**

The investigator is responsible for the detection and documentation of events meeting the criteria and definition of an adverse event (AE) or a serious adverse event (SAE) as provided in this protocol. During the study, when there is a safety evaluation, the investigator or site staff will be responsible for detecting AEs and SAEs, as detailed in this section of the protocol.

9.1 **Definitions of AE and SAE**

An Adverse Event (AE) is any untoward medical occurrence in a patient temporarily associated with the use of an investigational product, whether or not considered related to the investigational product. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the product, whether or not considered related to the product.

Events belonging to the normal procedure of disease diagnosis and treatment (e.g. rehospitalization for second-stage stenting) are not reported as AEs.

A Serious Adverse Event (SAE) is any untoward medical occurrence that, at any dose, meeting at least one of the following criteria

1) Results in death;

2) Is life threatening;

Note: The term ‘life-threatening’ in the definition of ‘serious’ refers to an event in which the subject was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death if it were more severe.

3) Requires hospitalization or prolongation of an existing hospitalization;

4) Results in permanent or severe disability;

5) Is a congenital abnormality/birth defect;

6) Is a significant medical event

Medical and scientific judgement should be exercised in deciding whether reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalization, but may jeopardize the subject or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These should also be considered serious. SAEs require immediate report to the ethics committee within 24 hours.
9.2 Recording of AEs/SAEs

1) AE

When an AE occurs, the investigator should record all relevant information regarding an AE in to the CRF regardless of its severity and causality with the investigational product, from the moment when the participant signs the informed consent or from the first study visit to the last study visit. The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. In the absence of a diagnosis, the individual signs/symptoms should be documented. For each adverse event, start and stop dates, action taken, outcome, intensity and relationship to study product (causality) must be documented.

2) SAEs

Serious Adverse Events require immediate action.

Once an investigator becomes aware that an SAE has occurred, he/she should immediately notify the principal investigator, and fax the AE page in the CRF with all available details of the event and any non-serious AEs related to the SAE, to the principal investigator and the ethics committee, within 24 hours.

9.3 Follow-up of AEs and SAEs

After the initial AE/SAE report, the investigator is required to actively follow each subject and provide further information to the Steering Committee on the subject’s condition.

All AEs and SAEs documented at a previous visit/contact and are designated as ongoing, will be reviewed at subsequent visits/contacts.

All AEs and SAEs will be followed until resolution, until the condition stabilizes, until the event is otherwise explained, or until the subject is lost to follow-up. Once resolved, the appropriate AE/SAE CRF page(s) will be updated. The investigator will ensure that follow-up includes any supplemental investigations as may be indicated to elucidate the nature and/or causality of the AE or SAE. This may include additional laboratory tests or investigations, or consultation with other health care professionals.

New or updated information will be recorded on the originally completed SAE form, with all changes signed and dated by the investigator.

10. Study Plan

Standard multi-modal CT are performed to assess the eligibility of patients, including non-contrast head CT, CTP, head and neck CTA. CTP imaging will be real-time processed by MIStar (Apollo Medical Imaging Technology, Melbourne, Victoria, Australia).

Neurological impairment and functional scores (NIHSS, pre-stroke mRS) will be assessed by a trained stroke neurologist.

Bloods for standard care diagnostic evaluations will be collected and analyzed. Patients will be assessed for trial eligibility according to the Inclusion/Exclusion criteria including including a reprocessing of the baseline imaging data for assessment of the occlusion site by the core imaging lab.

An informed consent will be obtained from patients or their authorized representative prior to enrollment.

10.1 Baseline assessments
1) Demographic Information: Name, sex, age, ethnicity, telephone number, type of health insurance

2) Time of last known well, time of symptom recognition and time of hospital arrival

3) Risk factor (medical history): hypertension, diabetes mellitus, stroke, transient ischemic attack, coronary heart disease, myocardial infarction, arrhythmia, history of medication (aspirin, clopidogrel, warfarin, antihypertensive drugs, lipid-lowering drugs, antidiabetic drugs, heart rate control drugs), dementia, peripheral artery disease, dyslipidemia, hepatic and/or renal dysfunction, cervical and intracranial artery stenosis or malformation, smoking, drinking

4) Clinical assessments: vital signs (blood pressure, heart rate, respiratory rate and body temperature), NIHSS, and pre-stroke mRS

5) Imaging: Patients will have standardized multimodal CT (non-contrast head CT, CTP, head and neck CTA) prior to treatment, as previously described (9.1 Radiological assessments).

6) ECG

7) Laboratory test (including HCG test for women of reproductive age, routine hematology, biochemistry and coagulation screening tests)
   - Routine hematology: red blood cell count, mean corpuscular volume, white blood cell count, neutrophil (count, percent), eosinophil (count, percent), basophils (count, percent), lymphocyte (count, percent), monocyte (count, percent), hematocrit, hemoglobin, mean corpuscular hemoglobin, platelet count
   - Biochemistry: Renal function (creatinine, uric acid, urea nitrogen or urea), hepatic function (aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, glutamyl transpeptidase, total bilirubin, direct bilirubin, indirect bilirubin, total protein, albumin), glucose
   - Cardiac markers and pro-BNP: Troponin-T, Myoglobin, CK-MB, NT-pro BNP
   - Coagulation: PT, APTT, TT, FIB, INR, D-Dimer, fibrinogen degradation products (FDP)
   - HCG test

10.2 Randomization

Randomization is allowed when all the inclusion criteria are confirmed to be met (including signed informed consent by the patient or the proxies) and all the exclusion criteria have been ruled out. Randomization is performed using permuted blocks through a centralized website named Easy Random Trial (ERT) designed by Chuang Da Medical Science and Technology (Shanghai) Co., Ltd. by a team of professional and independent statisticians. Patients are stratified according to the time of randomization after last known well (4.5-12 hours, 12-24 hours) and site of occlusion/severe stenosis (intracranial segment of internal carotid artery and M1-segment of middle cerebral artery; extracranial segment of internal carotid artery, M2-segment of middle cerebral artery and anterior cerebral artery). The purpose of randomization in the Phase IIa umbrella-designed trial with multiple strata is not to enable subsequent comparisons between dose strata, but to ensure that participants in both strata are equally representative of the patient population. The dosage of tenecteplase is open-label while the raters involved in the subsequent radiological and clinical evaluation are blinded to the allocation.

10.3 Treatment administration
1) Intravenous thrombolysis: Patients will receive intravenous tenecteplase, either 0.25mg/kg (maximum 25mg) or 0.32mg/kg (maximum 32mg), administered as a bolus over 5–10 seconds. Vital signs will be recorded during and after the period of infusion as per standard care. The time of infusion commencement, completion and the dose administered is recorded.

2) Endovascular treatment: Endovascular treatment is optional: If endovascular treatment is consented by the patient or the proxies and is considered feasible at the discretion of the neuro-interventionalists, the patient will be transferred to the interventional catheter suite to receive bridging endovascular treatment after thrombolysis. Thrombectomy will not be considered if hemorrhagic transformation or complete recanalization occurred before any operation of thrombectomy or angioplasty. Before any thrombectomy operation, catheter angiography should be performed to confirm the occlusion site and primary modified Treatment In Cerebral Infarction (mTICI) scale. Only at most 3 passes of thrombectomy operation are allowed for each occluded artery. Digital subtraction angioplasty (DSA) should be performed following each pass and at the completion of the thrombectomy operation. Type of anesthesia should be recorded. Angioplasty and/or stenting are allowed if necessary and may require the use of antiplatelets. Attention should be paid to maintaining stable blood pressure and minimizing delays in starting the procedure. The initial and final angiograms will be centrally graded for angiographic reperfusion using the mTICI classification. Vital signs and any occurrence of AEs or SAEs during treatment should be documented. Close neurological observation will be conducted primarily during the first 48 hours after treatment administration according to local clinical practice.

10.4 Study visits (Table 1)

1) 4-6 hours
   - Vital signs, concomitant medication, NIHSS, new-onset cardio-cerebral vascular events, AEs/SAEs
   - For patients transferred to the catheter room: time of arterial puncture, time of first angiographic run, time of recanalization
   - Imaging:
     - For patients not transferred to the catheter room: CTP (+neck CTA if patients are primarily with ICA-EC severe stenosis/occlusion)
     - For patients transferred to the catheter room: DSA

2) 24-48 hours
   - Vital signs, concomitant medication, NIHSS, new-onset cardio-cerebral vascular events, AEs/SAEs
   - Imaging: Non-contrast head CT
   - Laboratory test: routine hematology, renal and hepatic function, cardiac markers, cardiac enzymes, pro-BNP, blood lipid, routine urine analysis, coagulation
   - Symptomatic intracranial hemorrhage (ECASS II criteria)
   - Systematic hemorrhage (GUSTO criteria)

3) 3-5 days
- Vital signs, concomitant medication, NIHSS, new-onset cardio-cerebral vascular events, AEs/SAEs
- Imaging: head MRI (including DWI), head TOF-MRA (+neck MRA if patients are primarily with ICA-EC severe stenosis/occlusion) SWI (optional).
- Symptomatic intracranial hemorrhage (ECASS II criteria)
- Systematic hemorrhage (GUSTO criteria)

4) 7±1 days (or at discharge)
- Vital signs, concomitant medication, NIHSS, mRS, BI, TOAST classification, new-onset cardio-cerebral vascular events, AEs/SAEs, holter monitoring results
- Laboratory test: routine hematology, renal and hepatic function, cardiac markers, cardiac enzymes, pro-BNP, blood lipid, routine urine analysis, coagulation

5) 30±7 days
- Vital signs, concomitant medication, NIHSS, mRS, BI, TOAST classification, new-onset cardio-cerebral vascular events, AEs/SAEs, holter monitoring results
- Cognitive tests (optional): MoCA, MMSE

6) 90±7 days
- Vital signs, concomitant medication, NIHSS, mRS, BI, TOAST classification, new-onset cardio-cerebral vascular events, AEs/SAEs, holter monitoring results
- Cognitive tests (optional): MoCA, MMSE

10.5 Study outcomes

1) Primary outcome
   The primary outcome is a binary composite of efficacy and safety, i.e., major reperfusion and absence of symptomatic intracranial hemorrhagic transformation (ICH) at 24-48 hours after intravenous tenecteplase. Major reperfusion was considered as the restoration of blood flow of greater than 50% of the involved territory.
   - For patients not transferred to the catheter room after thrombolysis, major reperfusion was assessed as reperfusion greater than 50% of the involved baseline hypoperfusion lesion volume (delay time > 3s) on repeat CT perfusion imaging at 4-6 hours after thrombolysis.
   - For patients transferred to the catheter room, major reperfusion was evaluated as a modified Treatment In Cerebral Ischemia (mTICI) score 2b/3 at the initial catheter angiography.

   Symptomatic ICH was defined according to the European Co-operative Acute Stroke Study-II (ECASS II) criteria, where the patients presented any type of intracranial hemorrhage with no less than 4 point-increase in National Institutes of Health Stroke Scale (NIHSS) from baseline or from the lowest NIHSS between baseline at 24-48 hours, or leading to death.

2) Secondary outcomes
   - Secondary radiological efficacy outcomes
     ✓ Recanalization defined by the Thrombolysis in Myocardial Infarction (TIMI) scale of 2/3 at the 4- to 6- hour CTA (reconstructed from CTP) for patients not transferred to the catheter room, or at digital subtraction angiography imaging prior to thrombectomy for patients transferred to the catheter room after thrombolysis;
Infarct growth on diffusion-weighted imaging (DWI) or non-contrast head CT at 3-5 days.

Secondary clinical efficacy outcomes
- Excellent functional outcome (disability-free, defined as modified Rankin Scale [mRS] 0-1) at 90 days;
- Good functional outcome (functional independence, defined as mRS 0-2) at 90 days; mRS distribution at 90 days;
- Major neurological improvement at 24-48 hours (NIHSS reduction greater than 7 points or NIHSS 0-1);
- Change in NIHSS as a continuous variable at 24-48 hours.

Secondary radiological safety outcomes
- Type 2 parenchymal hematoma (PH2);
- Symptomatic ICH;
- Any ICH at 24-48 hours post treatment.

Secondary clinical safety outcomes
- Poor functional outcome (severe disability or death, defined as mRS 5-6) at 90 days;
- Systemic bleeding defined by The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) before discharge.

Others:
- Barthel index at 90 days.

All of these clinical assessments will be conducted through on-site personnel who are blinded to the treatment allocation.

10.6 Protocol compliance

Study visits before discharge (4-6 hours, 24-48 hours, 3-5 days, 7±1 days or at discharge) will be completed together by a fellow doctor in charge of the treatment patients in hospital and one of the investigators both of whom are blinded to the treatment allocation.

Study visits after discharge (30±7 days, 90±7 days) will be completed through stroke clinic by one of the investigators who is blinded to the treatment allocation. Transportation fee of the participants will be covered by the trial. If the participant is incapable of arrival to the clinic in-person due to disability, these visits will be completed through standardized telephone follow-up by a trained investigator who is blinded to the treatment allocation.

11. Data analysis and statistical consideration

11.1 Sample size calculation

The sample size is calculated based on the results derived from the EXTEND-IA TNK trial: 22% patients of the intravenous tenecteplase group and 10% patients of the intravenous alteplase group reached major reperfusion, and 1% patients in both groups respectively were found to have sICH. To adopt a conservative approach, for each dose stratum within the umbrella design, the null hypothesis was that not more than 10% of patients would achieve a positive primary outcome following the respective dose of tenecteplase, while the alternative hypothesis was that, not less than 25% of patients would achieve a positive primary outcome following the respective dose of tenecteplase. Sample size estimation using Simon’s two-stage design was conducted for each dose.
stratum, according to which the null hypothesis that the true response rate was 10% was tested against a one-sided alternative. In the first stage, 18 patients were to be accrued. If there were 2 or fewer positive responses in these 18 patients, meaning that the null hypothesis was not rejected and the dose stratum was to be stopped. Otherwise, 25 additional patients were to be accrued for a total of 43 patients for each dose stratum. The null hypothesis for each stratum was to be rejected if 8 or more positive responses were observed in 43 patients. This design was to yield a type I error rate of 0.05 and a power of 0.8 when the true response rate was 25%. Overall, at least 36 patients were to be enrolled with a maximum enrollment of 86 patients equally distributed between the 2 dose strata. This design would yield a one-sided type I error of 0.5 and a power of 80% to detect the presumed significant difference. In all, at least 36 patients would be enrolled with a maximum enrollment of 86 patients in sum of the 2 dose strata.

11.2 General principles of data analysis

All of the statistical analysis will be performed on STATA v15.1 (StataCorp, Ltd, College Station, Texas).

11.3 Analysis of primary outcome

For the analysis of primary endpoint, as described above, if 3 or more of the 18 patients in the first stage of either dose stratum reach the primary endpoint, then additional 25 patients would be enrolled in that dose stratum. If 8 or more out of the 43 patients reach the primary endpoint within a given stratum after the second stage, then the corresponding tenecteplase dose could be considered to be of sufficient promise in terms of efficacy and safety and could be a qualified candidate dose for the subsequent phase IIb trial.

11.4 Analysis of secondary outcome

Since the design of this study is not aimed to compare the safety and efficacy of the two tenecteplase doses within the umbrella design, the analysis of secondary outcomes only involved data description without comparative analysis. Secondary outcomes were described using percentages, mean and standard deviation, median and interquartile range (IQR) as appropriate. Normality will be tested using Shapiro-Wilk test.

11.5 Sensitivity analysis

Preplanned sensitivity analysis is conducted by removing patients with severe stenosis and analyzing the primary and secondary outcomes of patients with complete artery occlusion in the two tenecteplase dose groups.

In case of any post-hoc subgroup analysis, they will be justified and identified as data-driven and, they will follow the principles and regulatory recommendations.

12. Ethical and regulatory standards

12.1 Ethical principles

This study will be conducted in accordance with the principles laid down by the 18th World Medical Assembly (Helsinki, 1964) and all applicable amendments laid down by the World Medical Assemblies and the ICH guidelines for Good Clinical Practice.

12.2 Laws and regulations
This study will be conducted in compliance with all international laws and regulations, and Chinese laws and regulations in which the Clinical Trial is performed, as well as any applicable guidelines.

12.3 Informed Consent

The investigator (according to applicable regulatory requirements), or a person designated by the investigator and under the investigator's responsibility, should fully inform the patient of all pertinent aspects of the Clinical Trial including the written information giving approval/favorable opinion by the Ethics Committee (IRB/IEC). All participants should be informed to the fullest extent possible about the study, in language and terms they are able to understand.

Prior to a patient's participation in the CHABLIS-T trial, the written informed consent form should be signed, name filled in and personally dated by the patient or by the patient's legally acceptable representative, and by the person who conducted the informed consent discussion. A copy of the signed and dated written Informed Consent Form will be provided to the patient.

The informed consent form used by the investigator for obtaining the patient's informed consent must be reviewed and approved by the sponsor prior to submission to the appropriate Ethics Committee (IRB/IEC) for approval/favorable opinion.

The protocol will be submitted for approval to the appropriate local institutional ethics committee, and written approval obtained, before participants are recruited and enrolled. The Investigators will receive all the documentation needed for submitting the present protocol to the ethics committee. A copy of the respective approval letters will be transmitted to the Study Monitor before starting the study. The compliance/composition of the Ethics Committee will also be provided to the Study Monitor. If approval is suspended or terminated by the ethics committee, the investigator will notify the Study Monitor immediately.

It is the responsibility of the Investigator to report study progress to the ethics committee as required, or at intervals not greater than one year.

The principal investigator, or his/her nominee, will be responsible for reporting any SAEs to the ethics committee as soon as possible, and in accordance with the guidelines of the Ethics Committee.

12.4 Institutional Review Board/ Independent Ethics Committee (IRB/IEC)

The investigator or the sponsor must submit this protocol to the appropriate ethics committee (IRB/IEC), and is required to forward to the Sponsor a copy of the written and dated approval/favorable opinion signed by the chairman with ethics committee (IRB/IEC) composition.

The clinical trial (study number, Clinical Trial Protocol title and version number), the documents reviewed (clinical trial protocol, informed consent form, investigator's brochure, investigator's CV, etc.), the list of voting members along with their qualification and the date of the review should be clearly stated on the written (IRB/IEC) approval/favorable opinion.

Investigational product will not be released at the study site and the trial will not start until a copy of this written and dated approval/favorable opinion has been received by the Sponsor.

During the study, any amendment or modification to the protocol should be submitted to the Ethics Committee (IRB/IEC). It should also be informed of any event likely to affect the safety of patients or the continued conduct of this trial, in particular any change in safety. All updates to the investigator's brochure will be sent to the ethics committee (IRB/IEC).

If requested, a progress report will be sent to the ethics committee (IRB/IEC) annually and a summary of the trial's outcome at the end of this trial.
13. Study monitoring

13.1 Responsibilities of the investigators

The Investigator(s) undertake(s) to perform the clinical trial in accordance with this protocol, ICH guidelines for Good Clinical Practice and the applicable regulatory requirements.

The investigator is required to ensure compliance with all procedures required by the protocol and with all study procedures provided by the Sponsor (including security rules). The investigator agrees to provide reliable data and all information requested by the Clinical

Trial protocol (with the help of the Case Report Form [CRF], Discrepancy Resolution Form [DRF] or other appropriate instrument) in an accurate and legible manner according to the instructions provided and to ensure direct access to source documents by Sponsor representatives.

The investigator may appoint such other individuals as he/she may deem appropriate as sub-investigators to assist in the conduct of the trial in accordance with the protocol. All sub-investigators shall be appointed and listed in a timely manner. The sub-investigators will be supervised by and under the responsibility of the Investigator. The investigator will provide them with a copy of this protocol and all necessary information.

The Sponsor of this Clinical Trial is responsible to Health Authorities for taking all reasonable steps to ensure the proper conduct of the clinical trial protocol as regards ethics, clinical trial protocol compliance, and integrity and validity of the data recorded on the case report forms.

Thus, the main duty of the monitoring team is to help the Investigator and the Sponsor maintain a high level of ethical, scientific, technical and regulatory quality in all aspects of the trial.

At regular intervals during the clinical trial, the site will be contacted, through monitoring visits, letters or telephone calls, by a representative of the Monitoring Team to review study progress, Investigator and patient compliance with the protocol requirements and any emergent problems. During these monitoring visits, the following, but not exhaustive, points will be scrutinized with the Investigator: patient informed consent, patient recruitment and follow-up, SAE documentation and reporting, investigational product allocation, patient compliance with the investigational product regimen, investigational product accountability, concomitant therapy use and quality of data.

13.2 Source document requirements

According to the ICH guidelines for Good Clinical Practice, the monitoring team must check the case report form entries against the source documents, except for the pre-identified source data directly recorded in the case report form. The informed consent form will include a statement by which the patient allows the sponsor's duly authorized personnel, the ethics committee (IRS/IEC), and the regulatory authorities to have direct access to source data which support the data on the case report forms (e.g., patient's medical file, appointment books, original laboratory records, etc.). Such personnel, bound by professional secrecy, must keep confidential all personal identity or personal medical information (according to confidentiality rules).

13.3 Data management

Paper-based case report form (CRF) and electronic data capture (EDC) system will be used for data collection and entry. All the content required by the protocol in the system must be provided, the unfilled content should be explained, and the reason needs to be filled in the remarks under each form of the EDC system.
Site investigators should use black or blue-black recording pens to fill out the paper-based CRF neatly and clearly to ensure that the data is clear and readable. If the paper-based CRF information needs to be modified, it should not be altered or overwritten. The correct information should be written next to the original information, signed and dated by the person who modified it. The clinical research monitor (CRA) will review the completeness and accuracy of the case report form and guide the investigator to make necessary corrections and supplements. After the paper-based CRF is completed, the research coordinator (CRC) will input the content of the paper CRF into the EDC system. The paper-based CRF is submitted after the investigator has approved it. After the data is submitted, all data revisions and feedback are carried out through the EDC system. If the EDC system has submitted a form that needs to be modified, you need to contact the CRA of this center. After the CRA opens the form, the investigator can guide the CRC to modify the EDC system data. Data will then be monitored by the CRA according to a data monitoring plan in a regular basis. After the last study visit of the last participant is finished, the data from the EDC will be exported to a database (in excel sheets), then it will be proofread by the data administrator. Obvious errors will be corrected by the data administrator. Other errors or missing values will be filled in the data query form and returned to the participating center for solution through email, express, telephone and WeChat.

The participating centers are responsible for correcting the data in the EDC system after verifying the original data and related information. Site investigators must answer these queries by verifying or modifying relevant information or data.

13.4 Confidentiality

All of the personal data of research participants (subjects) must be kept strictly confidential. Information and data of the study participants (subjects) are identified only by subject numbers rather than names. Identifiable information of participants (subjects) will not be disclosed to members outside the investigator teams, unless permission is obtained from the research participants (subjects). All of the investigators are required to keep the identities of study participants (subjects) confidential. The files of study participants (subjects) will be kept in locked filing cabinets and will only be accessible to authorized investigators. In order to ensure that the study is carried out in accordance with laws and regulations, government authorities or members of the ethics committee can access to the personal data of the research participants (subjects) according to regulations when necessary. No personal information of the research participants (subjects) will be disclosed at the time of publication of this research.

The research data are also confidential. All of the investigators are required to keep confidential to the research data. They shall not disclose the research data without the permission of the principal investigator to anyone who is not the member of the research team, and shall not transfer the research data to other institute without the permission of the hospital. The research data are not allowed to be disclosed to foreign institutes, or domestic institutes with foreign capital, without the permission of Human Genetic Resource Administration Office of China, except for the publication of research results that meet regulatory requirements under normal circumstances.

14. Funding

The study is sponsored by the National Key Research and Development Program of China (2017YFC1308201), Science and Technology Ministry of China. Guangzhou Recomgen Biotech
Co., Ltd. supplied the investigative drug and covered the trial insurance, but had no role in study design and execution.

15. Study Organization

15.1 Principle investigator
Qiang Dong, Huashan Hospital, Fudan University, Shanghai, China

15.2 Trial steering committee members
Qiang Dong (Principal Investigator), Mark Parsons, Xin Cheng, Leonid Churilov, Yilong Wang

✓ The steering committee will provide scientific and strategic direction for the trial and will have overall responsibility for its design, execution, and publication.
✓ The steering committee will also be responsible for ensuring that study execution and management are of the highest quality.
✓ It will approve the protocol and the operational guidelines of the trial prior to its commencement.
✓ The steering committee will convene regularly by teleconference or face-to-face meetings to discuss and report on the progress of the study.

15.3 Data safety and monitoring board
The DSMB will meet regularly and monitor the progress of the CHABLIS-T study to ensure that the study meets the highest standards of ethics and patient safety. It is composed of Academic Members, including an independent statistician, who are not otherwise participating in the trial.

Written recommendations and their rationale will be provided to the Chairs of the Steering Committee immediately after each DSMB meeting.

16. References


<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screening and Randomization</th>
<th>Thrombolysis Commencement</th>
<th>Visits</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-24h--4.5h</td>
<td>0h</td>
<td>4-6h</td>
</tr>
<tr>
<td>Demographic</td>
<td>X</td>
<td></td>
<td>24-48h</td>
</tr>
<tr>
<td>Previous medical</td>
<td>X</td>
<td></td>
<td>3-5 days or Discharge</td>
</tr>
<tr>
<td>Concomitant</td>
<td>X</td>
<td>X</td>
<td>7±1 days</td>
</tr>
<tr>
<td>Vital signs</td>
<td>X</td>
<td>X</td>
<td>30±7 days</td>
</tr>
<tr>
<td>Physical examinations</td>
<td>X</td>
<td>X</td>
<td>90±7 days</td>
</tr>
<tr>
<td>Pregnancy test</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood lab tests</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electrocardiography</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion and exclusion criteria</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomization</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imaging (CT/MRI/DSA)</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Symptomatic intracranial</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Modified Rankin Scale</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIH Stroke Scale</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>TOAST Classification</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cognitive evaluations</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Adverse events</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Barthel Index</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Only for female patients at reproductive age
2. 24-hour Holter monitoring
**CHinese Acute tissue-Based imaging selection for Lysis In Stroke -Tenecteplase (CHABLIS-T)**

**Protocol**

**Research Team:** Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China

**Principle Investigator:** Qiang Dong, MD, PhD, Professor of Neurology

**Protocol Version:** 3.0

**Nov. 2020**
Catalogue

Protocol Summary ................................................................. 68

1. Introduction .................................................................................. 71

2. Study Objective ............................................................................. 72

3. Study Design .................................................................................. 72

4. Patient Population .......................................................................... 73

5. Subject withdrawal, removal and study termination ....................... 74

6. Sample size calculation ................................................................. 75

7. Treatment intervention ................................................................... 75

8. Radiological and clinical assessment ........................................... 77

9. Adverse Events (AEs) and Severe Adverse Events (SAEs) ............. 78

10. Study Plan ..................................................................................... 79

11. Data analysis and statistical consideration .................................... 83

12. Ethical and regulatory standards ................................................ 84

13. Study monitoring .......................................................................... 85

14. Funding ......................................................................................... 87

15. Study Organization ....................................................................... 87

16. References ..................................................................................... 88

Table 1 Study Visits in CHABLIS-T .................................................. 91
# Protocol Summary

<table>
<thead>
<tr>
<th><strong>Protocol Title</strong></th>
<th>CHABLIS-T: CHinese Acute tissue-Based imaging selection for Lysis In Stroke - Tenecteplase</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Protocol Number</strong></td>
<td>KY2019-474</td>
</tr>
<tr>
<td><strong>Development Phase</strong></td>
<td>Phase 2a</td>
</tr>
<tr>
<td><strong>Study Population</strong></td>
<td>Acute ischemic stroke patients with large/medium vessel occlusion or severe stenosis presented within 4.5 to 24 hours from last known well, with penumbral mismatch identified by multimodal CT.</td>
</tr>
<tr>
<td><strong>Study Objective</strong></td>
<td>To explore the promise of efficacy and safety of different doses of tenecteplase (0.25mg/kg vs. 0.32mg/kg) in Chinese acute ischemic stroke patients with large/medium vessel occlusion or severe stenosis in an extended time window.</td>
</tr>
</tbody>
</table>

## Trial Design

The CHABLIS-T trial is a phase IIa, randomized, multicenter, open-label, blinded-endpoint, Simon’s two-stage, umbrella design study.

Eligible patients will be enrolled and 1:1 randomized into 2 dose group (0.25mg/kg and 0.32mg/kg) of tenecteplase (Guangzhou Recomgen Biotech Co., Ltd). An interim analysis will be conducted when each treatment arm recruits 18 patients. If three or more patients achieve the primary endpoint in either arm, then the study would continue to the 2nd stage, which would enroll an addition of 25 patients in that tenecteplase dose group (resulting in a total of 43 patients in that dose group), otherwise the dose group would be stopped. The intervention dose would be deemed to be of sufficient promise if 8 or more out of 43 patients achieved the primary outcome.

## Inclusion criteria

1. Patients presenting with acute ischemic stroke within 4.5-24 hours from time last known well
2. Patients’ age ≥ 18 years
3. Premorbid modified Rankin Scale 0-2
4. Clinically significant acute neurologic deficit (with no lower or upper limit of the National Institutes of Health Stroke Scale [NIHSS] score) at the discretion of the investigator
5. Anterior large/medium vessel occlusion or severe stenosis (>70% of the vessel caliber), including extracranial or intracranial ICA, M1 or M2 segment of MCA, and A1 or A2 segment of ACA, identified on head and neck CTA
6. Penumbral mismatch on CTP: Hypoperfusion lesion volume (Delay time\[DT\] > 3 s) to infarct core volume ratio (relative cerebral blood flow [rCBF] < 30%) > 1.2, an absolute difference of volume > 10 ml, and an ischemic core volume < 70ml
7. Patient/Legally Authorized Representative has signed the Informed Consent form.
Exclusion criteria

1. Extensive hypoattenuation region (more than 1/3 of the MCA territory) identified on baseline non-contrast CT (NCCT)
2. Any sign of an acute intracranial hemorrhage or subarachnoid hemorrhage identified on baseline NCCT
3. Previous ischemic stroke within 3 months
4. Past history of intracranial hemorrhage
5. Acute head trauma at presentation or recent major head trauma within 3 months
6. Recent history of intracranial/intraspinal surgery within 3 months
7. Gastrointestinal malignancy or gastrointestinal bleed within 21 days
8. Known bleeding diatheses: platelets count <100 000/mm³, INR >1.7, APTT >40 s, or PT >15 s
9. Use of a full dosage of low-molecular weighted heparin treatment within the previous 24 hours
10. Use of direct thrombin inhibitors or direct factor Xa inhibitors within the previous 48 hours unless the laboratory test of coagulation function is normal
11. Symptoms consistent with infective endocarditis
12. Known or suspected with aortic arch dissection
13. Presence of an intra-axial intracranial neoplasm

In addition to:
1. Rapidly improving symptoms at the discretion of the investigator, which may indicate spontaneous recanalization
2. Contraindications for CT contrast precluding a CT angiography or perfusion study.
3. Pregnancy or breastfeeding
4. Recent Participation in another investigational drug or device study or registry in the past 30 days
5. Allergy to the test drug and its ingredients
6. Any terminal illness such that the patient would not be expected to survive more than three months
7. Other conditions in which investigators believe that participating in this study may be harmful to the patient

Investigational drug

Intravenous Tenecteplase

Interventions

Patients were randomized in a 1:1 ratio into 2 tenecteplase dose groups, 0.25mg/kg and 0.32 mg/kg. Randomization was performed using permuted blocks through a centralized website. Patients were stratified according to time of randomization after last known well (4.5-12 hours, 12-24 hours) and site of occlusion/severe stenosis (ICA-IC and MCA-M1; ICA-EC, MCA-M2 and ACA).

Patients received either dose of intravenous tenecteplase (0.25mg/kg, maximum 25 mg, or 0.32mg/kg, maximum 40mg) as a bolus over 5-10s and a following 2 mL bolus of saline for injection.

Study outcome

Primary outcome

The primary outcome is a binary composite of efficacy and safety, i.e. major reperfusion and absence of sICH at 24-48 hours after intravenous tenecteplase.

Secondary outcomes

1. Secondary radiological efficacy outcomes:
1) Recanalization defined by the Thrombolysis in Myocardial Infarction (TIMI) scale of 2/3 at the 4- to 6-hour CTA (reconstructed from CTP) for patients not transferred to the catheter room, or at the first digital subtraction angiography run prior to thrombectomy for patients transferred to the catheter room after thrombolysis

2. Secondary clinical efficacy outcomes
   6) Excellent functional outcome (mRS 0-1) at 90 days
   7) Good functional outcome (mRS 0-2) at 90 days
   8) mRS distribution at 90 days
   9) Neurological improvement at 24-48 hours (NIHSS 0-1 or a NIHSS-improvement of ≥8)
   10) Change in NIHSS as a continuous variable at 24-48 hours

3. Secondary radiological safety outcomes
   4) Type 2 parenchymal hematoma at 24-48 hours
   5) sICH according to the ECASS II criteria at 24-48 hours
   6) Any intracranial hemorrhagic transformation at 24-48 hours post-treatment

4. Secondary clinical safety outcomes
   3) Poor functional outcome (mRS 5-6) at 90 days
   4) Systemic bleeding defined by The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries before discharge

5. Others:
   Barthel Index at 90 days

**Primary analysis**

For the analysis of the primary endpoint, if more than 2 out of the 18 patients in the first stage of either dosage group reach the primary endpoint, then another additive 25 patients will be enrolled in that group. If more than 7 out of the 43 patients reach the primary endpoint after the second stage, then the tenecteplase dosage could be considered as a qualified candidate dosage for a phase IIb trial.

Secondary outcomes will be described using percentages, mean and standard deviation, median and interquartile range (IQR) as appropriate. Normality will be tested using the Shapiro-Wilk test.
1. Introduction

Intravenous thrombolysis using alteplase is recommended as the first-line therapy for acute ischemic stroke (AIS) patients presented within 4.5 hours after stroke onset. However, only a very limited number of patients are able to receive the treatment due to its short treatment time window. A comparison study based on the data of China National Stroke Registry (CNSR) and the American Heart Association Get With The Guidelines Stroke Program (GWTG-Stroke Program) has shown that only 2.5% patients in CNSR and 8.1% patients in the GWTG-Stroke Program received intravenous thrombolytic therapy. Therefore, extending the treatment time window for AIS patients has become a hot research topic of clinical trials recently. Additionally, because alteplase acquires 1-hour continuous infusion after bolus and its efficacy can be undermined by any infusion delay and interruption, the necessity for alteplase in patients with large vessel occlusion has been questioned since the effect of endovascular treatment has been validated and acknowledged.

Existence of penumbral mismatch (substantial volume of tissue to salvage) is of great importance to the effect of reperfusion therapy. Recent randomized controlled trials (RCTs) using perfusion imaging to select patients with penumbral mismatch have demonstrated that intravenous thrombolysis may also be beneficial for AIS patients in an extend time window beyond 4.5 hours.

Tenecteplase (TNK) is a mutant variant of alteplase with a longer half-time life and higher fibrin specificity. TNK currently is recommended as the first-line intravenous medication for myocardial infarction with a dose of 0.5mg/kg, and its safety and efficacy in acute ischemic stroke patients have long been studied. The meta-analysis of the 5 RCTs (Haley et al., Australian TNK, ATTEST, NOR-TEST, EXTEND-IA TNK) comparing the effect of TNK and alteplase reveals that though the imaging selection criteria and treatment time window for each trial differ, the dose of 0.25mg/kg and 0.4 mg/kg TNK are non-inferior to alteplase in AIS patients (the noninferiority test of 0.1mg/kg TNK was underpowered due to limited sample size). Furthermore, pooled analyses using data of Australian TNK and ATTEST show that TNK may have superior recanalization efficacy in patients with complete large vessel occlusion to alteplase, especially in patients with penumbral mismatch on perfusion imaging. EXTEND-IA TNK has proven that for anterior circulation stroke patients with large vessel occlusion and perfusion mismatch, TNK could lead to a significantly higher rate of major reperfusion preceding endovascular treatment and better functional outcome, compared with alteplase in the 4.5-hour time window (rate of major of reperfusion: TNK 22% vs. alteplase 10%; median [IQR] mRS at 90 days: TNK 2[0-3] vs. alteplase 3[1-4]). These previous results implicate that based on the noninferiority of TNK to alteplase in AIS patients without advanced imaging selection, the superiority of TNK to alteplase may emerge in large vessel occlusion patients with perfusion mismatch.

Endovascular treatment has become a routine practice for the treatment of AIS patients with large/medium vessel occlusion, and its time window has been extended to 24 hours after last known normal through advanced imaging selection. However, Chinese LVO patients have been faced with the challenge of a longer reperfusion time compared with the Western population. One of the main reasons may relate to the high prevalence of in-situ thrombosis due to intracranial atherosclerotic disease (ICAD) in Asian patients with acute LVO, which is refractory to the current stent retrievers or aspiration systems. Additionally, the number of comprehensive stroke centers with capability of endovascular treatment is still insufficient given the broad landscape of China, and the drip-and-ship transfer system is still under-developed. Therefore, TNK can be a great candidate for reperfusion therapy considering its performance in large/medium vessel occlusion patients to extend the time window.
window of intravenous thrombolysis, improving the clinical outcome of Chinese AIS patients with large/medium vessel occlusion.

The doses of TNK tested in the previous RCTs in acute ischemic stroke patients are generally 0.1mg/kg, 0.25mg/kg and 0.4mg/kg. Tenecteplase has been approved for the intravenous thrombolysis in myocardial infarction by China Food and Drug Administration (CFDA). The tenecteplase dose proven to be safe during the dose escalation study in Chinese myocardial infarction patients ranges from 0.08mg/kg to 0.32mg/kg. However, the optimal dose of tenecteplase for Chinese acute ischemic stroke patients with large/medium vessel occlusion still remains undetermined. Additionally, Australia TNK demonstrated that 0.25mg/kg TNK was superior to 0.1mg/kg TNK in reperfusion efficacy.

Therefore, the doses of 0.25mg/kg and 0.32mg/kg tenecteplase are chosen as candidates of this Phase IIa trial to select an optimal dose of Chinese AIS patients with large/medium vessel occlusion.

Umbrella design is a trial design allowing evaluation of multiple therapies of a single disease without a control group in a minimal sample size, and is frequently applied in trials of oncology therapies. Based on the umbrella design, Simon’s two-stage design is further acknowledged as a simpler and more effective dose selection study method, especially in oncology trials. In order to evaluate the promise of efficacy and safety of 0.25mg/kg and 0.32 mg/kg tenecteplase in AIS patients with large/medium vessel occlusion with a minimal sample size, we therefore adopted the Simon’s two stage umbrella design in the CHABLIS-T trial and designed it as a phase IIa, randomized, multicenter, open-label, blinded-endpoint study.

2. Study Objective

To explore the promise of efficacy and safety of different doses of tenecteplase (0.25mg/kg vs. 0.32mg/kg) in Chinese acute ischemic stroke patients with large/medium vessel occlusion or severe stenosis in an extended time window.

3. Study Design

3.1 Overall design

The CHALIS-T trial is a phase IIa, randomized, multicenter, open-label, blinded-endpoint, Simon’s two-stage, umbrella design study.

3.2 Investigational Drug

Tenecteplase (Guangzhou Recomgen Biotech Co., Ltd)

3.3 Treatment allocation

Eligible patients will be enrolled and 1:1 randomized into 2 dose group (0.25mg/kg and 0.32mg/kg) of tenecteplase (Guangzhou Recomgen Biotech Co., Ltd). An interim analysis will be conducted when each treatment arm recruits 18 patients. If three or more patients achieve the primary endpoint in either arm, then the study would continue to the second stage, which would enroll an addition of 25 patients in that tenecteplase dose group (resulting in a total of 43 patients in that dose group), otherwise the dose group would be stopped. The intervention dose would be deemed to be of sufficient promise if 8 or more out of 43 patients achieved the primary outcome.
4. Patient Population

4.1 Inclusion criteria
1) Patients presenting with acute ischemic stroke within 4.5-24 hours from time last known well
2) Patients’ age ≥ 18 years
3) Premorbid modified Rankin Scale 0-2
4) Clinically significant acute neurologic deficit (with no lower or upper limit of the National Institutes of Health Stroke Scale [NIHSS] score) at the discretion of the investigator
5) Anterior large/medium vessel occlusion or severe stenosis (>70% of the vessel caliber), including extracranial or intracranial ICA, M1 or M2 segment of MCA, and A1 or A2 segment of ACA, identified on head and neck CTA
6) Penumbral mismatch on CTP: Hypoperfusion lesion volume (Delay time[DT]> 3 s) to infarct core volume ratio (relative cerebral blood flow [rCBF]<30%) > 1.2, an absolute difference of volume > 10 ml, and an ischemic core volume < 70ml
7) Patient/Legally Authorized Representative has signed the Informed Consent form.

4.2 Exclusion criteria
Patients are not allowed to participate if they are presented with any of the following standard intravenous thrombolysis exclusion criteria:
1) Extensive hypoattenuation region (more than 1/3 of the MCA territory) identified on baseline non-contrast CT (NCCT)
2) Any sign of an acute intracranial hemorrhage or subarachnoid hemorrhage identified on baseline NCCT
3) Previous ischemic stroke within 3 months
4) Past history of intracranial hemorrhage
5) Acute head trauma at presentation or recent major head trauma within 3 months
6) Recent history of intracranial/intraspinal surgery within 3 months
7) Gastrointestinal malignancy or gastrointestinal bleeding within 21 days
8) Known bleeding diatheses: platelets count <100,000/mm³, INR >1.7, APTT >40 s, or PT >15 s
9) Use of a full dosage of low-molecular weighted heparin treatment within the previous 24 hours
10) Use of direct thrombin inhibitors or direct factor Xa inhibitors within the previous 48 hours unless the laboratory test of coagulation function is normal
11) Symptoms consistent with infective endocarditis
12) Known or suspected aortic arch dissection
13) Presence with an intra-axial intracranial neoplasm

In addition to:
1) Rapidly improving symptoms at the discretion of the investigator, which may indicate spontaneous recanalization
2) Contraindications for CT contrast precluding a CT angiography or perfusion study
3) Pregnancy or breastfeeding
4) Recent participation in another investigational drug or device study or registry in the past 30 days
5) Allergy to the test drug and its ingredients
6) Any terminal illness such that the patient would not be expected to survive more than three months
7) Other conditions in which investigators believe that participating in this study may be harmful to the patient

5. Subject withdrawal, removal and study termination

5.1 Subject withdrawal

Subjects who meet the inclusion criteria but fail to complete the study for some reasons are considered as withdrawers. Subject withdrawal includes two situations where subject withdraws by himself/herself and subjects withdraws by the discretion of investigators.

Subjects have the right to withdraw at any time during the study and are subjected to withdraw with occurrence of any of the following situations:
5) Poor study compliance: subjects do not take medication as prescribed or participate in study visits in time, affecting the analysis of efficacy and safety outcomes;
6) Suffering from adverse events or serious adverse events and are considered unsuitable to continue participating in the study by the judgement of the investigators;
7) Other situations that an investigator decides the subject’s participation should be ceased;
8) Subjects require to withdraw from the study.

Subjects who withdraw from the study should attend a final withdrawal visit. The date and reason for patient withdrawal should be recorded.

5.2 Subject removal

Subjects should be removed from the study if one of the following situations occurs.
1) Subject do not meet one of the inclusion criteria or meet one of the exclusion criteria after enrollment;
2) Violation of the principles of concomitant medication according to study protocol;
3) Subjects do not receive allocated treatment after enrollment;
4) Subjects do not complete any study visits after treatment;
5) Subjects with poor compliance that cannot guarantee to follow the prescribed treatment, therefore, affecting the analysis of efficacy and safety outcomes.

5.3 Study early termination


The study may be terminated prematurely by the principal investigator. Reasons include but are not limited to:
1) The number and/or severity of adverse events justifies discontinuation of the study
2) The number and/or severity of protocol violation justifies discontinuation of the study
3) New data become available which raise concern about the safety of the investigational product, so that continuation might cause unacceptable risks to subjects.

After such a decision, the Investigator must contact all participating subjects within two weeks, and written notification must be sent to the Ethics Committee.

6. Sample size calculation

The sample size is calculated based on the results derived from the EXTEND-IA TNK trial: 22% patients of the intravenous tenecteplase group and 10% patients of the intravenous alteplase group reached major reperfusion, and 1% patients in both groups respectively were found to have sICH. To adopt a conservative approach, for each dose stratum within the umbrella design, the null hypothesis was that not more than 10% of patients would achieve a positive primary outcome following the respective dose of tenecteplase, while the alternative hypothesis was that, not less than 25% of patients would achieve a positive primary outcome following the respective dose of tenecteplase. Sample size estimation using Simon’s two-stage design was conducted for each dose stratum, according to which the null hypothesis that the true response rate was 10% was tested against a one-sided alternative. In the first stage, 18 patients were to be accrued. If there were 2 or fewer positive responses in these 18 patients, meaning that the null hypothesis was not rejected and the dose stratum was to be stopped. Otherwise, 25 additional patients were to be accrued for a total of 43 patients for each dose stratum. The null hypothesis for each stratum was to be rejected if 8 or more positive responses were observed in 43 patients. This design was to yield a type I error rate of 0.05 and a power of 0.8 when the true response rate was 25%. Overall, at least 36 patients were to be enrolled with a maximum enrollment of 86 patients equally distributed between the 2 dose strata. This design would yield a one-sided type I error of 0.5 and a power of 80% to detect the presumed significant difference. In all, at least 36 patients would be enrolled with a maximum enrollment of 86 patients in sum of the 2 dose strata.

7. Treatment intervention

7.1 Investigational Product
1) Investigational product:
   Tenecteplase (Guangzhou Recomgen Biotech Co., Ltd)
2) Product labelling
   Commercial packages of tenecteplase(Guangzhou Recomgen Biotech Co., Ltd) are labelled by the manufacturer, Guangzhou Recomgen Biotech Co., Ltd, with storage conditions (store below 25°C), batch number and expiry date. The study sponsor shall provide supplementary labels which include protocol name and identification number, coordinating Principal Investigator details, sponsor contact details, and the words ‘for clinical trial use only’.
3) Administration
Patients will receive either dose of intravenous tenecteplase (0.25mg/kg, maximum 25 mg, or 0.32mg/kg, maximum 32mg) as a bolus over 5-10s and a following 2 mL bolus of saline for injection. Bridging endovascular treatment is optional.

4) Transportation and storage

Investigational products are delivered by the manufacturer Guangzhou Recomgen Biotech Co., Ltd with temperature controlled below 25°C through the whole process of transportation.

Investigational product will be stored below 25°C until use in accordance with manufacturer’s instructions.

The investigator or his/her designee must maintain an adequate record regarding the administration of all investigational product within the trial. Used vials of investigational product must be labelled and retained for accountability purposes.

7.2 Randomization and blinding

Randomization is allowed when all the inclusion criteria are confirmed to be met (including signed informed consent by the patient or the proxies) and all the exclusion criteria have been ruled out. Randomization is performed using permuted blocks through a centralized website named Easy Random Trial (ERT) designed by Chuang Da medical science and Technology (Shanghai) Co., Ltd. by a team of professional and independent statisticians. Patients are stratified according to the time of randomization after last known well (4.5-12 hours, 12-24 hours) and site of occlusion/severe stenosis (intracranial segment of internal carotid artery and M1-segment of middle cerebral artery; extracranial segment of internal carotid artery, M2-segment of middle cerebral artery and anterior cerebral artery). The purpose of randomization in the Phase IIa umbrella-designed trial with multiple strata is not to enable subsequent comparisons between dose strata, but to ensure that participants in both strata are equally representative of the patient population. The dosage of tenecteplase is open-label while the raters involved in the subsequent radiological and clinical evaluation are blinded to the allocation. The independent date safety monitoring board (DSMB) has the access to all the unblinded data.

7.3 Endovascular treatment

If endovascular treatment is consented by the patient or the proxies and is considered feasible at the discretion of the neuro-interventionalists, the patient would be transferred to the interventional catheter suite to receive bridging endovascular treatment after thrombolysis. Thrombectomy will not be considered if hemorrhagic transformation or complete recanalization occurred before any operation of thrombectomy or angioplasty. Before any thrombectomy operation, catheter angiography should be performed to confirm the occlusion site and primary score on the modified Treatment In Cerebral Infarction (mTICI) scale. Maximally 3 passes of thrombectomy operation are allowed for each occluded artery. Digital subtraction angioplasty (DSA) should be performed following each pass and at the completion of the thrombectomy operation. Type of anesthesia should be recorded. Angioplasty and/or stenting are allowed if necessary.

7.4 Concomitant medication

If endovascular treatment is not performed, any drugs that can affect coagulation is prohibited within 24 hours after tenecteplase thrombolysis, including antiplatelet agents, anticoagulation agents, defibrinated agents, thrombolytic agents, any drug that can affect the function of platelets, and any traditional Chinese medicine agents that can affect coagulation.

If only thrombectomy operation is performed during endovascular treatment, any drugs that can affect coagulation is prohibited within 24 hours after tenecteplase thrombolysis, including antiplatelet...
agents, anticoagulation agents, defibrinated agents, thrombolytic agents, any drug that can affect the function of platelets, and any traditional Chinese medicine agents that can affect coagulation.

If angioplasty and/or stenting is performed during endovascular treatment, antiplatelets and/or anticoagulants are allowed if necessary, within 24 hours after tenecteplase thrombolysis.

Any concomitant treatment is allowed (including antihypertensive treatment) except for the medications mentioned above.

Any prescription and treatment before randomization and during the study should be recorded in the case report form (CRF).

8. Radiological and clinical assessment

8.1 Radiological assessment

Standard multimodal CT (non-contrast head CT, CTP, head and neck CTA) imaging of each potentially eligible patient is acquired before enrollment. Perfusion imaging is real-time processed using fully-automated MIStar (Apollo Medical Imaging Technology, Melbourne, Victoria, Australia) with single value deconvolution with delay and dispersion correction to calculate volumes of hypoperfusion lesion (delay time [Delay Time]>3s) and infarct core (relative cerebral blood flow [rCBF] <30% within areas of DT>3s) at each site.

For patients not transferred to the catheter room after thrombolysis, repeat CT perfusion imaging (and neck CTA for patients with ICA-EC occlusion/severe stenosis) is performed at 4-6 hours after thrombolysis to assess reperfusion. For patients transferred to the catheter room, reperfusion is evaluated as a modified Treatment In Cerebral Ischemia (mTICI) score on the initial catheter angiography. CT angiography is centrally reconstructed from repeat CTP imaging also using MIStar to evaluate recanalization status at 4-6 hours after treatment for patients without catheter angiography. For patients transferred to the catheter room, recanalization status prior to thrombectomy/angioplasty is evaluated also using the first-run imaging of digital subtraction angiography (DSA).

A non-contrast head CT scan is performed at 24-48 hours after thrombolysis to check the occurrence of intracranial hemorrhagic transformation. Diffusion-weighted imaging (DWI) or non-contrast head CT for magnetic resonance (MR)-incompatible patients is performed at 3-5 days to calculate volumes of final infarct core using MIStar.

All of the imaging protocols of multimodal CT at each center will be centrally standardized through careful quality control. All of the imaging were centrally analyzed in a core lab. Baseline multimodal CT imaging will be re-analyzed to make sure that the entry criteria are met. The radiological outcome measurements will be evaluated by two independent and neuroradiologists, and a third independent rater will be consulted in cases of disagreement, who are all blinded to the treatment allocation.

8.2 Clinical assessments

Neurological defects and functional scores are measured by one certified investigator blinded to treatment allocation in each participating center.

1) NIHSS is evaluated before randomization, 4-6 hours and 24-48 hours after tenecteplase treatment, and repeated at 3-5 days, 7±1 days (or at discharge), 30±7 days and 90±7 days post treatment.
2) Modified Rankin Scale is assessed at 7±1 days (or at discharge), 30±7 days and 90±7 days post treatment through in-person visit or standardized telephone follow-up.

3) Barthel Index (BI) is assessed at 7±1 days (or at discharge), 30±7 days and 90±7 days post treatment through in-person visit or standardized telephone follow-up.

4) Cognitive evaluation is optional 90±7 days post treatment using MoCA and MMSE through an in-person visit.

9. Adverse Events (AEs) and Severe Adverse Events (SAEs)

The investigator is responsible for the detection and documentation of events meeting the criteria and definition of an adverse event (AE) or a serious adverse event (SAE) as provided in this protocol. During the study, when there is a safety evaluation, the investigator or site staff will be responsible for detecting AEs and SAEs, as detailed in this section of the protocol.

9.1 Definitions of AE and SAE

An Adverse Event (AE) is any untoward medical occurrence in a patient temporarily associated with the use of an investigational product, whether or not considered related to the investigational product. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the product, whether or not considered related to the product.

Events belonging to the normal procedure of disease diagnosis and treatment (e.g. rehospitalization for second-stage stenting) are not reported as AEs.

A Serious Adverse Event (SAE) is any untoward medical occurrence that, at any dose, meeting at least one of the following criteria

1) Results in death;
2) Is life threatening;
   Note: The term ‘life-threatening’ in the definition of ‘serious’ refers to an event in which the subject was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death if it were more severe.
3) Requires hospitalization or prolongation of an existing hospitalization;
4) Results in permanent or severe disability;
5) Is a congenital abnormality/birth defect;
6) Is a significant medical event

Medical and scientific judgement should be exercised in deciding whether reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalization, but may jeopardize the subject or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These should also be considered serious. SAEs require immediate report to the ethics committee within 24 hours.

9.2 Recording of AEs/SAEs

1) AE

When an AE occurs, the investigator should record all relevant information regarding an AE in to the CRF regardless of its severity and causality with the investigational product, from the moment when the participant signs the informed consent or from the first study visit to the last study visit. The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or
other clinical information. In the absence of a diagnosis, the individual signs/symptoms should be documented. For each adverse event, start and stop dates, action taken, outcome, intensity and relationship to study product (causality) must be documented.

2) SAEs

Serious Adverse Events require immediate action.

Once an investigator becomes aware that an SAE has occurred, he/she should immediately notify the principal investigator, and fax the AE page in the CRF with all available details of the event and any non-serious AEs related to the SAE, to the principal investigator and the ethics committee, within 24 hours.

9.3 Follow-up of AEs and SAEs

After the initial AE/SAE report, the investigator is required to actively follow each subject and provide further information to the Steering Committee on the subject’s condition on the subject’s condition.

All AEs and SAEs documented at a previous visit/contact and are designated as ongoing, will be reviewed at subsequent visits/contacts.

All AEs and SAEs will be followed until resolution, until the condition stabilizes, until the event is otherwise explained, or until the subject is lost to follow-up. Once resolved, the appropriate AE/SAE CRF page(s) will be updated. The investigator will ensure that follow-up includes any supplemental investigations as may be indicated to elucidate the nature and/or causality of the AE or SAE. This may include additional laboratory tests or investigations, or consultation with other health care professionals.

New or updated information will be recorded on the originally completed SAE form, with all changes signed and dated by the investigator.

10. Study Plan

Standard multi-modal CT are performed to assess the eligibility of patients, including non-contrast head CT, CTP, head and neck CTA. CTP imaging will be real-time processed by MIStar (Apollo Medical Imaging Technology, Melbourne, Victoria, Australia).

Neurological impairment and functional scores (NIHSS, pre-stroke mRS) will be assessed by a trained stroke neurologist.

Bloods for standard care diagnostic evaluations will be collected and analyzed. Patients will be assessed for trial eligibility according to the Inclusion/Exclusion criteria including a reprocessing of the baseline imaging data for assessment of the occlusion site by the core imaging lab.

An informed consent will be obtained from patients or their authorized representative prior to enrollment.

10.1 Baseline assessments

1) Demographic Information: Name, sex, age, ethnics, telephone number, type of health insurance
2) Time of last known well, time of symptom recognition and time of hospital arrival
3) Risk factor (medical history): hypertension, diabetes mellitus, stroke, transient ischemic attack, coronary heart disease, myocardial infarction, arrhythmia, history of medication (aspirin, clopidogrel, warfarin, antihypertensive drugs, lipid-lowering drugs, antidiabetic drugs, heart
rate control drugs), dementia, peripheral artery disease, dyslipidemia, hepatic and/or renal dysfunction, cervical and/or intracranial artery stenosis or malformation, smoking, drinking

4) Clinical assessments: vital signs (blood pressure, heart rate, respiratory rate and body temperature), NIHSS, and pre-stroke mRS

5) Imaging: Patients will have standardized multimodal CT (non-contrast head CT, CTP, head and neck CTA) prior to treatment, as previously described (9.1 Radiological assessments).

6) ECG

7) Laboratory test (including HCG test for women of reproductive age, routine hematology, biochemistry and coagulation screening tests)
   - Routine hematology: red blood cell count, mean corpuscular volume, white blood cell count, neutrophil (count, percent), eosinophil (count, percent), basophils (count, percent), lymphocyte (count, percent), monocyte (count, percent), hematocrit, hemoglobin, mean corpuscular hemoglobin, platelet count
   - Biochemistry: Renal function (creatinine, uric acid, urea nitrogen or urea), hepatic function (aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, glutamyl transpeptidase, total bilirubin, direct bilirubin, indirect bilirubin, total protein, albumin), glucose
   - Cardiac markers and pro-BNP: Troponin-T, Myoglobin, CK-MB, NT-pro BNP
   - Coagulation: PT, APTT, TT, FIB, INR, D-Dimer, fibrinogen degradation products (FDP)
   - HCG test

10.2 Randomization

Randomization is allowed when all the inclusion criteria are confirmed to be met (including signed informed consent by the patient or the proxies) and all the exclusion criteria have been ruled out. Randomization is performed using permuted blocks through a centralized website named Easy Random Trial (ERT) designed by Chuang Da medical science and Technology (Shanghai) Co., Ltd. by a team of professional and independent statisticians. Patients are stratified according to the time of randomization after last known well (4.5-12 hours, 12-24 hours) and site of occlusion/severe stenosis (intracranial segment of internal carotid artery and M1-segment of middle cerebral artery; extracranial segment of internal carotid artery, M2-segment of middle cerebral artery and anterior cerebral artery). The purpose of randomization in the Phase IIa umbrella-designed trial with multiple strata is not to enable subsequent comparisons between dose strata, but to ensure that participants in both strata are equally representative of the patient population. The dosage of tenecteplase is open-label while the raters involved in the subsequent radiological and clinical evaluation are blinded to the allocation.

10.3 Treatment administration

1) Intravenous thrombolysis: Patients will receive intravenous tenecteplase, either 0.25mg/kg (maximum 25mg) or 0.32mg/kg (maximum 32mg), administered as a bolus over 5–10 seconds. Vital signs will be recorded during and after the period of infusion as per standard care. The time of infusion commencement, completion and the dose administered is recorded.

2) Endovascular treatment: Endovascular treatment is optional: If endovascular treatment is consented by the patient or the proxies and is considered feasible at the discretion of the neuro-interventionalists, the patient will be transferred to the interventional catheter suite to receive bridging endovascular treatment after thrombolysis. Thrombectomy will not be considered if
hemorrhagic transformation or complete recanalization occurred before any operation of thrombectomy or angioplasty. Before any thrombectomy operation, catheter angiography should be performed to confirm the occlusion site and primary score on the modified Treatment In Cerebral Infarction (mTICI) scale. Maximally 3 passes of thrombectomy operation are allowed for each occluded artery. Digital subtraction angioplasty (DSA) should be performed following each pass and at the completion of the thrombectomy operation. Type of anesthesia should be recorded. Angioplasty and/or stenting are allowed if necessary and may require the use of antiplatelets. Attention should be paid to maintaining stable blood pressure and minimizing delays in starting the procedure. The initial and final angiograms will be centrally graded for angiographic reperfusion using the mTICI classification.

Vital signs and any occurrence of AEs or SAEs during treatment should be documented. Close neurological observation will be conducted primarily during the first 48 hours after treatment administration according to local clinical practice.

10.4 Study visits (Table 1)

1) 4-6 hours
   - Vital signs, concomitant medication, NIHSS, new-onset cardio-cerebral vascular events, AEs/SAEs
   - For patients transferred to the catheter room: time of arterial puncture, time of first angiographic run, time of recanalization
   - Imaging:
     - For patients not transferred to the catheter room: CTP (+neck CTA if patients are primarily with ICA-EC severe stenosis/occlusion)
     - For patients transferred to the catheter room: DSA

2) 24-48 hours
   - Vital signs, concomitant medication, NIHSS, new-onset cardio-cerebral vascular events, AEs/SAEs
   - Imaging: Non-contrast head CT
   - Laboratory test: routine hematology, renal and hepatic function, cardiac markers, cardiac enzymes, pro-BNP, blood lipid, routine urine analysis, coagulation
   - Symptomatic intracranial hemorrhage (ECASS II criteria)
   - Systematic hemorrhage (GUSTO criteria)

3) 3-5 days
   - Vital signs, concomitant medication, NIHSS, new-onset cardio-cerebral vascular events, AEs/SAEs
   - Imaging: head MRI (including DWI), head TOF-MRA (+neck MRA if patients are primarily with ICA-EC severe stenosis/occlusion) SWI (optional). Head non-contrast CT, head CTA (+neck CTA if patients are primarily with ICA-EC severe stenosis/occlusion), If patients are incompatible with MRI (e.g., mental device implantation).
   - Symptomatic intracranial hemorrhage (ECASS II criteria)
   - Systematic hemorrhage (GUSTO criteria)

4) 7±1 days (or at discharge)
Vital signs, concomitant medication, NIHSS, mRS, BI, TOAST classification, new-onset cardio-cerebral vascular events, AEs/SAEs, holter monitoring results

Laboratory test: routine hematology, renal and hepatic function, cardiac markers, cardiac enzymes, pro-BNP, blood lipid, routine urine analysis, coagulation

5) 30±7 days
- Vital signs, concomitant medication, NIHSS, mRS, BI, TOAST classification, new-onset cardio-cerebral vascular events, AEs/SAEs, holter monitoring results
- Cognitive tests (optional): MoCA, MMSE

6) 90±7 days
- Vital signs, concomitant medication, NIHSS, mRS, BI, TOAST classification, new-onset cardio-cerebral vascular events, AEs/SAEs, holter monitoring results
- Cognitive tests (optional): MoCA, MMSE

10.5 Study outcomes

1) Primary outcome
The primary outcome is a binary composite of efficacy and safety, i.e., major reperfusion and absence of symptomatic intracranial hemorrhagic transformation (ICH) at 24-48 hours after intravenous tenecteplase. Major reperfusion was considered as the restoration of blood flow of greater than 50% of the involved territory.
- For patients not transferred to the catheter room after thrombolysis, major reperfusion was assessed as reperfusion greater than 50% of the involved hypoperfusion lesion volume (delay time > 3s) at baseline repeated CT perfusion imaging at 4-6 hours after thrombolysis.
- For patients transferred to the catheter room, major reperfusion was evaluated as a modified Treatment In Cerebral Ischemia (mTICI) score 2b/3 at the initial catheter angiography. Symptomatic ICH was defined according to the European Co-operative Acute Stroke Study-II (ECASS II) criteria, where the patients presented any type of intracranial hemorrhage with no less than 4 point-increase in National Institutes of Health Stroke Scale (NIHSS) from baseline or from the lowest NIHSS between baseline at 24-48 hours, or leading to death.

2) Secondary outcomes
- Secondary radiological efficacy outcomes
  - Recanalization defined by the Thrombolysis in Myocardial Infarction (TIMI) scale of 2/3 at the 4- to 6-hour CTA (reconstructed from CTP) for patients not transferred to the catheter room, or at digital subtraction angiography imaging prior to thrombectomy for patients transferred to the catheter room after thrombolysis;
  - Infarct growth on diffusion-weighted imaging (DWI) or non-contrast head CT at 3-5 days.
- Secondary clinical efficacy outcomes
  - Excellent functional outcome (disability-free, defined as modified Rankin Scale [mRS] 0-1) at 90 days;
  - Good functional outcome (functional independence, defined as mRS 0-2) at 90 days;
  - mRS distribution at 90 days;
  - Major neurological improvement at 24-48 hours (NIHSS reduction greater than 7 points or NIHSS 0-1);
Change in NIHSS as a continuous variable at 24-48 hours.

Secondary radiological safety outcomes
- Type 2 parenchymal hematoma (PH2);
- Symptomatic ICH;
- Any ICH at 24-48 hours post treatment.

Secondary clinical safety outcomes
- Poor functional outcome (severe disability or death, defined as mRS 5-6) at 90 days;
- Systemic bleeding defined by The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) before discharge.

Others:
- Barthel index at 90 days.

All of these clinical assessments will be conducted through on-site personnel who are blinded to the treatment allocation.

Protocol compliance

Study visits before discharge (4-6 hours, 24-48 hours, 3-5 days, 7±1 days or at discharge) will be completed together by a fellow doctor in charge of the treatment patients in hospital and one of the investigators both of whom are blinded to the treatment allocation.

Study visits after discharge (30±7 days, 90±7 days) will be completed through stroke clinic by one of the investigators who is blinded to the treatment allocation. Transportation fee of the participants will be covered by the trial. If the participant is incapable of arrival to the clinic in-person due to disability, these visits will be completed through standardized telephone follow-up by a trained investigator who is blinded to the treatment allocation.

11. Data analysis and statistical consideration

11.1 Sample size calculation

The sample size is calculated based on the results derived from the EXTEND-IA TNK trial: 22% patients of the intravenous tenecteplase group and 10% patients of the intravenous alteplase group reached major reperfusion, and 1% patients in both groups respectively were found to have sICH. To adopt a conservative approach, for each dose stratum within the umbrella design, the null hypothesis was that not more than 10% of patients would achieve a positive primary outcome following the respective dose of tenecteplase, while the alternative hypothesis was that, not less than 25% of patients would achieve a positive primary outcome following the respective dose of tenecteplase. Sample size estimation using Simon’s two-stage design was conducted for each dose stratum, according to which the null hypothesis that the true response rate was 10% was tested against a one-sided alternative. In the first stage, 18 patients were to be accrued. If there were 2 or fewer positive responses in these 18 patients, meaning that the null hypothesis was not rejected and the dose stratum was to be stopped. Otherwise, 25 additional patients were to be accrued for a total of 43 patients for each dose stratum. The null hypothesis for each stratum was to be rejected if 8 or more positive responses were observed in 43 patients. This design was to yield a type I error rate of 0.05 and a power of 0.8 when the true response rate was 25%. Overall, at least 36 patients were to be enrolled with a maximum enrollment of 86 patients equally distributed between the 2 dose strata. This design would yield a one-sided type I error of 0.5 and a power of 80% to detect the presumed significant difference. In all, at least 36 patients would be enrolled with a maximum enrollment of 86 patients in sum of the 2 dose strata.
11.2 General principles of data analysis

All of the statistical analysis will be performed on STATA v15.1 (StataCorp, Ltd, College Station, Texas).

11.3 Analysis of primary outcome

For the analysis of primary endpoint, as described above, if 3 or more of the 18 patients in the first stage of either dose stratum reach the primary endpoint, then additional 25 patients would be enrolled in that dose stratum. If 8 or more out of the 43 patients reach the primary endpoint within a given stratum after the second stage, then the corresponding tenecteplase dose could be considered to be of sufficient promise in terms of efficacy and safety and could be a qualified candidate dose for the subsequent phase IIb trial.

11.4 Analysis of secondary outcome

Since the design of this study is not aimed to compare the safety and efficacy of the two tenecteplase doses within the umbrella design, the analysis of secondary outcomes only involved data description without comparative analysis. Secondary outcomes were described using percentages, mean and standard deviation, median and interquartile range (IQR) as appropriate. Normality will be tested using Shapiro-Wilk test.

11.5 Sensitivity analysis

Preplanned sensitivity analysis is conducted by removing patients with severe stenosis and analyzing the primary and secondary outcomes of patients with complete artery occlusion in the two tenecteplase dose groups.

In case of any post-hoc subgroup analysis, they will be justified and identified as data-driven and, they will follow the principles and regulatory recommendations.

12. Ethical and regulatory standards

12.1 Ethical principles

This study will be conducted in accordance with the principles laid down by the 18th World Medical Assembly (Helsinki, 1964) and all applicable amendments laid down by the World Medical Assemblies and the ICH guidelines for Good Clinical Practice.

12.2 Laws and regulations

This study will be conducted in compliance with all international laws and regulations, and Chinese laws and regulations in which the Clinical Trial is performed, as well as any applicable guidelines.

12.3 Informed Consent

The investigator (according to applicable regulatory requirements), or a person designated by the investigator and under the investigator's responsibility, should fully inform the patient of all pertinent aspects of the Clinical Trial including the written information giving approval/favorable opinion by the Ethics Committee (IRB/IEC). All participants should be informed to the fullest extent possible about the study, in language and terms they are able to understand.

Prior to a patient's participation in the CHABLIS-T trial, the written informed consent form should be signed, name filled in and personally dated by the patient or by the patient's legally acceptable representative, and by the person who conducted the informed consent discussion. A copy of the signed and dated written Informed Consent Form will be provided to the patient.
The informed consent form used by the investigator for obtaining the patient's informed consent must be reviewed and approved by the sponsor prior to submission to the appropriate Ethics Committee (IRB/IEC) for approval/favorable opinion.

The protocol will be submitted for approval to the appropriate local institutional ethics committee, and written approval obtained, before participants are recruited and enrolled. The Investigators will receive all the documentation needed for submitting the present protocol to the ethics committee. A copy of the respective approval letters will be transmitted to the Study Monitor before starting the study. The compliance/composition of the Ethics Committee will also be provided to the Study Monitor. If approval is suspended or terminated by the ethics committee, the investigator will notify the Study Monitor immediately.

It is the responsibility of the Investigator to report study progress to the ethics committee as required, or at intervals not greater than one year.

The principal investigator, or his/her nominee, will be responsible for reporting any SAEs to the ethics committee as soon as possible, and in accordance with the guidelines of the Ethics Committee.

12.4 Institutional Review Board/ Independent Ethics Committee (IRB/IEC)

The investigator or the sponsor must submit this protocol to the appropriate ethics committee (IRB/IEC), and is required to forward to the Sponsor a copy of the written and dated approval/favorable opinion signed by the chairman with ethics committee (IRB/IEC) composition.

The clinical trial (study number, Clinical Trial Protocol title and version number), the documents reviewed (clinical trial protocol, informed consent form, investigator's brochure, investigator's CV, etc.), the list of voting members along with their qualification and the date of the review should be clearly stated on the written (IRB/IEC) approval/favorable opinion.

Investigational product will not be released at the study site and the trial will not start until a copy of this written and dated approval/favorable opinion has been received by the Sponsor.

During the study, any amendment or modification to the protocol should be submitted to the Ethics Committee (IRB/IEC). It should also be informed of any event likely to affect the safety of patients or the continued conduct of this trial, in particular any change in safety. All updates to the investigator's brochure will be sent to the ethics committee (IRB/IEC).

If requested, a progress report will be sent to the ethics committee (IRB/IEC) annually and a summary of the trial's outcome at the end of this trial.

13. Study monitoring

13.1 Responsibilities of the investigators

The Investigator(s) undertake(s) to perform the clinical trial in accordance with this protocol, ICH guidelines for Good Clinical Practice and the applicable regulatory requirements.

The investigator is required to ensure compliance with all procedures required by the protocol and with all study procedures provided by the Sponsor (including security rules). The investigator agrees to provide reliable data and all information requested by the Clinical Trial protocol (with the help of the Case Report Form [CRF], Discrepancy Resolution Form [DRF] or other appropriate instrument) in an accurate and legible manner according to the instructions provided and to ensure direct access to source documents by Sponsor representatives.

The investigator may appoint such other individuals as he/she may deem appropriate as sub-investigators to assist in the conduct of the trial in accordance with the protocol. All sub-investigators
shall be appointed and listed in a timely manner. The sub-investigators will be supervised by and under
the responsibility of the Investigator. The investigator will provide them with a copy of this protocol
and all necessary information.

The Sponsor of this Clinical Trial is responsible to Health Authorities for taking all reasonable steps
to ensure the proper conduct of the clinical trial protocol as regards ethics, clinical trial protocol
compliance, and integrity and validity of the data recorded on the case report forms. Thus, the main
duty of the monitoring team is to help the Investigator and the Sponsor maintain a high level of ethical,
scientific, technical and regulatory quality in all aspects of the trial.

At regular intervals during the clinical trial, the site will be contacted, through monitoring visits,
letters or telephone calls, by a representative of the Monitoring Team to review study progress,
Investigator and patient compliance with the protocol requirements and any emergent problems. During
these monitoring visits, the following, but not exhaustive, points will be scrutinized with the
Investigator: patient informed consent, patient recruitment and follow-up, SAE documentation and
reporting, investigational product allocation, patient compliance with the investigational product
regimen, investigational product accountability, concomitant therapy use and quality of data.

13.2 Source document requirements

According to the ICH guidelines for Good Clinical Practice, the monitoring team must check the
case report form entries against the source documents, except for the pre-identified source data directly
recorded in the case report form. The informed consent form will include a statement by which the
patient allows the sponsor's duly authorized personnel, the ethics committee (IRS/IEC), and the
regulatory authorities to have direct access to source data which support the data on the case report
forms (e.g., patient's medical file, appointment books, original laboratory records, etc.). Such
personnel, bound by professional secrecy, must keep confidential all personal identity or personal
medical information (according to confidentiality rules).

13.3 Data management

Paper-based case report form (CRF) and electronic data capture (EDC) system will be used for data
collection and entry. All the content required by the protocol in the system must be provided, the
unfilled content should be explained, and the reason needs to be filled in the remarks under each form
of the EDC system.

Site investigators should use black or blue-black recording pens to fill out the paper-based CRF
neatly and clearly to ensure that the data is clear and readable. If the paper-based CRF information
needs to be modified, it should not be altered or overwritten. The correct information should be written
next to the original information, signed and dated by the person who modified it. The clinical research
monitor (CRA) will review the completeness and accuracy of the case report form and guide the
investigator to make necessary corrections and supplements. After the paper-based CRF is completed,
the research coordinator (CRC) will input the content of the paper CRF into the EDC system. The
paper-based CRF is submitted after the investigator has approved it. After the data is submitted, all data
revisions and feedback are carried out through the EDC system. If the EDC system has submitted a
form that needs to be modified, you need to contact the CRA of this center. After the CRA opens the
form, the investigator can guide the CRC to modify the EDC system data. Data will then be monitored
by the CRA according to a data monitoring plan in a regular basis. After the last study visit of the last
participant is finished, the data from the EDC will be exported to a database (in excel sheets), then it
will be proofread by the data administrator. Obvious errors will be corrected by the data administrator.
Other errors or missing values will be filled in the data query form and returned to the participating center for solution through email, express, telephone and WeChat.

The participating centers are responsible for correcting the data in the EDC system after verifying the original data and related information. Site investigators must answer these queries by verifying or modifying relevant information or data.

13.4 Confidentiality

All of the personal data of research participants (subjects) must be kept strictly confidential. Information and data of the study participants (subjects) are identified only by subject numbers rather than names. Identifiable information of participants (subjects) will not be disclosed to members outside the investigator teams, unless permission is obtained from the research participants (subjects). All of the investigators are required to keep the identities of study participants (subjects) confidential. The files of study participants (subjects) will be kept in locked filing cabinets and will only be accessible to authorized investigators. In order to ensure that the study is carried out in accordance with laws and regulations, government authorities or members of the ethics committee can access to the personal data of the research participants (subjects) according to regulations when necessary. No personal information of the research participants (subjects) will be disclosed at the time of publication of this research.

The research data are also confidential. All of the investigators are required to keep confidential to the research data. They shall not disclose the research data without the permission of the principal investigator to anyone who is not the member of the research team, and shall not transfer the research data to other institute without the permission of the hospital. The research data are not allowed to be disclosed to foreign institutes, or domestic institutes with foreign capital, without the permission of Human Genetic Resource Administration Office of China, except for the publication of research results that meet regulatory requirements under normal circumstances.

14. Funding

The study is sponsored by the National Key Research and Development Program of China (2017YFC1308201), Science and Technology Ministry of China. Guangzhou Recomgen Biotech Co., Ltd. supplied the investigative drug and covered the trial insurance, but had no role in study design and execution.

15. Study Organization

15.1 Principle investigator

Qiang Dong, Huashan Hospital, Fudan University, Shanghai, China

15.2 Trial steering committee members

Qiang Dong (Principal Investigator), Mark Parsons, Xin Cheng, Leonid Churilov, Yilong Wang

✓ The steering committee will provide scientific and strategic direction for the trial and will have overall responsibility for its design, execution, and publication.

✓ The steering committee will also be responsible for ensuring that study execution and management are of the highest quality.
✓ It will approve the protocol and the operational guidelines of the trial prior to its commencement.
✓ The steering committee will convene regularly by teleconference or face-to-face meetings to discuss and report on the progress of the study.

15.3 Data safety and monitoring board

The DSMB will meet regularly and monitor the progress of the CHABLIS-T study to ensure that the study meets the highest standards of ethics and patient safety. It is composed of Academic Members, including an independent statistician, who are not otherwise participating in the trial.

Written recommendations and their rationale will be provided to the Chairs of the Steering Committee immediately after each DSMB meeting.

16. References


BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s).


Table 1 Study Visits in CHABLIS-T

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Screening and Randomization</th>
<th>Thrombolysis Commencement</th>
<th>Visits</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-24h—4.5h</td>
<td>0h</td>
<td>4-6h</td>
</tr>
<tr>
<td>Demographic information</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Previous medical history</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant medications</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Vital signs</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Physical examinations</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy test¹</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood lab tests²</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electrocardiography</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion and exclusion criteria confirmation</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomization</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imaging (CT/MRI/DSA)</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Symptomatic intracranial hemorrhage</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Modified Rankin Scale</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIH Stroke Scale</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>TOAST Classification</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cognitive evaluations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse events</td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Barthel Index</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Only for female patients at reproductive age
2. 24-hour Holter monitoring
## Summary of protocol amendments

### Protocol changes version 1.0 (Sept. 2019) to 2.0 (Nov. 2019)

<table>
<thead>
<tr>
<th>Protocol 1.0</th>
<th>Protocol 2.0</th>
</tr>
</thead>
<tbody>
<tr>
<td>7) 7±1 days (or at discharge)</td>
<td>4) 7±1 days (or at discharge)</td>
</tr>
<tr>
<td>- Vital signs, concomitant medication, NIHSS, mRS, BI, new-onset cardio-cerebral vascular events, AEs/SAEs</td>
<td>- Vital signs, concomitant medication, NIHSS, mRS, BI, TOAST classification, new-onset cardio-cerebral vascular events, AEs/SAEs, holter monitoring results</td>
</tr>
<tr>
<td>- Laboratory test: routine hematology, renal and hepatic function, cardiac markers, cardiac enzymes, pro-BNP, blood lipid, routine urine analysis, coagulation</td>
<td>- Laboratory test: routine hematology, renal and hepatic function, cardiac markers, cardiac enzymes, pro-BNP, blood lipid, routine urine analysis, coagulation</td>
</tr>
<tr>
<td>8) 30±7 days</td>
<td>5) 30±7 days</td>
</tr>
<tr>
<td>- Vital signs, concomitant medication, NIHSS, mRS, BI, new-onset cardio-cerebral vascular events, AEs/SAEs,</td>
<td>- Vital signs, concomitant medication, NIHSS, mRS, BI, TOAST classification, new-onset cardio-cerebral vascular events, AEs/SAEs, holter monitoring results</td>
</tr>
<tr>
<td>- Cognitive tests (optional): MoCA, MMSE</td>
<td>- Cognitive tests (optional): MoCA, MMSE</td>
</tr>
<tr>
<td>9) 90±7 days</td>
<td>6) 90±7 days</td>
</tr>
<tr>
<td>- Vital signs, concomitant medication, NIHSS, mRS, BI, new-onset cardio-cerebral vascular events, AEs/SAEs</td>
<td>- Vital signs, concomitant medication, NIHSS, mRS, BI, TOAST classification, new-onset cardio-cerebral vascular events, AEs/SAEs, holter monitoring results</td>
</tr>
<tr>
<td>- Cognitive tests (optional): MoCA, MMSE</td>
<td>- Cognitive tests (optional): MoCA, MMSE</td>
</tr>
</tbody>
</table>

### Protocol changes Version 2.0 (Nov. 2019) to 3.0 (Nov. 2020)

<table>
<thead>
<tr>
<th>Protocol 2.0</th>
<th>Protocol 3.0</th>
</tr>
</thead>
<tbody>
<tr>
<td>3) 3-5 days</td>
<td>3) 3-5 days</td>
</tr>
<tr>
<td>- Vital signs, concomitant medication, NIHSS, new-onset cardio-cerebral vascular events, AEs/SAEs</td>
<td>- Vital signs, concomitant medication, NIHSS, new-onset cardio-cerebral vascular events, AEs/SAEs</td>
</tr>
<tr>
<td>- Imaging: head MRI (including DWI), head TOF-MRA (+neck MRA if patients are primarily with ICA-EC severe stenosis/occlusion) SWI (optional).</td>
<td>- Imaging: head MRI (including DWI), head TOF-MRA (+neck MRA if patients are primarily with ICA-EC severe stenosis/occlusion) SWI (optional). Head non-contrast CT, head CTA (+neck CTA if patients are primarily with ICA-EC severe</td>
</tr>
</tbody>
</table>
● Systematic hemorrhage (GUSTO criteria)

| stenosis/occlusion), If patients are incompatible with MRI (e.g., mental device implantation). |
| Symptomatic intracranial hemorrhage (ECASS II criteria) |
| Systematic hemorrhage (GUSTO criteria) |
CHinese Acute tissue-Based imaging selection for
Lysis In Stroke - Tenecteplase
(CHABLIS-T)

Statistical Analysis Plan

Research Team: Department of Neurology, Huashan Hospital,
Fudan University, Shanghai, China

Principle Investigator: Qiang Dong, MD, PhD, Professor of
Neurology

Biostatistician: Hongqiong Gu, China National Clinical Research
Center for Neurological Diseases, Beijing Tiantan Hospital,
Capital Medical University, Beijing 100085, China
Catalogue

1. Study Overview ............................................................................................................... 96
   1.1 Study design ........................................................................................................... 96
   1.2 Study aim .............................................................................................................. 96
   1.3 Patient population ............................................................................................... 96
   1.4 Randomization procedure .................................................................................... 97
   1.5 Baseline and follow-up assessments .................................................................. 97
   1.6 Sample size justification ....................................................................................... 98
   1.7 Unblinding ............................................................................................................. 98
   1.8 Definition of outcomes ......................................................................................... 98

2. Funding ........................................................................................................................... 99

3. Statistical analysis ......................................................................................................... 100
   3.1 Descriptive analysis .............................................................................................. 100
   3.2 Analysis of primary outcome .............................................................................. 100
   3.3 Analysis of secondary outcome .......................................................................... 100
   3.4 Interim analysis .................................................................................................... 101
   3.5 Sensitivity analysis .............................................................................................. 102
   3.6 Handling of missing data .................................................................................... 102
   3.7 Interim analysis .................................................................................................... 102
   3.8 Data blind review ............................................................................................... 102
   3.9 Data safety monitoring board ............................................................................. 102
1. Study Overview

1.1 Study design

The CHALIS-T trial is a phase IIa, randomized, multicenter, open-label, blinded-endpoint, Simon’s two-stage, umbrella design study.

1.2 Study aim

To explore the promise of efficacy and safety of different doses of tenecteplase (0.25mg/kg vs. 0.32mg/kg) in Chinese acute ischemic stroke patients with large/medium vessel occlusion or severe stenosis in an extended time window.

1.3 Patient population

1.3.1 Inclusion criteria

1) Patients presenting with acute ischemic stroke within 4.5-24 hours from time last known well.
2) Patient's age ≥ 18 years
3) Premorbid modified Rankin Scale 0-2
4) Clinically significant acute neurologic deficit (with no lower or upper limit of the National Institutes of Health Stroke Scale [NIHSS] score) at the discretion of the investigator.
5) Anterior large/medium vessel occlusion or severe stenosis (>70% of the vessel caliber), including extracranial or intracranial ICA, M1 or M2 segment of MCA, and A1 or A2 segment of ACA, identified on head and neck CTA
6) Penumbral mismatch on CTP: Hypoperfusion lesion volume (Delay time[DT]> 3 s) to infarct core volume ratio (relative cerebral blood flow [rCBF]<30%) > 1.2, an absolute difference of volume > 10 ml, and an ischemic core volume < 70ml.
7) Patient/Legally Authorized Representative has signed the Informed Consent form.

1.3.2 Exclusion criteria

Patients are not allowed to participate if they are presented with any of the following standard intravenous thrombolysis exclusion criteria:

1) Extensive hypoattenuation region (more than 1/3 of the MCA territory) identified on baseline non-contrast CT (NCCT).
2) Any sign of an acute intracranial hemorrhage or subarachnoid hemorrhage identified on baseline NCCT.
3) Previous ischemic stroke within 3 months
4) Past history of intracranial hemorrhage.
5) Acute head trauma at presentation or recent major head trauma within 3 months
6) Recent history of intracranial/intraspinal surgery within 3 months
7) Gastrointestinal malignancy or gastrointestinal bleeding within 21 days
8) Known bleeding diatheses: platelets count <100 000/mm3, INR >1.7, APTT >40 s, or PT >15 s
9) Use of a full dosage of low-molecular weighted heparin treatment within the previous 24 hours
10) Use of direct thrombin inhibitors or direct factor Xa inhibitors within the previous 48 hours
unless the laboratory test of coagulation function is normal
11) Symptoms consistent with infective endocarditis
12) Known or suspected aortic arch dissection
13) Presence with an intra-axial intracranial neoplasm

In addition to:
14) Rapidly improving symptoms at the discretion of the investigator, which may indicate spontaneous recanalization
15) Contraindications for CT contrast precluding a CT angiography or perfusion study
16) Pregnancy or breastfeeding
17) Recent participation in another investigational drug or device study or registry in the past 30 days
18) Allergy to the test drug and its ingredients
19) Any terminal illness such that the patient would not be expected to survive more than three months
20) Other conditions in which investigators believe that participating in this study may be harmful to the patient

1.4 Randomization procedure

Randomization is allowed when all the inclusion criteria are confirmed to be met (including signed informed consent by the patient or the proxies) and all the exclusion criteria have been ruled out, as well as informed consent is signed by the patient or the proxies. Randomization is performed using permuted blocks through a centralized website named Easy Random Trial (ERT) designed by Chuang Da medical science and Technology (Shanghai) Co., Ltd. by a team of professional and independent statisticians. Patients are stratified according to the time of randomization after last known well (4.5-12 hours, 12-24 hours) and site of occlusion/severe stenosis (intracranial segment of internal carotid artery and M1-segment of middle cerebral artery; extracranial segment of internal carotid artery, M2-segment of middle cerebral artery and anterior cerebral artery). The dosage of tenecteplase is open-label while the raters involved in the subsequent radiological and clinical evaluation are blinded to the allocation. The independent data safety monitoring board (DSMB) has the access to all the unblinded data.

1.5 Baseline and follow-up assessments

All responsible investigators receive training in the systems for data collection and data entry and training in Good Clinical Practice (GCP). All investigators responsible for patient assessment participate in training in critical assessment items (NIHSS, mRS).

The assessment schedule for this trial is found in the protocol. Briefly, once eligibility is confirmed and informed consent is obtained, the responsible investigator is able to randomize the patient through the Easy Random Trial (ERT) webpage. The baseline assessments include NIHSS, pre-morbid mRS, demographic data, past medical history, previous stroke history and cerebral imaging information.
All patients are followed up at 4-6 hours, 24-48 hours, 3-5 days, 7±1 days or discharge, 30±7 days, 90±7 days, unless death occurs. The 3-month assessments are conducted by telephone, by an assessor at each site trained in study procedures who is blinded to treatment allocation.

The trial management team are responsible for ensuring that all data are completed in a timely manner. Institutions receive small reimbursements for their staff time involved in data collection and in the provision of the intervention for this trial. Patients do not receive payment for participation.

1.6 Sample size justification

The sample size is calculated based on the results derived from the EXTEND-IA TNK trial: 22% patients of the intravenous tenecteplase group and 10% patients of the intravenous alteplase group reached major reperfusion, and 1% patients in both groups respectively were found to have sICH. To adopt a conservative approach, for each dose stratum within the umbrella design, the null hypothesis was that not more than 10% of patients would achieve a positive primary outcome following the respective dose of tenecteplase, while the alternative hypothesis was that, not less than 25% of patients would achieve a positive primary outcome following the respective dose of tenecteplase. Sample size estimation using Simon’s two-stage design was conducted for each dose stratum, according to which the null hypothesis that the true response rate was 10% was tested against a one-sided alternative. In the first stage, 18 patients were to be accrued. If there were 2 or fewer positive responses in these 18 patients, meaning that the null hypothesis was not rejected and the dose stratum was to be stopped. Otherwise, 25 additional patients were to be accrued for a total of 43 patients for each dose stratum. The null hypothesis for each stratum was to be rejected if 8 or more positive responses were observed in 43 patients. This design was to yield a type I error rate of 0.05 and a power of 0.8 when the true response rate was 25%. Overall, at least 36 patients were to be enrolled with a maximum enrollment of 86 patients equally distributed between the 2 dose strata. This design would yield a one-sided type I error of 0.5 and a power of 80% to detect the presumed significant difference. In all, at least 36 patients would be enrolled with a maximum enrollment of 86 patients in sum of the 2 dose strata.

1.7 Unblinding

Only the Data and Safety Monitoring Board (DSMB) have access to interim data and results. The DSMB Chair is Professor Anding Xu, Department of Neurology and Stroke Center, The First Affiliated Hospital, Jinan University, Guangzhou, China. The DSMB review unblinded data in accordance with the DSMB Charter. Treatment allocations are securely stored and separated from the outcome assessors. Statisticians not involved in the DSMB will remain blinded and work on dummy datasets until the computer codes for statistical analysis are validated.

1.8 Definition of outcomes

1.8.1 Primary outcome

The primary outcome is a binary composite of efficacy and safety, i.e., major reperfusion and absence of symptomatic intracranial hemorrhagic transformation (ICH) at 24-48 hours after intravenous tenecteplase. Major reperfusion was considered as the restoration of blood flow of greater than 50% of the involved territory.
For patients not transferred to the catheter room after thrombolysis, major reperfusion was assessed as reperfusion greater than 50% of the involved hypoperfusion lesion volume (delay time >3s) at baseline repeated CT perfusion imaging at 4-6 hours after thrombolysis.

For patients transferred to the catheter room, major reperfusion was evaluated as a modified Treatment In Cerebral Ischemia (mTICI) score 2b/3 at the initial catheter angiography.

Symptomatic ICH was defined according to the European Co-operative Acute Stroke Study-II (ECASS II) criteria, where the patients presented any type of intracranial hemorrhage with no less than 4 or more point-increase in National Institutes of Health Stroke Scale (NIHSS) from baseline or from the lowest NIHSS between baseline at 24-48 hours, or leading to death.

1.8.2 Secondary outcomes

- Secondary radiological efficacy outcomes
  - Recanalization defined by the Thrombolysis in Myocardial Infarction (TIMI) scale of 2/3 at the 4- to 6- hour CTA (reconstructed from CTP) for patients not transferred to the catheter room, or at digital subtraction angiography imaging prior to thrombectomy for patients transferred to the catheter room after thrombolysis;
  - Infarct growth on diffusion-weighted imaging (DWI) or non-contrast head CT at 3-5 days.

- Secondary clinical efficacy outcomes
  - Excellent functional outcome (disability-free, defined as modified Rankin Scale [mRS] 0-1) at 90 days;
  - Good functional outcome (functional independence, defined as mRS 0-2) at 90 days;
  - mRS distribution at 90 days;
  - Major neurological improvement at 24-48 hours (NIHSS reduction greater than 7 points or NIHSS 0-1);
  - Change in NIHSS as a continuous variable at 24-48 hours.

- Secondary radiological safety outcomes
  - Type 2 parenchymal hematoma (PH2);
  - Symptomatic ICH;
  - Any ICH at 24-48 hours post treatment.

- Secondary clinical safety outcomes
  - Poor functional outcome (severe disability or death, defined as mRS 5-6) at 90 days;
  - Systemic bleeding defined by The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) before discharge.

- Others:
  - Barthel index at 90 days

All of these clinical assessments will be conducted through on-site personnel who were blinded to the treatment allocation.

2. Funding

This study is supported by National Key R&D Program of China (2017YFC1308201), Clinical Research Plan of SHDC (SHDC2020CR4016).
3. Statistical analysis

3.1 Descriptive analysis

3.1.1 Continuous variables: Continuous variables will be described using mean and standard deviation (SD) if normally distributed, or median and interquartile range (IQR) if skewedly distributed. Normality will be tested using Shapiro-Wilk test.

3.1.2 Categorical variables: Categorical variables will be described using the exact number in each category and percentage.

3.2 Analysis of primary outcome

For the analysis of primary endpoint, as described above, if 3 or more of the 18 patients in the first stage of either dose stratum reach the primary endpoint, then additional 25 patients will be enrolled in that dose stratum. If 8 or more out of the 43 patients reach the primary endpoint within a given stratum after the second stage, then the corresponding tenecteplase dose can be considered to be of sufficient promise in terms of efficacy and safety and could be a qualified candidate dose for the subsequent phase IIb trial.

3.3 Analysis of secondary outcome

Since the design of this study is not aimed to compare the safety and efficacy of the two tenecteplase doses within the umbrella design, the analysis of secondary outcomes only involved data description without comparative analysis. Secondary outcomes were described using percentages, mean and standard deviation, median and interquartile range (IQR) as appropriate.

3.3.1 Secondary radiological efficacy outcomes

- **Recanalization defined by the Thrombolysis in Myocardial Infarction (TIMI) scale of 2/3 at the 4- to 6-hour CTA (reconstructed from CTP) for patients not transferred to the catheter room, or at digital subtraction angiography imaging prior to thrombectomy for patients transferred to the catheter room after thrombolysis:**
  This outcome will be presented using the exact number and percentage of patients reaching recanalization at 4-6 hours in each dose stratum.

- **Infarct growth on diffusion-weighted imaging (DWI) or non-contrast head CT at 3-5 days.**
  This outcome will be presented using mean and standard deviation (SD) if infarct growth at 3-5 days is normally distributed, or median and interquartile range (IQR) if skewedly distributed in each dose stratum. Normality will be tested using Shapiro-Wilk test.

3.3.2 Secondary clinical efficacy outcomes

- **Excellent functional outcome (disability-free, defined as modified Rankin Scale [mRS] 0-1) at 90 days:**
  This outcome will be presented using the exact number and percentage of patients reaching excellent functional outcome at 90 days in each dose stratum.

- **Good functional outcome (functional independence, defined as mRS 0-2) at 90 days; mRS distribution at 90 days;**
This outcome will be presented using the exact number and percentage of patients reaching
good functional outcome at 90 days in each dose stratum.

- **Major neurological improvement at 24-48 hours** *(NIHSS reduction greater than 7 points
or NIHSS 0-1)*;
  
  This outcome will be presented using the exact number and percentage of patients reaching
  major neurological improvement at 24-48 hours in each dose stratum.

- **Change in NIHSS as a continuous variable at 24-48 hours**.

  This outcome will be presented using mean and standard deviation (SD) if change in NIHSS
  at 24-48 hours is normally distributed, or median and interquartile range (IQR) if skewedly
  distributed in each dose stratum. Normality will be tested using Shapiro-Wilk test.

### 3.3.3 Secondary radiological safety outcomes

- **Type 2 parenchymal hematoma (PH2) at 24-48 hours post treatment**;

  This outcome will be presented using the exact number and percentage of patients
demonstrating PH2 at 24-48 hours in each dose stratum.

- **Symptomatic ICH at 24-48 hours post treatment**;

  This outcome will be presented using the exact number and percentage of patients
demonstrating symptomatic ICH at 24-48 hours in each dose stratum.

- **Any ICH at 24-48 hours post treatment**.

  This outcome will be presented using the exact number and percentage of patients
demonstrating any ICH at 24-48 hours in each dose stratum.

### 3.3.4 Secondary clinical safety outcomes

- **Poor functional outcome** *(severe disability or death, defined as mRS 5-6) at 90 days**;

  This outcome will be presented using the exact number and percentage of patients suffering
  from poor functional outcome at 90 days at 24-48 hours in each dose stratum.

- **Systemic bleeding defined by The Global Utilization of Streptokinase and Tissue
  Plasminogen Activator for Occluded Coronary Arteries (GUSTO) before discharge**.

  This outcome will be presented using the exact number and percentage of patients suffering
  from systemic bleeding before discharge in each dose stratum.

### 3.3.5 Others:

- **Barthel index at 90 days**.

  This outcome will be presented using mean and standard deviation (SD) if Barthel index at
  90 days is normally distributed, or median and interquartile range (IQR) if skewedly
  distributed in each dose stratum. Normality will be tested using Shapiro-Wilk test.

### 3.4 Interim analysis

Interim analysis will be conducted when 18 patients have been enrolled in each dose stratum. If
more than 2 out of the 18 patients in either dose stratum reach the primary endpoint, then another
additive 25 patients will be enrolled in that group, otherwise the dose strata will be dropped.
3.5 Sensitivity analysis

3.5.1 Preplanned sensitivity analysis

Preplanned sensitivity analysis is conducted removing patients with severe stenosis, analyzing the primary and second outcomes of patients with complete artery occlusion in the two tenecteplase dose groups.

3.5.2 Post-hoc sensitivity analysis

In case of any post-hoc subgroup analysis, they will be justified and identified as data-driven and, they will follow the principles and regulatory recommendations.

3.6 Handling of missing data

If missing data were observed, multiple imputations would be performed for the primary outcome. However, we did not plan any imputations for secondary outcomes, and frequencies with percentages of missing data on secondary outcomes would be reported.

3.7 Interim analysis

An interim analysis will be conducted when each treatment arm has recruited 18 patients. If three or more patients achieve the positive primary endpoint in either arm, then the study will continue to the 2nd stage, which will enroll an addition of 25 patients in that tenecteplase dose group (43 patients in total in each dose group), otherwise the dose group will be stopped. The intervention dose will be deemed to be of sufficient promise if 8 or more out of 43 patients achieve positive primary outcome.

3.8 Data blind review

The Data Blind Review (DBR) will be performed before lock of database. Data will be examined for compliance with the trial protocol by the monitor and the data manager. Criteria for deviations will be sent to the project statistician to plan listings for the Data Blind Review (DBR). The objective is to carry out the population selection and definition of the final study populations as well as a preliminary assessment of the quality of the trial data and the applicability of some statistical procedures such as the handling of missing data.

During the DBR, missing data and intercurrent events will be classified according to the plan described in section 3.6. Changes from that plan to adapt to new/unexpected intercurrent events during the blinded review are permitted but they should be traced and justified in the statistical report.

3.9 Data safety monitoring board

An independent Data Safety Monitoring Board (DSMB) will be established. The purpose of the DSMB is to review, on a regular basis, accumulating data from the ongoing trial. The DSMB will be composed of two stroke neurologists and a statistician who are not participating in the study and are not affiliated with the sponsor. The role of the DSMB will be to: 1) Review the occurrence of AEs and SAEs and 2) Make recommendations to the Executive Committee regarding safety of the
study. A strict control of predefined AEs and SAEs will be ensured through monitoring by the CRO.

A DSMB will follow up the safety of the study. DSMB will review the data in a blinded manner so that the study will maintain the integrity and will avoid any operational bias. Any potential analysis amendment will be traced and justified, if applicable. The study followed the regulatory recommendations regarding the functions and procedures of these committees.